

B10

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 March 2002 (28.03.2002)

PCT

(10) International Publication Number  
**WO 02/24234 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 48/00**

(21) International Application Number: **PCT/US01/29480**

(22) International Filing Date:  
20 September 2001 (20.09.2001)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
09/665,493 20 September 2000 (20.09.2000) **US**

(71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MANNING, William, C., Jr.** [US/US]; 3660 Country Club Drive, Redwood City, CA 94061 (US). **DWARKI, Varavani, J.** [US/US]; 16 Grove Farm Road, Pittstown, NJ 08867 (US). **RENDAHL, Katherine** [US/US]; 1221 Grizzly Peak Boulevard, Berkeley, CA 94708 (US). **ZHOU, Shangzhen** [CN/US]; 125 Fundy Bay, Alameda, CA

94502 (US). **McGEE, Laura, H.** [US/US]; 652 54th Street, Oakland, CA 94609 (US). **LAU, Dana** [US/US]; Apartement A, 280 Lenox Avenue, Oakland, CA 94610 (US). **FLANNERY, John, G.** [US/US]; 1728 Marin Avenue, Berkeley, CA 94707 (US). **MILLER, Sheldon, S.** [US/US]; 186 Hillcrest Road, Berkeley, CA 94705 (US). **WANG, Fei** [CN/US]; 981 9th Street, Albany, CA 94710 (US). **DIPOLO, Adriana** [VE/CA]; 704 Champagneur Avenue, Outremont, Quebec H2V 3P8 (CA).

(74) Agents: **CULLMAN, Louis, C. et al.**; Oppenheimer Wolff & Donnelly LLP, 840 Newport Center Drive, Suite 700, Newport Beach, CA 92660-7007 (US).

(81) Designated States (national): **AU, CA, JP, US.**

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **USE OF RECOMBINANT GENE DELIVERY VECTORS FOR TREATING OR PREVENTING DISEASES OF THE EYE**

(57) Abstract: Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.

WO 02/24234 A2

## USE OF RECOMBINANT GENE DELIVERY VECTORS FOR TREATING OR PREVENTING DISEASES OF THE EYE

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Patent Application No. 5 09/525,956, filed March 15, 2000, which application claims priority to U.S. Provisional Application No. 60/124,460, filed March 15, 1999, and U.S. Provisional Application No. 60/174,984, filed January 6, 2000, all of which applications are incorporated by reference in their entirety.

### TECHNICAL FIELD

10 The present invention relates generally to compositions and methods for treating diseases of the eye, and more specifically, to the use of various gene delivery vectors which direct the expression of selected gene products suitable for treating or preventing diseases of the eye.

### BACKGROUND OF THE INVENTION

15 Eye diseases represent a significant health problem in the United States and world-wide. Presently, over 80 million Americans are affected with potentially blinding eye disease, with 1.1 million being legally blind. Twelve million individuals suffer from some degree of visual impairment that cannot be corrected. The total economic impact of eye disease is also very significant. In 1981, the estimated economic impact of visual 20 impairment on the U.S. economy was 14 billion per year. By 1995, this impact had grown to an estimated 38.4 billion (National Eye Institute NIH).

A wide variety of eye diseases can cause visual impairment, including for example, macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, glaucoma, retinal detachment or injury and retinopathies (whether 25 inherited, induced by surgery, trauma, a toxic compound or agent, or, photically).

One structure in the eye that can be particularly affected by disease is the retina. Briefly, the retina, which is found at the back of the eye, is a specialized light-sensitive tissue that contains photoreceptor cells (rods and cones) and neurons connected to a neural network for the processing of visual information (see Figure 10). This information  
5 is sent to the brain for decoding into a visual image.

The retina depends on cells of the adjacent retinal pigment epithelium (RPE) for support of its metabolic functions. Photoreceptors in the retina, perhaps because of their huge energy requirements and highly differentiated state, are sensitive to a variety of genetic and environmental insults. The retina is thus susceptible to an array of diseases that  
10 result in visual loss or complete blindness.

Retinitis pigmentosa (RP), which results in the destruction of photoreceptor cells, the RPE, and choroid typify inherited retinal degenerations. This group of debilitating conditions affects approximately 100,000 people in the United States.

A great deal of the progress made in addressing this important clinical  
15 problem has depended on advances in research on photoreceptor cell biology, molecular biology, molecular genetics, and biochemistry over the past two decades. Animal models of hereditary retinal disease have been vital in helping unravel the specific genetic and biochemical defects that underlie abnormalities in human retinal diseases. It now seems clear that both genetic and clinical heterogeneity underlie many hereditary retinal diseases.

20 The leading cause of visual loss in the elderly is Age-related Macular Degeneration (AMD). The social and economic impact of this disease in the United States is increasing. The macula is a structure near the center of the retina that contains the fovea. This specialized portion of the retina is responsible for the high-resolution vision that permits activities such as reading. The loss of central vision in AMD is devastating.  
25 Degenerative changes to the macula (maculopathy) can occur at almost any time in life but are much more prevalent with advancing age. With growth in the aged population, AMD will become a more prevalent cause of blindness than both diabetic retinopathy and glaucoma combined. Laser treatment has been shown to reduce the risk of extensive macular scarring from the "wet" or neovascular form of the disease. The effects of this

treatment are short-lived, however, due to recurrent choroidal neovascularization. Thus, there are presently no effective treatments in clinical use for the vast majority of AMD patients.

Other diseases of the eye, such as glaucoma, are also major public health problems in the United States. In particular, blindness from glaucoma is believed to impose significant costs annually on the U.S. Government in Social Security benefits, lost tax revenues, and healthcare expenditures.

Briefly, glaucoma is not a uniform disease but rather a heterogeneous group of disorders that share a distinct type of optic nerve damage that leads to loss of visual function. The disease is manifest as a progressive optic neuropathy that, if left untreated, leads to blindness. It is estimated that as many as 3 million Americans have glaucoma and, of these, as many as 120,000 are blind as a result. Furthermore, it is the number one cause of blindness in African-Americans. Its most prevalent form, primary open-angle glaucoma, can be insidious. This form usually begins in midlife and progresses slowly but relentlessly. If detected early, disease progression can frequently be arrested or slowed with medical and surgical treatment.

Glaucoma can involve several tissues in the front and back of the eye. Commonly, but not always, glaucoma begins with a defect in the front of the eye. Fluid in the anterior portion of the eye, the aqueous humor, forms a circulatory system that brings nutrients and supplies to various tissues. Aqueous humor enters the anterior chamber via the ciliary body epithelium (inflow), flows through the anterior segment bathing the lens, iris, and cornea, and then leaves the eye via specialized tissues known as the trabecular meshwork and Schlemm's canal to flow into the venous system. Intraocular pressure is maintained *vis-à-vis* a balance between fluid secretion and fluid outflow. Almost all glaucomas are associated with defects that interfere with aqueous humor outflow and, hence, lead to a rise in intraocular pressure. The consequence of this impairment in outflow and elevation in intraocular pressure is that optic nerve function is compromised. The result is a distinctive optic nerve atrophy, which clinically is characterized by excavation and cupping of the optic nerve, indicative of loss of optic nerve axons.



Primary open-angle glaucoma is, by convention, characterized by relatively high intraocular pressures believed to arise from a blockage of the outflow drainage channel or trabecular meshwork in the front of the eye. However, another form of primary open-angle glaucoma, normal-tension glaucoma, is characterized by a severe optic neuropathy in the absence of abnormally high intraocular pressure. Patients with normal-tension glaucoma have pressures within the normal range, albeit often in the high normal range. Both these forms of primary open-angle glaucoma are considered to be late-onset diseases in that, clinically, the disease first presents itself around midlife or later. However, among African-Americans, the disease may begin earlier than middle age. In contrast, juvenile open-angle glaucoma is a primary glaucoma that affects children and young adults. Clinically, this rare form of glaucoma is distinguished from primary open-angle glaucoma not only by its earlier onset but also by the very high intraocular pressure associated with this disease. Angle-closure glaucoma is a mechanical form of the disease caused by contact of the iris with the trabecular meshwork, resulting in blockage of the drainage channels that allow fluid to escape from the eye. This form of glaucoma can be treated effectively in the very early stages with laser surgery. Congenital and other developmental glaucomas in children tend to be severe and can be very challenging to treat successfully. Secondary glaucomas result from other ocular diseases that impair the outflow of aqueous humor from the eye and include pigmentary glaucoma, pseudoexfoliative glaucoma, and glaucomas resulting from trauma and inflammatory diseases. Blockage of the outflow channels by new blood vessels (neovascular glaucoma) can occur in people with retinal vascular disease, particularly diabetic retinopathy.

Primary open-angle glaucoma can be insidious. It usually begins in midlife and progresses slowly but relentlessly. If detected, disease progression can frequently be arrested or slowed with medical and surgical treatment. However, without treatment, the disease can result in absolute irreversible blindness. In many cases, even when patients have received adequate treatment (e.g., drugs to lower intraocular pressure), optic nerve degeneration and loss of vision continues relentlessly.

The present invention provides compositions and methods for treating and preventing a number of diseases of the eye, including for example, retinal diseases and degenerations such as RP and AMD, as well as other diseases such as neovascular disease. The present invention also provides other, related advantages.

## 5 SUMMARY OF THE INVENTION

Briefly stated, the present invention provides compositions and methods for treating, preventing, or, inhibiting diseases of the eye. Within one aspect of the present invention, methods are provided for treating or preventing diseases of the eye comprising the step of intraocularly administering a gene delivery vector which directs the expression  
10 of one or more neurotrophic factors, or, anti-angiogenic factors, such that the disease of the eye is treated or prevented. Within related aspects of the present invention, gene delivery vectors are provided which direct the expression of one or more neurotrophic factors such as FGF, as well as gene therapy vectors which direct the expression of one or more anti-angiogenic factors. Within certain embodiments of the invention, a viral promoter (*e.g.*,  
15 CMV) or an inducible promoter (*e.g.*, tet) is utilized to drive the expression of the neurotrophic factor.

Representative examples of gene delivery vectors suitable for use within the present invention may be generated from viruses such as retroviruses (*e.g.*, FIV or HIV), herpesviruses, adenoviruses, adeno-associated viruses, and alphaviruses, or from non-viral  
20 vectors.

Utilizing the methods and gene delivery vectors provided herein a wide variety of diseases of the eye may be readily treated or prevented, including for example, glaucoma, macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, retinal detachment or injury and retinopathies (whether inherited,  
25 induced by surgery, trauma, a toxic compound or agent, or, photically). Similarly, a wide variety of neurotrophic factors may be utilized (either alone or in combination) within the context of the present invention, including for example, NGF, BDNF, CNTF, NT-3, NT-4, FGF-2, FGF-5, FGF-18, FGF-20 and FGF-21.

Within certain embodiments of the invention, it is preferred that the gene delivery vector be utilized to deliver and express an anti-angiogenic factor for the treatment, prevention, or, inhibition of diabetic retinopathy, wet AMD, and other neovascular diseases of the eye (*e.g.*, ROP). Within other embodiments it is desirable that

5 the gene delivery vector be utilized to deliver and express a neurotrophic growth factor to treat, prevent, or, inhibit diseases of the eye, such as, for example, glaucoma, retinitis pigmentosa, and dry AMD. Within yet other embodiments, it may be desirable to utilize either a gene delivery vector which expresses both an anti-angiogenic molecule and a neurotrophic growth factor, or two separate vectors which independently express such

10 factors, in the treatment, prevention, or inhibition of an eye disease (*e.g.*, for diabetic retinopathy).

Within further embodiments of the invention, the above-mentioned methods utilizing gene delivery vectors may be administered along with other methods or therapeutic regimens, including for example, photodynamic therapy (*e.g.*, for wet AMD),

15 laser photocoagulation (*e.g.*, for diabetic retinopathy and wet AMD), and intraocular pressure reducing drugs (*e.g.*, for glaucoma).

Also provided by the present invention are isolated nucleic acid molecules comprising the sequence of Figure 2, vectors which contain, and/or express this sequence, and host cells which contain such vectors.

20 Within further aspects of the present invention gene delivery vectors are provided which direct the expression of a neurotrophic factor, or, an anti-angiogenic factor. As noted above, representative examples of neurotrophic factors include NGF, BDNF, CNTF, NT-3, NT-4, FGF-2, FGF-5, FGF-18, FGF-20 and FGF-21. Representative examples of anti-angiogenic factors include soluble Flt-1, soluble Tie-2 receptor, and

25 PEDF. Representative examples of suitable gene delivery vectors include adenovirus, retroviruses (*e.g.*, HIV or FIV-based vectors), alphaviruses, AAV vectors, and naked DNA vectors.

Within yet other aspects of the invention non-human animal models of neovascular diseases of the eye are provided, comprising an animal having an angiogenic

(i.e., pro-angiogenic) transgene in the eye. Within various embodiments, the neovascularization may be retinal or choroidal neovascularization. Within other embodiments, the animal may be a mouse or rat. As noted herein, a wide variety of angiogenic transgenes may be utilized to generate the non-human animal model, including  
5 for example, angiogenic transgenes that encode VEGF and/or an angiopoietin such as angiopoietin-1.

Also provided are methods of making such non-human animal models comprising the general steps of administering to a non-human animal a gene delivery vector which directs the expression of an angiogenic transgene. As noted above, a wide  
10 variety of gene delivery vectors (e.g., rAV and rAAV) can be utilized, as well as nucleic acid molecules which encode the angiogenic transgene (e.g., nucleic acid molecules encoding VEGF or angiopoietin). Within certain embodiments, the gene delivery vector can be administered subretinally or intravitreally. Within further embodiments the animal model can be utilized as a model for Age-related Macular Degeneration (AMD), diabetic  
15 retinopathy, or, retinopathy of prematurity (ROP).

Also provided are methods for determining the ability of an anti-angiogenic factor to inhibit neovascularization of the eye, comprising the general steps of (a) administering to an animal model as described herein an anti-angiogenic factor, and (b) determining the ability of the anti-angiogenic factor to inhibit neovascularization of the  
20 eye. As noted herein, the anti-angiogenic factor may be administered by a variety of routes, including for example, topically, subretinally, or, intravitreally. Further, the animal model may be utilized to test the efficacy of drugs, compounds, or other factors or agents for a wide variety of eye-related neovascular diseases (including AMD and ROP).

These and other aspects of the present invention will become evident upon  
25 reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incorporated by reference in their entirety.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration of pKm201bFGF-2.

Figures 2A and 2B are the nucleic acid sequence of pKm201bFGF-2 (SEQ I.D. No. \_\_\_\_).

5                Figure 3 is a schematic illustration of pD10-CMV-FGF-5.

Figure 4 is a western analysis of FGF-5 rAAV infected 293 cells.

Figure 5 is a schematic illustration of pD10-CMV-FGF-5 (sig-).

Figure 6 is a western analysis of pD10-CMV-FGF-5 (sig-) transfected 293 cells.

10              Figure 7 is a schematic illustration of pD10-CMV-FGF-18.

Figure 8 western analysis of 293 cells transfected pD10-CMV-FGF-18.

Figures 9A and 9B are photographs which show that blue-gal staining is visible across 40% of a retina transfected with AAV-CMV-lacZ. All photoreceptors appear to express lacZ at the injection site, except at the edge where individual cells are visible.

15              Figure 10 is a schematic illustration which shows the retina within the eye, and the organization of cells within the retina.

Figures 11A and 11B are photographs of wild-type and degenerated S334ter rat retinas. S334ter is a rat model for retinitis pigmentosa.

20              Figures 12A, 12B and 12C are photographs of degenerated S334ter, FGF-2 injected S334ter and PBS injected S334ter rat retinas. As can be seen in these figures, FGF-2 injected into the S334ter rat retina substantially slows the progression of disease.

Figure 13 is a graph which plots Outer Nuclear Layer (ONL) thickness for FGF-2 subretinally injected, PBS subretinally injected, and an uninjected control.

Figure 14 is a bar graph which plots ONL thickness at p60.

25              Figures 15A, 15B and 15C are photographs of FGF-2 expressing cells stained with an anti-FGF-2 antibody.

Figures 16A and 16B are photographs which show gene delivery to cells in the ganglion cell layer following intraocular injection of recombinant rAAV-CMV-lacZ. a) superior quadrant of a retinal flat-mount processed for Blue-Gal staining to visualize AAV-

infected neurons. Notice the large number of axons converging at the optic nerve head (asterisk). b) Retinal radial section showing the AAV-mediated LacZ gene product in cells of the ganglion cell layer. A large number of these cells can be identified as RGCs because of the intense LacZ staining in axons projecting to the optic nerve head (asterisk). RPE: 5 retinal pigment epithelium, PS: photoreceptor segments, ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell layer. Scale bars: a) 0.5 mm, b) 50  $\mu$ m.

Figure 17 is a graph which shows the time-course of AAV-mediated transgene expression in the ganglion cell layer of the adult rat retina. A recombinant AAV 10 vector (rAAV-CMV-lacZ) was injected into the vitreous chamber of adult rats and 2, 4 and 8 weeks later, Lac-Z positive neurons in the ganglion cell layer (GCL) were counted in retinal flat-mounts. The values are the mean of 3-4 retinas per time point  $\pm$  standard deviation ( $p < 0.001$ ).

Figures 18A and 18B are photographs which show the localization of the 15 AAV-mediated LacZ gene product in retrogradely labeled RGCs. a) Retinal radial section showing LacZ immunopositive RGCs transduced with AAV (excitation 520-560, barrier 580, emission 580); b) Same section examined under a different fluorescent filter (excitation 355-425, barrier 460, emission 470) to visualize RGCs backlabeled with Fluorogold from the superior colliculus. Notice that the vast majority of LacZ 20 immunopositive neurons are also labeled with Fluorogold. An exception, a LacZ positive cell that is not Fluorogold labeled, is shown (arrow), and could represent a displaced amacrine cell or RGC that did not incorporate the retrograde tracer. INL: inner nuclear layer, IPL: inner plexiform layer; GCL: ganglion cell layer. Scale bar: 10  $\mu$ m.

Figure 19 is a graph which quantifies Fluorogold- and LacZ-positive cells in 25 the ganglion cell layer following intravitreal injection of rAAV-CMV-lacZ. The number of Fluorogold-positive cells (FG+) was compared to the number of cells that expressed both the Fluorogold and LacZ markers (FG+, LacZ+) and the number of cells expressing only the reporter gene (LacZ+). Values represent the mean of 4-5 retinal radial sections per animal ( $n=4$ )  $\pm$  standard deviation (S.D.) ( $p < 0.001$ ).

Figure 20 is a photograph which shows the localization of the heparan sulfate (HS) proteoglycan receptor, the cellular receptor for AAV, in the intact adult rat retina. Retinal cryosection immunostained with a polyclonal antibody against the heparan sulfate (HepSS-1; diluted 1:200) followed by biotinylated anti-rabbit Fab fragment, avidin-biotin-peroxidase reagent (ABC Elite Vector Labs, Burlingame, CA). The section was reacted in a solution containing 0.05% diaminobenzidine tetrahydrochloride (DAB) and 0.06% hydrogen peroxide in PB (pH 7.4) for 5 min. Notice the strong labeling in RGCs in the ganglion cell layer (GCL). RPE: retinal pigment epithelium, PS: photoreceptor segments, ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer. Scale bar: 50  $\mu$ m.

Figure 21 is a schematic illustration of pD10-VEGFuc.

Figure 22A and 22B are the nucleotide sequence of pD10-VEGFuc.

Figure 23 is a bar graph which shows pD10-VEGFuc rAAV virus infection of 293 cells.

Figure 24 is a three dimensional bar-graph which shows VEGF secretion by hRPE after infection with VEGF AAV.

Figure 25 is a three dimensional bar-graph which shows VEGF secretion by hRPE after infection with VEGF AV

Figure 26 is a three dimensional bar-graph which shows resistance of hRPE after infection with VEGF AV.

Figure 27 is a schematic illustration of pD10-sFlt-1.

Figure 28A and 28B provide the nucleotide sequence of pD10-sFlt-1.

Figure 29 is the nucleotide sequence of FGF-20.

Figure 30 is the nucleotide sequence of FGF-21.

Figure 31 is a schematic illustration of pD10K-FGF-2Sc.

Figure 32A and 32B are the nucleotide sequence of pD10K-FGF-2Sc.

Figure 33 is a graph that compares ONL thickness ( $\mu$ m) after injection of various vectors into the eye.

Figure 34 is a bar graph that shows inhibition of HMVEC proliferation by sFlt-1 rAAV.

Figures 35A and 35B are photographic images showing retinal blood vessels from a live animal, before sacrifice.

5                Figures 36A, 36B, 36C, and 36D are a series of images showing epoxy sections of an eye at various distances from an AAV-VEGF injection site.

Figures 37A, 37B, 37C, and 37D are photographs which show lectin / BrdU double-staining of the rat retina.

10              Figures 38A and 38B are bar graphs which show sFlt-1 and PEDF rescue of ERGs.

Figure 39 is a graph which shows the ERG of a test and control eye of sFlt-1 treated rats.

## DETAILED DESCRIPTION OF THE INVENTION

15

### DEFINITIONS

Prior to setting forth the invention, it may be helpful to an understanding thereof to first set forth definitions of certain terms that will be used hereinafter.

20              "Gene delivery vector" refers to a construct which is capable of delivering, and, within preferred embodiments expressing, one or more gene(s) or sequence(s) of interest in a host cell. Representative examples of such vectors include viral vectors, nucleic acid expression vectors, naked DNA, and certain eukaryotic cells (*e.g.*, producer cells).

25              "Recombinant adeno-associated virus vector" or "rAAV vector" refers to a gene delivery vector based upon an adeno-associated virus. The rAAV vectors, should contain 5' and 3' adeno-associated virus inverted terminal repeats (ITRs), and a transgene or gene of interest operatively linked to sequences which regulate its expression in a target cell. Within certain embodiments, the transgene may be operably linked to a heterologous



promoter (such as CMV), or, an inducible promoter such as (tet). In addition, the rAAV vector may have a polyadenylation sequence.

"Neurotrophic Factor" or "NT" refers to proteins which are responsible for the development and maintenance of the nervous system. Representative examples of neurotrophic factors include NGF, BDNF, CNTF, NT-3, NT-4, and Fibroblast Growth Factors.

"Fibroblast Growth Factor" or "FGF" refers to a family of related proteins, the first of which was isolated from the pituitary gland (see Gospodarowicz, D., *Nature*, 249:123-127, 1974). From this original FGF (designated basic FGF) a family of related proteins, protein muteins, and protein analogs have been identified (see, e.g., U.S. Patent Nos. 4,444,760, 5,155,214, 5,371,206, 5,464,774, 5,464,943, 5,604,293, 5,731,170, 5,750,365, 5,851,990, 5,852,177, 5,859,208, and 5,872,226), all of which are generally referred to as Fibroblast Growth Factors within the context of the present invention.

"Anti-angiogenic Factor" refers to a factor or molecule which is able to inhibit the proliferation of vascular growth. A variety of assays may be utilized to assess the anti-angiogenic activity of a given molecule, including for example, the assay provided in Example 15, which measures HMVEC (human dermal microvascular endothelial cell) proliferation. Representative examples of anti-angiogenic factors include for example, Angiostatin, 1,25-Di-hydroxy-vitamin D<sub>3</sub>, Endostatin, IGF-1 receptor antagonists, Interferons alpha, beta and gamma, Interferon gamma-inducible protein IP-10, Interleukin 1 alpha and beta, Interleukin 12, 2-Methoxyestradiol, PEDF, Platelet factor 4, Prolactin (16kd fragment), Protamin, Retinoic acid, Thrombospondin-1 and 2, Tissue inhibitor of metalloproteinase-1 and -2, Transforming growth factor beta, anti-VEGF antibodies (which should be understood to include fragments of antibodies such as a single chain antibodies, Fab fragments, or, CDR regions), soluble Tie-2 receptor, soluble Tie-2 receptor, soluble Flt-1 and Tumor necrosis factor - alpha.

"Diseases of the Eye" refers to a broad class of diseases wherein the functioning of the eye is affected due to damage or degeneration of the photoreceptors; ganglia or optic nerve; or neovascularization. Representative examples of such diseases

include macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, glaucoma, retinal detachment or injury and retinopathies (whether inherited, induced by surgery, trauma, a toxic compound or agent, or, photically).

As noted above, the present invention provides compositions and methods  
5 for treating, preventing, or, inhibiting diseases of the eye, comprising the general step of administering intraocularly a recombinant adeno-associated viral vector which directs the expression of one or more neurotrophic factors, such that the disease of the eye is treated or prevented. In order to further an understanding of the invention, a more detailed discussion is provided below regarding (A) gene delivery vectors; (B) Neurotrophic Factors; (C) Anti-  
10 angiogenic factors; and (D) methods of administering the rAAVs in the treatment or prevention of diseases of the eye.

A. Gene Delivery Vectors

1. Construction of retroviral gene delivery vectors

Within one aspect of the present invention, retroviral gene delivery vectors  
15 are provided which are constructed to carry or express a selected gene(s) or sequence(s) of interest. Briefly, retroviral gene delivery vectors of the present invention may be readily constructed from a wide variety of retroviruses, including for example, B, C, and D type retroviruses as well as spumaviruses and lentiviruses (see RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985). Such retroviruses may be readily obtained  
20 from depositories or collections such as the American Type Culture Collection ("ATCC"; Rockville, Maryland), or isolated from known sources using commonly available techniques.

Any of the above retroviruses may be readily utilized in order to assemble or construct retroviral gene delivery vectors given the disclosure provided herein, and  
25 standard recombinant techniques (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Kunkel, *PNAS* 82:488, 1985). In addition, within certain embodiments of the invention, portions of the retroviral gene

delivery vectors may be derived from different retroviruses. For example, within one embodiment of the invention, retrovirus LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

5           Within one aspect of the present invention, retrovector constructs are provided comprising a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein the vector construct lacks *gag/pol* or *env* coding sequences.

Other retroviral gene delivery vectors may likewise be utilized within the  
10   context of the present invention, including for example EP 0,415,731; WO 90/07936; WO 91/0285, WO 9403622; WO 9325698; WO 9325234; U.S. Patent No. 5,219,740; WO 9311230; WO 9310218; Vile and Hart, *Cancer Res.* 53:3860-3864, 1993; Vile and Hart, *Cancer Res.* 53:962-967, 1993; Ram et al., *Cancer Res.* 53:83-88, 1993; Takamiya et al., *J. Neurosci. Res.* 33:493-503, 1992; Baba et al., *J. Neurosurg.* 79:729-735, 1993 (U.S. Patent  
15   No. 4,777,127, GB 2,200,651, EP 0,345,242 and WO91/02805).

Packaging cell lines suitable for use with the above described retrovector constructs may be readily prepared (see U.S. Serial No. 08/240,030, filed May 9, 1994; see also U.S. Serial No. 07/800,921, filed November 27, 1991), and utilized to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant  
20   vector particles.

## 2.   Recombinant Adeno-Associated Virus Vectors

As noted above, a variety of rAAV vectors may be utilized to direct the expression of one or more desired neurotrophic factors. Briefly, the rAAV should be comprised of, in order, a 5' adeno-associated virus inverted terminal repeat, a transgene or  
25   gene of interest operatively linked to a sequence which regulates its expression in a target cell, and a 3' adeno-associated virus inverted terminal repeat. In addition, the rAAV vector may preferably have a polyadenylation sequence.

Generally, rAAV vectors should have one copy of the AAV ITR at each end of the transgene or gene of interest, in order to allow replication, packaging, and efficient integration into cell chromosomes. The ITR consists of nucleotides 1 to 145 at the 5' end of the AAV DNA genome, and nucleotides 4681 to 4536 (*i.e.*, the same sequence) at the 3' end of the AAV DNA genome. Preferably, the rAAV vector may also include at least 10 nucleotides following the end of the ITR (*i.e.*, a portion of the "D region").

Within preferred embodiments of the invention, the transgene sequence will be of about 2 to 5 kb in length (or alternatively, the transgene may additionally contain a "stuffer" or "filler" sequence to bring the total size of the nucleic acid sequence between the two ITRs to between 2 and 5 kb). Alternatively, the transgene may be composed of same heterologous sequence several times (*e.g.*, two nucleic acid molecules which encode FGF-2 separated by a ribosome readthrough, or alternatively, by an Internal Ribosome Entry Site or "IRES"), or several different heterologous sequences (*e.g.*, FGF-2 and FGF-5, separated by a ribosome readthrough or an IRES).

Recombinant AAV vectors of the present invention may be generated from a variety of adeno-associated viruses, including for example, serotypes 1 through 6. For example, ITRs from any AAV serotype are expected to have similar structures and functions with regard to replication, integration, excision and transcriptional mechanisms.

Within certain embodiments of the invention, expression of the transgene may be accomplished by a separate promoter (*e.g.*, a viral promoter). Representative examples of suitable promoters in this regard include a CMV promoter, RSV promoter, SV40 promoter, or MoMLV promoter. Other promoters that may similarly be utilized within the context of the present invention include cell or tissue specific promoters (*e.g.*, a rod, cone, or ganglia derived promoter), or inducible promoters. Representative examples of suitable inducible promoters include tetracycline-response promoters ("Tet", see, *e.g.*, Gossen and Bujard, *Proc. Natl. Acad. Sci. USA.* 89:5547-5551, 1992; Gossen et al., *Science* 268, 1766-1769, 1995; Baron et al., *Nucl. Acids Res.* 25:2723-2729, 1997; Blau and Rossi, *Proc. Natl. Acad. Sci. USA.* 96:797-799, 1999; Bohl et al., *Blood* 92:1512-1517, 1998; and Haberman et al., *Gene Therapy* 5:1604-1611, 1998), the ecdysone system (see *e.g.*, No et

al., *Proc. Natl. Acad. Sci. USA.* 93:3346-3351, 1996), and other regulated promoters or promoter systems (see, e.g., Rivera et al., *Nat. Med.* 2:1028-1032, 1996;).

The rAAV vector may also contain additional sequences, for example from an adenovirus, which assist in effecting a desired function for the vector. Such sequences  
5 include, for example, those which assist in packaging the rAAV vector in adenovirus-associated virus particles.

Packaging cell lines suitable for producing adeno-associated viral vectors may be readily accomplished given readily available techniques (see e.g., U.S. Patent No. 5,872,005).

10 Particularly preferred methods for constructing and packaging rAAV vectors are described in more detail below in Examples 1, 2, 3, and 4.

### 3. Alphavirus delivery vectors

The present invention also provides a variety of Alphavirus vectors which may function as gene delivery vectors. For example, the Sindbis virus is the prototype  
15 member of the alphavirus genus of the togavirus family. The unsegmented genomic RNA (49S RNA) of Sindbis virus is approximately 11,703 nucleotides in length, contains a 5' cap and a 3' poly-adenylated tail, and displays positive polarity. Infectious enveloped Sindbis virus is produced by assembly of the viral nucleocapsid proteins onto the viral genomic RNA in the cytoplasm and budding through the cell membrane embedded with  
20 viral encoded glycoproteins. Entry of virus into cells is by endocytosis through clathrin coated pits, fusion of the viral membrane with the endosome, release of the nucleocapsid, and uncoating of the viral genome. During viral replication the genomic 49S RNA serves as template for synthesis of the complementary negative strand. This negative strand in turn serves as template for genomic RNA and an internally initiated 26S subgenomic RNA.  
25 The Sindbis viral nonstructural proteins are translated from the genomic RNA while structural proteins are translated from the subgenomic 26S RNA. All viral genes are expressed as a polyprotein and processed into individual proteins by post translational

proteolytic cleavage. The packaging sequence resides within the nonstructural coding region, therefore only the genomic 49S RNA is packaged into virions.

Several different Sindbis vector systems may be constructed and utilized within the present invention. Representative examples of such systems include those  
5 described within U.S. Patent Nos. 5,091,309 and 5,217,879, and PCT Publication No. WO 95/07994.

#### 4. Other viral gene delivery vectors

In addition to retroviral vectors and alphavirus vectors, numerous other viral vectors systems may also be utilized as a gene delivery vector. Representative examples of  
10 such gene delivery vectors include viruses such as pox viruses, such as canary pox virus or vaccinia virus (Fisher-Hoch et al., *PNAS* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330 and 5,017,487; WO 89/01973); SV40 (Mulligan et al., *Nature* 277:108-114, 1979); influenza virus (Luytjes et al., *Cell* 59:1107-1113, 1989; McMichael et al., *N. Eng. J. Med.* 309:13-17, 1983; and Yap et al., *Nature* 273:238-239, 1978); herpes (Kit, *Adv. Exp. Med. Biol.* 215:219-236, 1989; U.S. Patent No. 5,288,641); HIV (Poznansky, *J. Virol.* 65:532-536, 1991); measles (EP 0 440,219); Semliki Forest Virus, and coronavirus, as well as other viral systems (e.g., EP 0,440,219; WO 92/06693; U.S. Patent No. 5,166,057). In addition, viral carriers may be homologous, non-pathogenic(defective), replication  
15 competent virus (e.g., Overbaugh et al., *Science* 239:906-910,1988), and nevertheless induce cellular immune responses, including CTL.

#### 5. Non-viral gene delivery vectors

In addition to the above viral-based vectors, numerous non-viral gene delivery vectors may likewise be utilized within the context of the present invention.  
25 Representative examples of such gene delivery vectors include direct delivery of nucleic acid expression vectors, naked DNA alone (WO 90/11092), polycation condensed DNA linked or unlinked to killed adenovirus (Curiel et al., *Hum. Gene Ther.* 3:147-154, 1992),

DNA ligand linked to a ligand with or without one of the high affinity pairs described above (Wu et al., *J. of Biol. Chem* 264:16985-16987, 1989), nucleic acid containing liposomes (e.g., WO 95/24929 and WO 95/12387) and certain eukaryotic cells (e.g., producer cells - see U.S. Serial No. 08/240,030, filed May 9, 1994, and U.S. Serial  
5 No. 07/800,921).

#### B. Neurotrophic Factors

As noted above, the term neurotrophic factor refers to proteins which are responsible for the development and maintenance of the nervous system. Representative examples of neurotrophic factors include NGF, BDNF, CNTF, NT-3, NT-4, and Fibroblast

#### 10 Growth Factors.

Fibroblast Growth Factor refers to a family of related proteins, the first of which was isolated from the pituitary gland (see Gospodarowicz, D., *Nature*, 249:123-127, 1974). From this original FGF (designated basic FGF) a family of related proteins, protein mutants, and protein analogs have been identified (see, e.g., U.S. Patent Nos. 4,444,760,  
15 5,155,214, 5,371,206, 5,464,774, 5,464,943, 5,604,293, 5,731,170, 5,750,365, 5,851,990, 5,852,177, 5,859,208, and 5,872,226; see generally Baird and Gospodarowicz, *D. Ann N.Y. Acad. Sci.* 638:1, 1991. The first two members of the family to be identified were acidic fibroblast growth factor (aFGF/FGF-1) and basic fibroblast growth factor (bFGF/FGF-2). Additional members of the FGF family include: i-nt-2/FGF-3, (Smith et al., *EMBO J.* 7:  
20 1013, 1988); FGF-4 (Delli-Bovi et al., *Cell* 50: 729, 1987); FGF-6 (Marics et al., *Oncogene* 4: 335 (1989); keratinocyte growth factor/FGF-7, (Finch et al., *Science* 245: 752, 1989); FGF-8 (Tanaka et al., *Proc. Natl. Acad. Sci. USA* 89: 8928, 1992); and FGF-9 (Miyamoto et al., *Mol. Cell Biol.* 13: 4251, 1993).

FGF-5 was originally isolated as an oncogene. See Goldfarb et al. US  
25 Patent Nos. 5,155,217 and 5,238,916, Zhan et al. "Human Oncogene Detected by a Defined Medium Culture Assay" (*Oncogene* 1:369-376, 1987), Zhan et al. "The Human FGF-5 Oncogene Encodes a Novel Protein Related to Fibroblastic Growth Factors" (*Molecular*

and *Cellular Biology* 8:3487-3495, 1988), and Bates et al. "Biosynthesis of Human Fibroblast Growth Factor 5": (*Molecular and Cellular Biology* 11:1840-1845, 1991):

Other FGFs include those disclosed in U.S. Patent Nos. 4,444,760, 5,155,214, 5,371,206, 5,464,774, 5,464,943, 5,604,293, 5,731,170, 5,750,365, 5,851,990, 5,852,177, 5,859,208, and 5,872,226. 5,852,177, and 5,872,226, as well as FGF-20 (U.S. Provisional Application No. 60/161,162) and FGF-21 (U.S. Provisional Application No. 60/166,540).

### C. Anti-Angiogenic Factors

A wide variety of anti-angiogenic factors may also be expressed from the gene delivery vectors of the present invention, including for example, Angiostatin (O'Reilly et al., *Cell* 79:315-328, 1994; O'Reilly et al., *Nat. Med.* 2:689-92, 1996; Sim et al., *Cancer Res.* 57:1329-34, 1997), 1,25-Di-hydroxy-vitamin D<sub>3</sub> (Shibuya et al., *Oncogene* 5:519-24, 1990; Oikawa et al., *Eur. J. Pharmacol.* 178:247-50, 1990; and 182:616, 1990), Endostatin (O'Reilly et al., *Cell* 88:277-85, 1997), Interferons alpha and beta (Sidky et al., *Cancer Res.* 47:5155-61, 1987; Singh et al., *Proc. Natl. Acad. Sci. USA* 92:4562-6, 1995), Interferon gamma (Friesel et al., *J. Cell. Biol.* 104:689-96, 1987), IGF-1 receptor antagonists, Interferon gamma-inducible protein IP-10 (Arenberg et al., *J. Exp. Med.* 1996;184:981-92; Strieter et al., *J. Leukoc. Biol.* 1995;57:752-62; Angiolillo et al., *J. Exp. Med.* 182:155-62, 1995), Interleukin 1alpha and beta (Cuzzolino et al., *Proc. Natl. Acad. Sci. USA* 87:6487-91, 1990), Interleukin 12 (Kerbel and Hawley, *J. Natl Cancer Inst.* 87:557-9, 1995; Majewski et al., *J. Invest. Dermatol* 106:1114-8, 1996; Voest et al., *J. Natl Cancer Inst.* 87:581-6, 1995), 2-Methoxyestradiol (Fotsis et al., *Nature* 368:237-9, 1994), Platelet factor 4 (Taylor and Folkman, *Nature* 297:307-12, 1982; Gengrinovitch et al., *J. Biol. Chem* 270:15059-65, 1995), Prolactin (16kd fragment) (Clapp et al., *Endocrinology* 133:1292-9, 1993; Ferrara, *Endocrinology* 129:896-900, 1991), Protamin, Retinoic acid (Lingen et al., *Lab. Invest* 74:476-83, 1996), Thrombospondin-1 and 2 (Lawler, *Blood*, 67:1197-209, 1986; Raugi and Lovett, *Am. J. Pathol* 129:364-72, 1987; Volpert et al., *Biochem. Biophys. Res. Commun* 217:326-32, 1995), Tissue inhibitor of metalloproteinase-1 and -2 (Moses



and Langer, *J. Cell Biochem* 47:230-5, 1991; Ray and Stetler-Stevenson, *Eur. Respir. J.* 7:2062-72, 1994), Transforming growth factor beta (RayChaudhury, *J. Cell. Biochem* 47:224-9, 1991; Roberts et al., *Proc. Natl Acad. Sci USA* 83:4167-71, 1986), and Tumor necrosis factor – alpha (Frater-Schroeder et al., *Proc. Natl. Acad. Sci. USA* 84:5277-81, 5 1987; Leibovich et al., *Nature* 329:630-2, 1987).

Other anti-angiogenic factors that can be utilized within the context of the present invention include VEGF antagonists such as soluble Flt-1 (Kendall and Thomas, *PNAS* 90: 10705, 1993), pigment epithelium-derived factor or "PEDF" (Dawson et al., *Science* 285:245, 1999), and Ang-1 antagonists such as soluble Tie-2 receptor (Thurston 10 et al., *Science* 286:2511, 1999; see also, generally Aiello et al., *PNAS* 92:10457, 1995; Robinson et al., *PNAS* 93:4851, 1996; Seo et al., *Am. J. Pathol.* 154:1743, 1999).

The ability of a given molecule to be "anti-angiogenic" can be readily assessed utilizing a variety of assays, including for example, the HMVEC assay provided in Example 15.

15 D. Method for Treating and/or Preventing Diseases of the Eye, and Pharmaceutical Compositions

As noted above, the present invention provides methods which generally comprise the step of intraocularly administering a gene delivery vector which directs the expression of one or more neurotrophic factor to the eye, or an anti-angiogenic factor to the 20 eye in order to treat, prevent, or inhibit the progression of an eye disease. As utilized herein, it should be understood that the terms "treated, prevented, or, inhibited" refers to the alteration of a disease course or progress in a statistically significant manner. Determination of whether a disease course has been altered may be readily assessed in a variety of model systems, discussed in more detail below, which analyze the ability of a 25 gene delivery vector to delay, prevent or rescue photoreceptors, as well as other retinal cells, from cell death.

1. Diseases of the eye

A wide variety of diseases of the eye may be treated given the teachings provided herein. For example, within one embodiment of the invention gene delivery vectors are administered to a patient intraocularly in order to treat or prevent macular degeneration. Briefly, the leading cause of visual loss in the elderly is macular degeneration (MD), which has an increasingly important social and economic impact in the United States. As the size of the elderly population increases in this country, age related macular degeneration (AMD) will become a more prevalent cause of blindness than both diabetic retinopathy and glaucoma combined. Although laser treatment has been shown to reduce the risk of extensive macular scarring from the "wet" or neovascular form of the disease, there are currently no effective treatments for the vast majority of patients with MD.

Within another embodiment, gene delivery vectors can be administered to a patient intraocularly in order to treat or prevent an inherited retinal degeneration. One of the most common inherited retinal degenerations is retinitis pigmentosa (RP), which results in the destruction of photoreceptor cells, and the RPE. Other inherited conditions include Bardet-Biedl syndrome (autosomal recessive); Congenital amaurosis (autosomal recessive); Cone or cone-rod dystrophy (autosomal dominant and X-linked forms); Congenital stationary night blindness (autosomal dominant, autosomal recessive and X-linked forms); Macular degeneration (autosomal dominant and autosomal recessive forms); Optic atrophy, autosomal dominant and X-linked forms); Retinitis pigmentosa (autosomal dominant, autosomal recessive and X-linked forms); Syndromic or systemic retinopathy (autosomal dominant, autosomal recessive and X-linked forms); and Usher syndrome (autosomal recessive). This group of debilitating conditions affects approximately 100,000 people in the United States alone.

As noted above, within other aspects of the invention, gene delivery vectors which direct the expression of a neurotrophic growth factor can be administered to a patient intraocularly in order to treat or prevent glaucoma. Briefly, glaucoma is not a uniform disease but rather a heterogeneous group of disorders that share a distinct type of optic

nerve damage that leads to loss of visual function. The disease is manifest as a progressive optic neuropathy that, if left untreated leads to blindness. It is estimated that as many as 3 million Americans have glaucoma and, of these, as many as 120,000 are blind as a result. Furthermore, it is the number one cause of blindness in African-Americans. Its most prevalent form, primary open-angle glaucoma, can be insidious. This form usually begins in midlife and progresses slowly but relentlessly. If detected early, disease progression can frequently be arrested or slowed with medical and surgical treatment. Representative factors that may be expressed from the vectors of the present invention to treat glaucoma include neurotrophic growth factors such as FGF-2, 5, 18, 20, and, 21.

10           Within yet other embodiments gene delivery vectors can be administered to a patient intraocularly in order to treat or prevent injuries to the retina, including retinal detachment, photic retinopathies, surgery-induced retinopathies, toxic retinopathies, retinopathies due to trauma or penetrating lesions of the eye.

          As noted above, the present invention also provides methods of treating, preventing, or, inhibiting neovascular disease of the eye, comprising the step of administering to a patient a gene delivery vector which directs the expression of an anti-angiogenic factor. Representative examples of neovascular diseases include diabetic retinopathy, AMD (wet form), and retinopathy of prematurity. Briefly, choroidal neovascularization is a hallmark of exudative or wet Age-related Macular Degeneration (AMD), the leading cause of blindness in the elderly population. Retinal neovascularization occurs in diseases such as diabetic retinopathy and retinopathy of prematurity (ROP), the most common cause of blindness in the young.

20           Particularly preferred vectors for the treatment, prevention, or, inhibition of neovascular diseases of the eye direct the expression of an anti-angiogenic factor such as, for example, soluble tie-2 receptor or soluble Flt-1.

## 2.     Animal Models

          In order to assess the ability of a selected gene therapy vector to be effective for treating diseases of the eye which involve neovascularization, a novel model for

neovascularization (either choroidal or subretinal) can be generated by subretinal injection of a recombinant virus (e.g., rAV or rAAV) containing an angiogenic transgene such as VEGF and/or angiopoietin. Within certain embodiments, an angiogenic transgene such as angiopoietin-1 can be used in combination with another factor such as VEGF, in order to  
5 generate neovascularization. The extent and duration of neovascularization induced by the gene delivery vectors containing an angiogenic transgene such as VEGF can be determined using fundus photography, fluorescein angiography and histochemistry.

To assess the ability of anti-angiogenic molecules to prevent neovascularization in the model described above, a D10- sFlt-1 rAAV (or other gene  
10 delivery vector which directs the expression of an anti-angiogenic factor) is intraocularly injected, either by subretinal or intravitreal routes of injection. Generally, subretinal injection of the gene delivery vector may be utilized to achieve delivery to both the choroidal and inner retinal vasculature. Intravitreal injection can be utilized to infect Muller cells and retinal ganglion cells (RGCs), which deliver anti-angiogenic protein to the  
15 retinal vasculature. Muller cells span the retina and would secrete the therapeutic protein into the subretinal space.

Such injections may be accomplished either prior to, simultaneous with, or subsequent to administration of an angiogenic factor or gene delivery vector which expresses an angiogenic factor. After an appropriate time interval, inhibition of  
20 neovascularization can be determined using fundus photography, fluorescein angiography and/or histochemistry.

While there are many animal models of retinal neovascularization such as oxygen-induced ischemic retinopathy (Aiello et al., PNAS 93: 4881, 1996.) and the VEGF transgenic mouse (Okamoto et al., Am. J. Pathol. 151: 281, 1997), there are fewer models  
25 of choroidal neovascularization (e.g., laser photocoagulation as described by Murata et al., IOVS 39: 2474, 1998). Subretinal neovascularization from the retinal rather than choroidal blood supply is also observed in VEGF transgenic animals (Okamoto et al., Am. J. Pathol. 151: 281, 1997). Hypoxic stimulation of VEGF expression is known to correlate with neovascularization in human ocular disease.

The pathologic hallmark of glaucomatous optic neuropathy is the selective death of retinal ganglion cells (RGCs) (Nickells, R.W., *J. Glaucoma* 5:345-356, 1996; Levin, L.A. and Louhab, A., *Arch. Ophthalmol.* 114:488-491, 1996.; Kerrigan, L.A., Zack, D.J., Quigley, H.A., Smith, S.D. and Pease, M.E., *Arch. Ophthalmol.* 115:1031-1035, 5 1997). Recent studies indicate that RGCs die with characteristics of apoptosis after injury to the axons of adult RGCs such as axotomy of the optic nerve (ON), and in glaucoma and anterior ischemic optic neuropathy in humans (Nickells, 1996). Thus, damage to the optic nerve by axotomy is used by many researchers as a model for selective apoptotic cell death of adult RGCs.

10 The loss of RGCs caused by ON transection in adult mammals varies from 50% to more than 90% depending on the techniques used to identify RGCs, the proximity of the lesion to the eye, and the age and species of the animal. For example, in a study in adult rats, in which retrogradely transported tracers were used to distinguish RGCs from displaced amacrine cells (Villegas-Pérez, M.P., Vidal-Sanz, M., Bray, G.M. and Aguayo, 15 A.J., *J. Neurosci.* 8:265-280, 1988). ON transection near the eye (0.5-1 mm) leads to the loss of more than 90% of the RGCs by 2 weeks. In contrast, in adult animals in which the ON was cut nearly 10 mm from the eye, 54% of RGCs survived by 3 months (Richardson, P.M., Issa, V.M.K. and Shemie, S., *J. Neurocytol.* 11:949-966, 1982.).

Briefly, the posterior pole of the left eye and the origin of the optic nerve 20 (ON) are exposed through a superior temporal intraorbital approach. A longitudinal excision of the ON dural sheath is performed. The ON is then gently separated from the dorsal aspect of this sheath and completely transected within the orbit, within 1 mm of the optic disc. Care is taken to avoid damage to the ophthalmic artery, which is located on the inferomedial dural sheath of the ON.

25 RGC survival and death following gene delivery can also be examined using two alternative models of ON injury: 1) ON crush; and (2) increased intraocular pressure. In the first model the ON is exposed, and then clamped at a distance of about one millimeter from the posterior pole using a pair of calibrated forceps as previously described (Li et al., *Invest. Ophthalmol. Vis. Sci.* 40:1004, 1999). In the second model, chronic

moderately elevated intraocular pressure can be produced unilaterally by cauterization of three episcleral vessels as described by Neufeld et al. in *PNAS* 17:9944, 1999).

A variety of animal models can be utilized for photoreceptor degeneration, including the RCS rat model, P23H transgenic rat model, the rd mouse, and the S334ter  
5 transgenic rat model.

Briefly, in the S334ter transgenic rat model, a mutation occurs resulting in the truncation of the C-terminal 15 amino acid residues of rhodopsin (a seven-transmembrane protein found in photoreceptor outer segments, which acts as a photopigment). The S334ter mutation is similar to rhodopsin mutations found in a subset  
10 of patients with retinitis pigmentosa (RP). RP is a heterogeneous group of inherited retinal disorders in which individuals experience varying rates of vision loss due to photoreceptor degeneration. IN many RP patients, photoreceptor cell death progresses to blindness. Transgenic S334ter rats are born with normal number of photoreceptors. The mutant rhodopsin gene begins expression at postnatal day 5 in the rat, and photoreceptor cell death  
15 begins at postnatal day 10-15. In transgenic line S334ter-3 , approximately 70% of the outer nuclear layer has degenerated by day 60 in the absence of any therapeutic intervention. The retinal degeneration in this model is consistent from animal to animal and follows a predictable and reproducible rate. This provides an assay for therapeutic effect by morphological examination of the thickness of the photoreceptor nuclear layer  
20 and comparison of the treated eye to the untreated (contralateral) eye in the same individual animal.

S334ter rats are utilized as a model for RP as follows. Briefly, S334ter transgenic rats are euthanized by overdose of carbon dioxide inhalation and immediately perfused intracardially with a mixture of mixed aldehydes (2% formaldehyde and 2.5 %  
25 glutaraldehyde). Eyes are removed and embedded in epoxy resin, and 1  $\mu$ m thick histological sections are made along the vertical meridian. Tissue sections are aligned so that the ROS and Müller cell processes crossing the inner plexiform layer are continuous throughout the plane of section to assure that the sections are not oblique, and the thickness of the ONL and lengths of RIS and ROS are measured. These retinal thickness

measurements are plotted and establish the baseline retinal degeneration rates for the animal model. The assessment of retinal thickness is as follows: briefly, 54 measurements of each layer or structure were made at set points around the entire retinal section. These data were either averaged to provide a single value for the retina, or plotted as a distribution of thickness or length across the retina. The greatest 3 contiguous values for ONL thickness in each retina is also compared in order to determine if any region of retina (e.g., nearest the injection site) showed proportionally greater rescue; although most of these values were slightly greater than the overall mean of all 54 values, they were no different from control values than the overall mean. Thus, the overall mean was used in the data cited, since it was based on a much larger number of measurements.

One particularly preferred line of transgenic rats, TgN(s334ter) line 4 (abbreviated s334ter 4) can be utilized for *in vivo* experiments. Briefly, in this rat model expression of the mutated opsin transgene begins at postnatal day P5 in these rats, leading to a gradual death of photoreceptor cells. These rats develop an anatomically normal retina up to P15, with the exception of a slightly increased number of pyknotic photoreceptor nuclei in the outer nuclear layer (ONL) than in non-transgenic control rats. In this animal model, the rate of photoreceptor cell death is approximately linear until P60, resulting in loss of 40-60% of the photoreceptors. After P60, the rate of cell loss decreases, until by one year the retinas have less than a single row of photoreceptor nuclei remaining.

### 20           3.     Methods of Administration

Gene delivery vectors of the present invention may be administered intraocularly to a variety of locations depending on the type of disease to be treated, prevented, or, inhibited, and the extent of disease. Examples of suitable locations include the retina (e.g., for retinal diseases), the vitreous, or other locations in or adjacent to the eye.

Briefly, the human retina is organized in a fairly exact mosaic. In the fovea, the mosaic is a hexagonal packing of cones. Outside the fovea, the rods break up the close hexagonal packing of the cones but still allow an organized architecture with cones rather

evenly spaced surrounded by rings of rods. Thus in terms of densities of the different photoreceptor populations in the human retina, it is clear that the cone density is highest in the foveal pit and falls rapidly outside the fovea to a fairly even density into the peripheral retina (see Osterberg, G. (1935) Topography of the layer of rods and cones in the human  
5 retina. *Acta Ophthal.* (suppl.) 6, 1-103; see also Curcio, C. A., Sloan, K. R., Packer, O., Hendrickson, A. E. and Kalina, R. E. (1987) Distribution of cones in human and monkey retina: individual variability and radial asymmetry. *Science* 236, 579-582).

Access to desired portions of the retina, or to other parts of the eye may be readily accomplished by one of skill in the art (see, generally Medical and Surgical Retina:  
10 Advances, Controversies, and Management, Hilel Lewis, Stephen J. Ryan, Eds., medical illustrator, Timothy C. Hengst. St. Louis: Mosby, c1994. xix, 534; see also *Retina*, Stephen J. Ryan, editor in chief, 2nd ed., St. Louis, Mo.: Mosby, c1994. 3 v. (xxix, 2559 p.).

The amount of the specific viral vector applied to the retina is uniformly  
15 quite small as the eye is a relatively contained structure and the agent is injected directly into it. The amount of vector that needs to be injected is determined by the intraocular location of the chosen cells targeted for treatment. The cell type to be transduced will be determined by the particular disease entity that is to be treated.

For example, a single 20-microliter volume (of  $10^{13}$  physical particle titer/ml  
20 rAAV) may be used in a subretinal injection to treat the macula and fovea. A larger injection of 50 to 100 microliters may be used to deliver the rAAV to a substantial fraction of the retinal area, perhaps to the entire retina depending upon the extent of lateral spread of the particles.

A 100- $\mu$ l injection will provide several million active rAAV particles into  
25 the subretinal space. This calculation is based upon a titer of  $10^{13}$  physical particles per milliliter. Of this titer, it is estimated that 1/1000 to 1/10,000 of the AAV particles are infectious. The retinal anatomy constrains the injection volume possible in the subretinal space (SRS). Assuming an injection maximum of 100 microliters, this would provide an



infectious titer of  $10^8$  to  $10^9$  rAAV in the SRS. This would have the potential of infecting all of the  $\sim 150 \times 10^6$  photoreceptors in the entire human retina with a single injection.

Smaller injection volumes focally applied to the fovea or macula may adequately transfect the entire region affected by the disease in the case of macular  
5 degeneration or other regional retinopathies.

Gene delivery vectors can alternately be delivered to the eye by intraocular injection into the vitreous. In this application, the primary target cells to be transduced are the retinal ganglion cells, which are the retinal cells primarily affected in glaucoma. In this application, the injection volume of the gene delivery vector could be substantially larger,  
10 as the volume is not constrained by the anatomy of the subretinal space. Acceptable dosages in this instance can range from 25  $\mu$ l to 1000  $\mu$ l.

#### 4. Assays

A wide variety of assays may be utilized in order to determine appropriate dosages for administration, or to assess the ability of a gene delivery vector to treat or  
15 prevent a particular disease. Certain of these assays are discussed in more detail below.

##### a. Electroretinographic analysis

Electroretinographic analysis can be utilized to assess the effect of gene delivery administration into the retina. Briefly, rats are dark adapted overnight and then in dim red light, then anesthetized with intramuscular injections of xylazine (13 mg/kg) and  
20 ketamine (87 mg/kg). Full-field scotopic ERGs are elicited with 10- $\mu$ sec flashes of white light and responses were recorded using a UTAS-E 2000 Visual Electrodiagnostic System (LKC Technologies, Inc., Gaithersburg, MD). The corneas of the rats are anesthetized with a drop of 0.5% proparacaine hydrochloride, and the pupils dilated with 1% atropine and 2.5% phenylephrine hydrochloride. Small contact lenses with gold wire loops are  
25 placed on both corneas with a drop of 2.5% methylcellulose to maintain corneal hydration. A silver wire reference electrode is placed subcutaneously between the eyes and a ground electrode is placed subcutaneously in the hind leg. Stimuli are presented at intensities of -

1.1, 0.9 and 1.9 log cd m<sup>-2</sup> at 10-second, 30-second and 1-minute intervals, respectively. Responses are amplified at a gain of 4,000, filtered between 0.3 to 500 Hz and digitized at a rate of 2,000 Hz on 2 channels. Three responses are averaged at each intensity. The a-waves are measured from the baseline to the peak in the cornea-negative direction, and b-waves are measured from the cornea-negative peak to the major cornea-positive peak. For quantitative comparison of differences between the two eyes of rats, the values from all the stimulus intensities are averaged for a given animal.

b. Retinal tissue analysis

As described in more detail above and below, retinal tissue analysis can also be utilized to assess the effect of gene delivery administration into the retina.

5. Pharmaceutical Compositions

Gene delivery vectors may be prepared as a pharmaceutical product suitable for direct administration. Within preferred embodiments, the vector should be admixed with a pharmaceutically acceptable carrier for intraocular administration. Examples of suitable carriers are saline or phosphate buffered saline.

DEPOSIT INFORMATION

The following material was deposited with the American Type Culture Collection:

<u>Name</u>	<u>Deposit Date</u>	<u>Accession No.</u>
PKm201bFGF-2	3/11/99	#207160
PD10-Kan-FGF-2-Sc		

20

The above material was deposited by Chiron Corporation with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, telephone 703-365-2700. This deposit will be maintained under the terms of the Budapest

Treaty on the International Recognition of the Deposit of Microorganisms for purposes of Patent Procedure. The deposit will be maintained for a period of 30 years following issuance of this patent, or for the enforceable life of the patent, whichever is greater. Upon issuance of the patent, the deposits will be available to the public from the ATCC without  
5 restriction.

This deposit is provided merely as a convenience to those of skill in the art, and is not an admission that a deposit is required under 35 U.S.C. § 112. The nucleic acid sequence of this deposit, as well as the amino acid sequence of the polypeptide encoded thereby, are incorporated herein by reference and should be referred to in the event of an  
10 error in the sequence described herein. A license may be required to make, use, or sell the deposited materials, and no such license is granted hereby.

The following examples are offered by way of illustration, and not by way of limitation.

## EXAMPLES

### EXAMPLE 1

#### CONSTRUCTION OF A RAAV VECTOR EXPRESSING FGF-2

5           pKm201CMV is an AAV cloning vector in which an expression cassette, consisting of a CMV immediate early promoter/enhancer and a bovine growth hormone (BGH) polyadenylation site, is flanked by inverted terminal repeat (ITR) sequences from AAV-2. Briefly, pKm201CMV was derived from pKm201, a modified AAV vector plasmid in which the ampicillin resistance gene of pEMBL-AAV-ITR (see Srivastava,  
10 (1989) *Proc. Natl. Acad. Sci. USA* 86:8078-8082) had been replaced with the gene for kanamycin resistance. The expression cassette from pCMVlink, a derivative of pCMV6c (see Chapman, *Nucleic Acids Res.* 19:193-198 (1991)) in which the BGH poly A site has been substituted for the SV40 terminator; was inserted between the ITRs of pKm201 to generate pKm201CMV.

15           pKm201bFGF-2 was constructed by cloning the following, in order, into the multiple cloning site of pKm201CMV: the encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES), the bovine FGF-2 cDNA, and the human growth hormone polyadenylation sequence. The cDNA for FGF-2 has two mutations that change amino acid 121 from serine to threonine and amino acid 137 from proline to serine. The DNA  
20 sequence of pKm201bFGF-2 is shown in Figure 2 and the plasmid has been deposited with the American Type Culture Collection (ATCC).

          rAAV vector particles were produced by a triple transfection protocol (*Nucleic Acids Res.* 24:596-601, 1996; *J. Exp. Med.* 179:1867-1875, 1994). Briefly, human embryonic kidney 293 cells, grown to 50% confluence in a 10 layer Nunclon cell factory  
25 (Nalge Nunc, Int., Naperville, IL), were co-transfected with 400 µg of helper plasmid pKSrep/cap (*Hum. Gene Ther.* 9:477-485, 1998) 400 µg of vector plasmid, and 800 µg of adenovirus plasmid pBHG10 (Microbix Biosystems, Inc., Toronto, Ontario) using the calcium phosphate co-precipitation method. Forty-eight hours after co-transfection, media

was replaced with IMDM + 10% FBS containing adenovirus type 5 dl312 at a multiplicity of infection (MOI) of 2. Seventy-two hours after infection cells were harvested and resuspended in HEPES buffer (200 ml total) and lysed by three cycles of freezing and thawing. Cell debris was removed by centrifugation at 12,000X g for 20 min. Packaged  
5 rAAV was purified from adenovirus by two rounds of cesium chloride equilibrium density gradient centrifugation. Residual adenovirus contamination was inactivated by heating at 56°C for 45 min. Though three plasmids were used in the production of rAAV vector in this example, it is possible to combine the rAAV vector construct and the AAV helper gene construct on one plasmid. This would allow rAAV to be produced by transfecting 293  
10 cells with two plasmids. Alternatively, one could add the adenovirus helper genes to this plasmid to make a single plasmid containing all that is required to make rAAV particles.

To estimate total number of rAAV particles, the virus stock was treated with DNase I, and encapsidated DNA was extracted with phenol-chloroform, and precipitated with ethanol. DNA dot blot analysis against a known standard was used to determine titer  
15 (*Blood* 76:1997-2000, 1990).

To assay for adenovirus contamination, 293 cells were infected with 10 µl of purified rAAV stock and followed for any signs of cytopathic effect. All stocks were negative for adenovirus contamination (level of detection greater than or equal to 100 PFU/ml).

20 To assay for wild type AAV, 293 cells were co-infected with serial dilutions of rAAV stocks and adenovirus dl312 at a MOI of 2. Three days later the cells were harvested, lysed by three cycles of freezing/thawing, and centrifuged to remove cell debris. The supernatant was heat inactivated (56°C for 10 min) and fresh plates of 293 cells ( $6 \times 10^6$ ) were infected in the presence of adenovirus dl312 at a MOI of 2. Forty-eight hours  
25 after infection, low molecular-weight DNA was isolated (*J. Mol. Biol.* 26:365-369, 1967) subjected to agarose gel electrophoresis, and transferred to a nylon membrane. The membrane was hybridized with a biotinylated oligonucleotide probe specific for the AAV capsid region. The wild type AAV titer was defined as the highest dilution of rAAV vector

stock demonstrating a positive hybridization signal. The rAAV preparations contained less than 1 wild type AAV genome per  $10^9$  rAAV genomes.

## EXAMPLE 2

### INFECTION OF CELLS WITH RAAV-CMV-FGF-2 RESULTS IN THE EXPRESSION OF FGF-2

5

293 cells were plated the day before infection at  $5 \times 10^5$  cells/well in 6-well plates and were infected with rAAV-CMV-bFGF-2 virus, prepared as described above in Example 1, at different multiplicities of infection (MOI) with and without etoposide ( $3\mu\text{M}$ ). Etoposide is a topoisomerase inhibitor which has been shown to increase transduction efficiency of rAAV vectors (*Proc. Natl. Acad. Sci. USA*, 92:5719-5723, 1995). Forty-eight hours after infection, culture supernatant was collected and cells were lysed in 0.5 mL 1x lysis buffer (100 mM NaCl, 20 mM Tris pH 7.5, 1 mM EDTA, 0.5% NP40, and 0.5% deoxycholate). FGF-2 in the supernatants and lysates was assayed by ELISA (cat. # DFB00, R & D Systems, Minneapolis, MN) following manufacturer's instructions. The results are shown below in Table 1.

TABLE 1

### FGF-2 PRODUCTION IN 293 CELLS FOLLOWING INFECTION WITH RAAV-FGF-2

#### Culture Medium Supernatant (1.5 ml)

sample	infection MOI	Etoposide	FGF2 protein
1	0	-	<5 pg/ml
2	$2 \times 10^5$	-	<5 pg/ml
3	$2 \times 10^4$	-	<5 pg/ml
4	$2 \times 10^3$	-	<5 pg/ml
1	0	+	<5 pg/ml
2	$2 \times 10^5$	+	106 pg/ml $\approx$ 300pg/24h/ $10^6$ cells
3	$2 \times 10^4$	+	<5 pg/ml
4	$2 \times 10^3$	+	<5 pg/ml

## Cell Lysate (0.5 ml)

sample	infection MOI	Etoposide	FGF2 protein
1	0	-	8.95 ng/ml
2	$2 \times 10^3$	-	114. ng/ml
3	$2 \times 10^4$	-	18.8 ng/ml
4	$2 \times 10^5$	-	11.3 ng/ml
1	0	+	5.05 ng/ml
2	$2 \times 10^3$	+	296. ng/ml $\approx 300\text{ng}/24\text{h}/10^6\text{ cells}$
3	$2 \times 10^4$	+	48.0 ng/ml
4	$2 \times 10^5$	+	13.2 ng/ml

## EXAMPLE 3

## CONSTRUCTION OF RAAV VECTORS

A. Construction of pD10-bFGF-2

5 The pD10 AAV vector is constructed by replacing the AAV gene encoding sequences of pD-10 (see Wang, X. et al. *J. Virol.* 71:3077 (1997), with the CMV promoter, multiple cloning site, and BGH polyadenylation sequences from pKm201CMV. Briefly, oligonucleotides 5'-ggattttaa acttgcgcc gcggaattc gactctagc c-3' (SEQ I.D. No. \_\_\_\_)

10 and 5'-gctgcccgagg actgctagc tggatgatcc tccagcgagg ggatctcatg -3' (SEQ I.D. No. \_\_\_\_) are used to amplify the CMV expression cassette from pKm201CMV. The product of this PCR amplification is digested with SmaI and DraI and cloned into pD-10 digested with EcoRV. This new vector is named pD10-CMV.

To construct pD10-bFGF-2, the synthetic gene for bovine FGF-2 (see US Patent 5,464,774 for sequence) is digested with EcoRI and SalI, treated with T4 polymerase

15 to blunt the ends, and then cloned into the StuI site of pD10-CMV. The synthetic gene described above encodes the mature, processed form of bovine FGF-2.

B. Construction of a rAAV Vector Expressing FGF-2-Sc.

pD10-K-FGF-2-Sc (see Figure 31) was constructed by cloning the FGF-2 full length humanized bovine cDNA obtained from Scios, into the pD10 vector backbone

containing the kanamycin (Kan) resistance gene. This cDNA contains the mutations at amino acid positions 121 and 137 described in example 1. Briefly, the FGF-2-Sc cDNA was digested from the parent plasmid with the enzyme NdeI, the ends blunted with T4 DNA polymerase, cut with the restriction enzyme HindIII, and cloned into the pD10-CMV vector which had been digested with the enzymes StuI and HindIII. The nucleotide sequence of pD10-K-FGF-2-Sc is illustrated in Figure 32.

C. Infection of Cells with rAAV-FGF-2-Sc Results in the Expression of FGF-2

293 cells were infected as in example 2, with the following modifications: 4 x 10<sup>5</sup> cells/well were plated in a 12 well dish, and all wells contained 3 uM etoposide. Three different particle numbers of FGF-2-virus, and a negative control CMV-lacZ virus were used to infect the cells. 48 hours after infection, tissue culture media was collected and cells lysed in 100 ul lysis buffer containing Triton-X 100 and Complete™ protein inhibitor cocktail (Boehringer Mannheim, Germany). FGF-2 protein in the media and lysates was assayed by ELISA. The results are shown below in Table 2 below.

TABLE 2.

FGF-2 PRODUCTION IN 293 CELLS FOLLOWING INFECTION WITH RAAV  
D10-K-FGF-2-Sc

Vector	Viral Particles	Lysates(pg/mL)	Culture media (pg/mL)
D10-K-FGF-2-Sc	1 x 10 <sup>10</sup>	324492.919	438.621
D10-K-FGF-2-Sc	1 x 10 <sup>9</sup>	32876.106	46.984
D10-K-FGF-2-Sc	1 x 10 <sup>8</sup>	6950.039	14.649
CMV -lacZ	1 x 10 <sup>10</sup>	2327.527	17.096



## EXAMPLE 4

## CONSTRUCTION OF RAAV VECTORS WHICH EXPRESS FGF5 AND FGF18

A. Cloning FGF-5 into the pD10-CMV rAAV Vector.

The FGF-5 coding region (see U.S. Serial No. 08,602,147) was cloned into  
5 the rAAV pD10-CMV vector by digestion with the enzymes SacII and XmnI, resulting in  
an 814 bp fragment. This removed an ORF (ORF-1) upstream of and overlapping with the  
FGF-5 coding region. The ends of the FGF-5 fragment were then blunted with T4 DNA  
polymerase, and it was cloned into the rAAV pD10-CMV vector linearized with StuI. This  
vector contains a 1353 bp insertion of a bacteriophage Phi X174 HaeIII fragment.

10 The pD10-CMV-FGF-5 vector is illustrated schematically in Figure 3. In  
summary, this plasmid contains the CMV immediate/early enhancer + promoter, the CMV  
intron A, an FGF-5 coding region, the bovine growth hormone polyA site, and AAV ITR  
sequences. There is a 1353 bp insertion of PhiX 174 bacteriophage DNA cloned into the  
NotI site between one ITR and the CMV immediate early enhancer + promoter region.

15 B. Packaging and Functional Analysis of FGF-5 rAAV.

rAAV virus was packaged using a triple transfection method as described in  
Example 1. However, rather than cesium chloride equilibrium density gradient  
centrifugation, heparin sulfate column chromatography is utilized. More specifically, a cell  
pellet is resuspended in TNM buffer: 20mM Tris pH 8.0, 150mM NaCl, 2mM MgCl<sub>2</sub>.  
20 Deoxycholic Acid is added to 0.5% to lyse the cells. 50 U/ml Benzonase is added and the  
lysed cells are incubated at 37 degrees to digest any nucleic acids. The cell debris is  
pelleted and the supernatant is filtered through a 0.45um filter and then a 0.22um filter.  
The virus is then loaded onto a 1.5ml Heparin sulfate column using the Biocad HPLC. The  
column is then washed with 20mM Tris pH 8.0, 100mM NaCl. The rAAV particles are  
25 eluted with a gradient formed with increasing concentrations of NaCl. The fractions under  
the peak are pooled and filtered through a 0.22um filter before overnight precipitation with

8% PEG 8000.  $\text{CaCl}_2$  is added to 25mM and the purified particles are pelleted and then resuspended in HBS#2: 150mM NaCl, 50mM Hepes pH7.4.

Briefly,  $8 \times 10^8$  or  $8 \times 10^9$  particles of the resulting FGF-5 virus were used to infect 293 cells, which were simultaneously treated with 3  $\mu\text{M}$  etoposide to enhance viral expression levels. At 24 hours post-infection, tissue culture media and cell lysates were harvested and analysed by Western blotting. Briefly, protein samples were run on a 4-20% tris-glycine gradient gel, and transferred to nitrocellulose by standard procedures. After blocking with 5% milk in PBS, the membrane was incubated with an anti-human FGF-5 antibody (R and D systems, made in goat) at a dilution of 1:1,000 for one hour at room temperature. After the membrane was washed 3 times in PBS + 0.05% Tween-20, it was incubated with an anti-goat secondary antibody conjugated to peroxidase (1:5,000 dilution). The membrane was then washed and the FGF-5 protein detected by chemiluminescence.

Results of the Western blot are shown in Figure 4. Briefly, lane 1 represents 50 ng of the 29.5 Kd recombinant FGF-5 protein (R and D systems). Lane 2, media from cells infected with  $8 \times 10^9$  viral particles and treated with etoposide, shows no FGF-5 expression. Lane 3 is an uninfected cell lysate control. Lane 4 and 5 are lysates from cells infected with  $8 \times 10^8$  or  $8 \times 10^9$  viral particles, respectively, and Lanes 6 and 7 are lysates from cells infected with  $8 \times 10^8$  or  $8 \times 10^9$  viral particles and treated with 3  $\mu\text{M}$  etoposide. Lanes 4-7 all show positive FGF-5 expression. Lane 8 is a negative control of lysate from uninfected cells.

In summary, although the FGF-5 signal sequence was intact, FGF-5 protein was detected in the cell lysate only.

#### C. Cloning FGF-5 Lacking a Signal Sequence, into rAAV pD10-CMV.

Oncogenic activity is associated with the wild-type FGF-5 molecule (Zhan et al., 1988; Bates et al., 1991). To improve its safety, the codons for the first 21 amino acids of FGF-5's signal sequence were removed by PCR amplification of the above pD10-CMV-FGF-5 plasmid with the following primers: AGA/TAT/AAG/CTT/AC

C/ATG/GGT/GAA/AAG/CG T/CTC/GCC/CCC/AAA (5', 5FGFMUTB; SEQ I.D. No. )  
and CGC/GCG/CTC/GAG/AC C/ATG/AGG/AAT/ATT/AT C/CAA/AGC/GAA/ACT (3',  
3FGF5WT; SEQ I.D. No. \_\_\_\_). The 5' primer contains point mutations which destabilize  
G/C rich hairpin structures of the FGF-5 mRNA, and should increase levels of gene  
5 expression. The PCR product was digested with HindIII and XhoI (restriction sites  
introduced by the primers), and cloned by standard methods, into the pD10 vector digested  
with the same enzymes. The pD10-CMV-FGF-5 (sig-) vector is illustrated schematically in  
Figure 5.

In summary, the pD10-CMV-FGF-5 (sig-) plasmid contains the CMV  
10 immediate/early enhancer + promoter, the CMV intron A, the FGF-5 coding region with  
the modifications described in Example C above, the bovine growth hormone polyA site,  
and the AAV ITR sequences. There is a 1353 bp insertion of PhiX 174 bacteriophage  
DNA clones into the NotI site between one ITR and the CMV immediate early enhancer +  
promoter region.

15 D. Western Analysis of 293 Cells Transfected with pD10-CMV-FGF-5 (sig-).

Expression of FGF-5 protein was demonstrated by transient transfection of  
293 cells with the plasmid pD10-CMV-FGF-5 (sig-), by standard methods. After 48 hours,  
tissue culture media and cell lysates were harvested. Western analysis was performed with  
an anti-human FGF-5 antibody (R and D systems) as described above.

20 Results of the Western analysis are provided below in Figure 6. Briefly,  
lane 1 represents 50 ng of the 29.5 Kd recombinant FGF-5 protein (R and D systems).  
Lanes 2 and 3, showing FGF-5 expression, are cell lysates from 293 cells transfected with  
two different clones of the pD10-CMV-FGF-5 sig- plasmid. Lane 4 is lysate from cells  
transfected with a negative control plasmid CMV-Epo. Lanes 5, 6 and 7 represent media  
25 from cells transfected with different clones of the pD10-CMV-FGF-5 sig- plasmid,  
respectively, and the CMV-Epo plasmid. As is evident from this figure, FGF-5 protein was  
detected in the cell lysate only.

E. Generation of FGF-5 (signal -) rAAV.

FGF-5 (sig-) rAAV virus is packaged using the triple transfection method described in more detail above.

F. Cloning FGF-18 into the pD10-CMV rAAV Vector.

5           The FGF-18 coding region (see U.S. Provisional Application Serial No. 60/083,553) was cloned into the pD10-CMV vector as a PstI to EcoRV fragment, using restriction sites found in both the FGF-18 and the multiple cloning site of the pD10-CMV vector. The vector contains a 1353 bp insertion of PhiX174 bacteriophage DNA (see Example A).

10           A schematic illustration of pD10-CMV-FGF-18 is provided in Figure 7. Briefly, this plasmid contains the CMV immediate/early enhancer + promoter, the CMV intron A, the FGF-18 coding region, the bovine growth hormone polyA site, and the AAV ITR sequences. There is a 1353 bp insertion of PhiX 174 bacteriophage DNA cloned into the NotI site between one ITR and the CMV immediate early enhancer + promoter region.

15 G. Analysis of 293 Cells Transfected with pD10-CMV-FGF-18 Plasmid.

          Expression of FGF-18 protein was assessed by transient transfection of 293 cells followed by Western analysis, using standard methods. Cell lysates and tissue culture media were harvested at 48 hours post transfection. An anti-peptide FGF-18 rabbit polyclonal antibody, generated against a selected polypeptide from recombinant FGF-18, 20 was used at a dilution of 1:2,500 for one hour at room temperature. The secondary antibody, an anti-rabbit IgG conjugated to peroxidase, was used at a dilution of 1:25,000.

          Results of the Western analysis are provided in Figure 8. Briefly, lanes 1-3 represent 1, 2 and 10 ul of tissue culture media from cells transfected with the pD10-CMV-FGF-18 plasmid. Lane 4 is blank. Lanes 5, 6 and 7 contain 2, 10 and 20 ul of lysate from 25 the transfected cells. Lanes 8 and 9 are negative controls; 20 ul of tissue culture media and cell lysate, respectively, from uninfected cells. Lane 10 contains a positive control; an FGF-18-maltose binding protein fusion ((MBP); predicted size = 80 Kd, larger than the FGF-18 protein).

H. Packaging of the pD10CMV-FGF-18 plasmid into rAAV particles

FGF-18 rAAV virus was generated by the triple transfection method.

EXAMPLE 5

AAV – LACZ INJECTED RETINA

5 A. Subretinal injection of rAAV

Albino Sprague-Dawley rats were injected at 14 –15 days postnatal (P14-P15). Animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. Subretinal injections of 2-3 $\mu$ l of AAV-  
10 CMV-Lac-Z were then made by inserting a blunt 32 gauge needle through the opening and delivering the rAAV suspension into the subretinal space in the posterior retina. The contralateral eye was either uninjected, injected subretinally with PBS, or with a control rAAV containing a reporter gene.

B. Staining Protocol

15 Cryosections of the retina were stained with Bluo-gal for b-galactosidase reaction product of lacZ. In all wild type rats tested (3), positive staining was visible in the interior of the whole eyecup upon gross examination (see Figure 9). 100 $\mu$ m thick agarose or 20 $\mu$ m thick cryosections of retinas indicated that most of the b-gal positive staining localized to the photoreceptors. There were a small number of LacZ positive retinal  
20 ganglion cells observed.

C. Anti-b-galactosidase immunocytochemistry

Sections from 3 wildtype and 2 transgenic rats were stained with a polyclonal antibody against b-galactosidase. These results were comparable to the bluo-gal results, primarily demonstrating photoreceptor-specific staining. Two out of five rats  
25 showed no positive staining.

#### D. Results

Subretinal injection of 2  $\mu$ l of AAV-CMV-lacZ effectively transduced a large number of photoreceptor and retinal pigment epithelial (rpe) cells following a single intraocular inoculation of AAV-CMV-lacZ into the subretinal space (SRS) of the rat eye.

- 5 The lateral extent of lacZ reporter gene expression was typically 1/3 to 1/2 of the retinal expanse following a single AAV-CMV-LacZ injection. This finding was confirmed by blue-gal staining of the b-galactosidase reaction product of the lacZ gene as well as by immunocytochemistry using an antibody specific for b-galactosidase. The AAV-CMV-lacZ vector was effective at transducing photoreceptor and RPE cells in both the normal  
10 (wildtype) and affected, degenerating (transgenic) rat retina.

### EXAMPLE 6

#### RETINAL TISSUE ANALYSIS OF rAAV-FGF-2 INFECTED CELLS, VS. CONTROLS

##### A. Subretinal injection of rAAV

- Line 3 albino transgenic rats (P23H-3) on an albino Sprague-Dawley  
15 background (produced by Chrysalis DNX Transgenic Sciences, Princeton, NJ) were injected at the ages of P14 or P15. Animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. The subretinal injections of 2  $\mu$ l were then made by inserting a blunt 32 gauge needle through  
20 the opening and delivering the rAAV suspension into the subretinal space in the posterior retina. The intent was to inject into the subretinal space of the posterior superior hemisphere, but sometimes upon histological examination it was found that the injection site was located just inferior to the optic nerve head. The opposite eye was either uninjected, injected subretinally with PBS, with control rAAV containing no neurotrophin  
25 or containing proteins not known to possess neurotrophic properties.

B. Histopathology Protocol / Retinal tissue analysis

The rats were euthanized by overdose of carbon dioxide inhalation and immediately perfused intracardially with a mixture of mixed aldehydes (2% formaldehyde and 2.5 % glutaraldehyde). Eyes were removed and embedded in epoxy resin, and 1  $\mu$ m thick histological sections were made along the vertical meridian. Tissue sections were aligned so that the ROS and Müller cell processes crossing the inner plexiform layer were continuous throughout the plane of section to assure that the sections were not oblique, and the thickness of the ONL and lengths of RIS and ROS were measured as described (see e.g., LaVail, et al. PNAS 1992, 89(23):11249-53 and LaVail et al., Invest. Ophthalmol. Vis. Sci 1998, 39(3):592-602). Briefly, 54 measurements of each layer or structure were made at set points around the entire retinal section. These data were either averaged to provide a single value for the retina, or plotted as a distribution of thickness or length across the retina. The 3 greatest contiguous values for ONL thickness was also compared in each retina, to determine if any region of retina (e.g., nearest the injection site) showed proportionally greater rescue; although most of these values were slightly greater than the overall mean of all 54 values, they were no different from control values than the overall mean. Thus, the overall mean was used in the data cited, since it was based on a much larger number of measurements.

C. Results

Two surgical methods of delivery of rAAV-CMV-FGF2 were completed, intravitreal and subretinal injection.

1. Intravitreal injection

RAAV-CMV-FGF-2 was injected into the right eye of nine transgenic S334ter rats after day P15 (the left eye was not injected). S334(4) transgenic animals were used to assess the rescue effect of rAAV-CMV-FGF-2 on degenerating photoreceptor cells when delivered by intravitreal injection. The rats were all sacrificed at age p60 and the embedded in plastic and sectioned to assess morphology and therapeutic effect as assayed

by the preservation of thickness of outer nuclear layer. Superior and inferior regions of eyecup are quantitated by measuring the ONL thickness using a BioQuant morphometric measuring system (BioQuant). Injected eyes were evaluated along with uninjected control eyes.

5

Control Left superior – 16.52 +/- 2.77 um

Injected Right superior – 19.71 +/- 5.27 um

Control Left inferior – 22.64 +/- 2.11 um

10

Injected Right inferior – 26.47 +/- 3.55 um

Based upon these results it was evident that there is a rescue effect of AAV-CMV-FGF-2 when delivered intraocularly into the vitreous cavity.

## 2. Subretinal injection of rAAV-CMV-FGF-2

15

Experiment A. - Location of injection – subretinal , 7 rats-both right and left eyes injected, 3 rats-(left eye = uninjected). Number of rats injected – 10 rats all wild type p15 on day of injection. One rat was sacrificed every week starting at week 2. Expression of FGF-2 was assessed, as well as any signs of inflammation or neovascularization.

Experiment B. - Location of injection – subretinal, 5 rats- right eyes injected w/vector left eyes injected with PBS, 4 rats- right eyes injected w/vector (left eye = uninjected). Number of rats injected – 11 transgenic S334(4) rats – all were p15 on day of injection. The rats were sacrificed at age p60 and the embedded in plastic and sectioned to assess histopathology and number of surviving photoreceptor cells. .

Anatomic indication of therapeutic effect (photoreceptor rescue) was assessed histologically. Briefly, eyes injected with rAAV-CMV-FGF2 retained significantly more photoreceptors at P60, P75 and P90 than uninjected contralateral control eyes of the same animal. Retinas receiving a subretinal injection of AAV-CMV-FGF2 at



P14-15 retained 71% of the normal ONL thickness, compared to about 47% in the uninjected controls (see Figures 11, 12, 13 and 14).

There was little or no rescue in PBS-injected control eyes ( $p > 0.169$  in all cases). This is consistent with previous reports that needle injury to the retina in young rats (P14-P15) does not rescue photoreceptors or up-regulate bFGF mRNA expression.

### 3. Subretinal injection of rAAV-CMV-FGF-2

Two to three microliters of rAAV-CMV-FGF-2 vector was injected into the subretinal space between the photoreceptors and the adjacent retinal pigment epithelium at P14 or P15. Rats were sacrificed and eyes examined at time points between P60-P90. At these ages in uninjected control eyes of S334ter rats, the ONL thickness, which is an index of photoreceptor cell number, was reduced to about 60% of normal.

Evidence of anatomic rescue was found to be significant to the  $p = .005$  confidence level in retinas transfected by rAAV-CMV-FGF-2 when compared to the control AAV vectors or sham injection of PBS by ANOVA (analysis of Variance statistical measures). JMP statistical analysis software (Copyright (c) 1999 SAS Institute Inc. Cary, North Carolina, USA).

## EXAMPLE 7

### ANTIBODY STAINING OF RAAV-FGF-2 INFECTED CELLS

#### A. Injection Protocol

Albino Sprague-Dawley rats were injected with rAAV-CMV-FGF-2 at the ages of P14 or P15 essentially as follows. Briefly, wild-type animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. The subretinal injections of 2-3  $\mu$ l of rAAV-CMV-FGF-2 were then made by inserting a blunt 32 gauge needle through the opening and delivering the rAAV suspension

into the subretinal space in the posterior retina. The contralateral eye was either uninjected, injected subretinally with PBS, wild-type rAAV, or with rAAV-CMV-lacZ.

#### B. Staining Protocol

Fixed eyecups were embedded in OCT and cryosectioned in 20um thick sections. Sections from 10 wt rats were stained with antibody to FGF-2. (primary- anti-FGF-2 1:500 (commercial antibody purchased from R&D systems) (secondary-anti-goat Cy3 conjugate (Sigma, St. Louis. MO)

#### C. Results

Immunohistochemistry was used to look for expression of FGF-2 in the eye. Two rats were examined every week starting at 3 weeks post-injection. Retinas were examined for expression of FGF-2 and also examined histopathologically for signs of inflammation or neovascularization.

Results are shown in Figure 15. Briefly, expression of FGF-2 was found in retinal photoreceptor cells as well as RPE cells at 35 days following inoculation with 2-3 ul of rAAV-CMV-FGF-2. Less significant expression was noted in retinal bipolar interneurons and retinal ganglion cells (RGCs) following injection into the subretinal space (SRS). No significant staining above background was observed in sections injected with PBS or rAAV-CMV-lacZ vectors.

### EXAMPLE 8

RETINAL TISSUE ANALYSIS OF RAAV-FGF-5 (SIG-) AND -18 INFECTED CELLS, VS. CONTROLS

#### A. Subretinal injection of rAAV

Line 4 albino transgenic rats (S334ter-4) on an albino Sprague-Dawley background (produced by Chrysalis DNX Transgenic Sciences, Princeton, NJ) were injected at age P15. Animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. The subretinal injections of

2.5 µl were then made by inserting a blunt 32 gauge needle through the opening and delivering the rAAV suspension into the subretinal space in the posterior retina. The opposite eye was either uninjected, injected subretinally with PBS, with control rAAV containing no neurotrophin or containing proteins not known to possess neurotrophic properties.

B. Histopathology Protocol / Retinal tissue analysis

The rats were euthanized by overdose of carbon dioxide inhalation and immediately perfused intracardially with a mixture of mixed aldehydes (2% formaldehyde and 2.5 % glutaraldehyde). Eyes were removed and embedded in epoxy resin, and 1 µm thick histological sections were made along the vertical meridian. Tissue sections were aligned so that the ROS and Müller cell processes crossing the inner plexiform layer were continuous throughout the plane of section to assure that the sections were not oblique, and the thickness of the ONL was measured as described (LaVail, et al). Briefly, 54 measurements of each layer or structure were made at set points around the entire retinal section. The 27 measurements from the inferior region and the superior region of the retina were averaged separately to give two values for each eye. This separation was made because the retina degenerates at different rates in these two regions of the S334ter-4 animal model.

C. Results

Sub-retinal injections of both rAAV-CMV-FGF-5 (sig-) and rAAV-CMV-FGF-18 were performed.

1. Sub-retinal injection of rAAV-CMV-FGF-5 (sig-)

Experiment. - Location of injection – subretinal, 3 rats- right eyes injected w/vector left eyes injected with PBS, 8 rats- right eyes injected w/vector left eyes injected with rAAV-CMV-LacZ, 4 rats- right eyes injected w/vector (left eye = uninjected). Number of rats injected – 15 transgenic S334ter-4 rats – all were p15 on day of injection.

The rats were sacrificed at age p60. The retinas were embedded in plastic and sectioned to assess histopathology and number of surviving photoreceptor cells.

Anatomic indication of therapeutic effect (photoreceptor rescue) was assessed histologically. The injection of rAAV-CMV-FGF-5 (sig-) resulted in significant rescue of photoreceptors, compared to PBS injected, rAAV-CMV-LacZ injected, and uninjected eyes (see Figure 33). The rescue was significant to the  $p=.05$  confidence level for all three comparisons, by ANOVA (analysis of Variance statistical measures). JMP statistical analysis software (Copyright (c) 1999 SAS Institute Inc. Cary, North Carolina, USA).

## 10           2.     Sub-retinal injection of rAAV-CMV-FGF-18

Experiment. - Location of injection – subretinal, 3 rats- right eyes injected w/vector left eyes injected with PBS, 3 rats- right eyes injected w/vector left eyes injected with rAAV-CMV-LacZ, 4 rats- right eyes injected w/vector (left eye = uninjected). Number of rats injected – 10 transgenic S334ter-4 rats – all were p15 on day of injection.

15   The rats were sacrificed at p60, and the retinas embedded in plastic and sectioned.

Eyes injected with rAAV-CMV-FGF-18 retained significantly more photoreceptors at P60 than PBS injected, rAAV-CMV-LacZ injected, or uninjected control eyes. Each comparison, by ANOVA, was statistically significant to the  $p=.05$  confidence level.

20

## EXAMPLE 9

### IN VIVO DELIVERY TO RETINAL GANGLION CELLS (RGCs)

#### A.     Intra-vitreous injection of AAV vectors

All surgical procedures were performed in female adult Sprague-Dawley rats (180-200 g; Charles River Breeders) under general anesthesia (7% chloral hydrate; 0.42 mg per g of body weight, i.p.) in accordance with the Use of Animals in Neuroscience

25

Research and McGill University Animal Care Committee guidelines for the use of experimental animals.

Briefly, rAAV-CMV-lacZ (5  $\mu$ l; see above) was injected into the vitreous chamber in the superior (dorsal) hemisphere of the retina using a posterior approach as described (Di Polo, PNAS, 1998). Control eyes were injected with equal volumes of Hepes-buffered saline (HBS, virus vector).

#### B. Identification of RPCs

For visualization of RGCs, neurons were retrogradely labeled with the fluorescent tracer Fluorogold (Fluorochrome, Englewood, CO) at 2% in 0.9% NaCl containing 10% dimethyl sulfoxide by application of the tracer to both superior colliculi 7 days prior to analyses as described (Vidal-Sanz *et al.*, 1988). Anesthetized rats were then perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) and the eyes were immediately enucleated. The anterior part of the eye and the lens were removed and the remaining eye cup was immersed in the same fixative for 2 hr at 4°C. Eye cups were cryoprotected in graded sucrose solutions (10-30% in PB) for several hours at 4°C, embedded in O.C.T. compound (Tissue-Tek, Miles Laboratories, Elkhart, IN) and frozen in a 2-methylbutane/liquid nitrogen bath. Retinal radial cryosections (12-15  $\mu$ m), obtained along the vertical meridian of the eye, were collected onto gelatin-coated slides and processed for immunocytochemistry. Alternatively, entire eyes were rinsed three times (15 min each) in PBS at room temperature with gentle shaking, to whole-mount histochemical staining as described below.

#### C. Histochemical Analysis

Expression of the bacterial LacZ gene in whole retinas was detected by standard histochemical staining reactions using halogenated indoyl- $\beta$ -D-galactoside (Bluogal; GIBCO BRL). Following removal of the anterior eye structures and lens, eye cups were incubated overnight in a staining solution containing 5mM K-ferricyanide, 5

mM K-ferrocyanide, 2 mM MgCl<sub>2</sub>, and 0.5 mg/ml Blue-gal at 37°C. Retinas were then dissected, fixed for an additional 30 min and flat-mounted vitreal side up on glass slides.

For visualization of the AAV-mediated lacZ gene product in retinal radial sections, cryosections were incubated in 10% normal goat serum (NGS) in 0.2% Triton X-100 (Sigma, St. Louis, MO) in phosphate buffer saline (PBS) for 30 min at room temperature to block non-specific binding. Two primary antibodies raised against the lacZ gene product were used with similar results. A polyclonal anti-beta-gal antibody (diluted 1:1000; 5 prime→3 prime, Inc., Boulder, CO) and a monoclonal anti-LacZ antibody (diluted 1:500; Promega, Madison, WI). Primary antibodies were added in 2% NGS in 0.2% Triton X-100 and incubated overnight at 4°C. Sections were subsequently processed with anti-rabbit Cy3-conjugated IgG (diluted 1:500, Jackson Immunoresearch, West Grove, PA) or anti-mouse Cy3-conjugated IgG (diluted 1:500, Jackson Immunoresearch) and mounted. Control sections were treated in the same way but with omission of the primary antibody. Sections were visualized by fluorescent microscopy (Polyvar, Reichert-Jung).

Expression of the heparan sulfate proteoglycan receptor in the retina was examined using a monoclonal anti-heparan sulfate antibody (HepSS-1, diluted 1:1,000, Seikagaku Corporation, Tokyo, Japan). Following overnight incubation at 4°C, sections were processed with biotinylated anti-mouse Fab fragment (Jackson Immunoresearch), avidin-biotin-peroxidase reagent (ABC Elite Vector Labs, Burlingame, CA), followed by reaction in a solution containing 0.05% diaminobenzidine tetrahydrochloride (DAB) and 0.06% hydrogen peroxide in PB (pH 7.4) for 5 min. For analysis of co-localization of heparan sulfate in Fluorogold-labeled neurons, sections were processed with Cy3-coupled anti-mouse IgG (Jackson Immunoresearch) after incubation in primary antibody. In all cases, the primary antibody was omitted in control sections. Sections were mounted and visualized by light or fluorescent microscopy.

Quantification of AAV-transduced cells in the ganglion cell layer of retinal flat-mounts was performed in two ways: i) by counting the entire number of Blue-gal positive cells in each of the retinal quadrants (superior, inferior, temporal and nasal); and ii)

by counting the number of cells in three standard areas (at 1, 2 and 3 mm from the optic disc) of each quadrant as previously described (Villegas-Perez *et al.*, 1993).

For quantification of Fluorogold, Blue-gal or HepSS-1 positive cells in retinal radial sections, the entire number of labeled cells per section was counted under fluorescent microscopy. Four to five serial sections per eye were routinely counted and a mean value per animal was obtained, followed by the calculation of a mean value for the entire experimental group which consisted of 4-5 rats. Results were analyzed using the Sigmastat program (Jandel, San Rafael Madera, CA) by a student's *t* test (paired groups).

#### D. Results

Analysis of retinas from eyes that received a single intravitreal injection of rAAV-CMV-lacZ demonstrated a large number of LacZ-positive cells throughout the entire GCL as assessed by histochemical LacZ staining of both flat-mounts (Figure 16A) and radial sections (Figure 16B). In many cases, RGCs transduced by AAV could be unequivocally identified because the LacZ reaction product filled their axons that converged at the level of the optic nerve head. In addition, LacZ-positive photoreceptor nuclei were observed but were always restricted to the vicinity of the injection site (not shown). No staining was observed in control eyes injected with virus vector. No signs of cytotoxic damage or cellular immune reaction to the viral vector were observed in any of the retinas examined.

Quantification of LacZ-positive cells in the GCL of retinal flat-mounts demonstrated a 2.8-fold increase between 2 and 4 weeks after intravitreal injection of the rAAV-CMV-lacZ vector (Figure 17). For example, it was found that  $27,569 \pm 7,646$  cells/retina (mean  $\pm$  S.D.;  $n=3$ ) and  $79,043 \pm 10,321$  cells/retina ( $n=4$ ) expressed the LacZ gene product at 2 and 4 weeks after intraocular administration of the vector, respectively. A comparable number of cells expressing the AAV-mediated transgene at 4 weeks was observed at 8 weeks ( $70,221 \pm 12,500$ ;  $n=3$ ) following rAAV-CMV-lacZ injection. Although the majority of LacZ-positive cells were observed in the superior hemisphere at 2 weeks after virus administration, there was robust transgene expression throughout the

entire retina by 4 and 8 weeks as assessed by quantification of Lac-Z positive cell densities in all retinal quadrants at these time points (Figure 17).

To identify the cellular localization of the AAV-mediated LacZ gene product, immunocytochemical staining of LacZ was combined with retrograde tracing of RGC bodies using Fluorogold backlabeling from the superior colliculi. Double-labeling experiments indicated that the majority of cells in the GCL expressing the LacZ gene product were also Fluorogold-positive (Figure 18). Analysis of the number of Fluorogold-labeled cells in the GCL expressing the LacZ gene product indicated that  $300 \pm 29$  (mean  $\pm$  S.D.;  $n=4$ ) expressed both markers out of  $330 \pm 32$  Fluorogold-labeled cells (the average RGC population per retinal radial section). This indicates that ~92% of RGCs, identified by the Fluorogold label, also expressed the AAV-mediated LacZ gene product (Figure 19). In all retinas examined, it was routinely observed that a number of Lac-Z positive cells that were not labeled with Fluorogold (Figures 18 and 19). Thus, it is possible that these cells are displaced amacrine cells or RGCs that failed to incorporate the retrograde tracer. Together, these results indicate that RGCs are preferentially transduced by recombinant AAV following intravitreal injection of this viral vector.

To investigate the molecular mechanisms underlying preferential transduction of RGCs by AAV, expression of the heparan sulfate proteoglycan (which mediates both AAV attachment and infection of target cells (Summerford *et al.*, 1998)) in the adult retina was observed. Immunostaining of retinal radial sections with a specific antibody against heparan sulfate (HepSS-1) demonstrated robust staining in the GCL (Figure 20). Positive immunolabeling was clearly visualized in both neuronal somata and axonal bundles in the fiber layer. More diffuse and sparse staining was observed in some photoreceptor nuclei and cells in the inner nuclear layer. No staining was observed in control retinal sections in which the primary antibody was omitted (not shown).

To determine the cell type within the GCL that express the heparan sulfate proteoglycan receptor, a double-labeling study was performed in which RGCs were first retrogradely labeled from the superior colliculi followed by immunostaining of retinal sections with HepSS-1. Our analysis showed that  $299 \pm 23$  (mean  $\pm$  S.D.;  $n=4$ ) cells in the



GCL expressed both Fluorogold and HepSS-1 markers out of  $315 \pm 34$  Fluorogold-labeled cells which represent the average RGC population visualized per retinal radial section. The large population of RGCs (~95%) expressing heparan sulfate proteoglycan receptor correlated well with the number of RGCs expressing the AAV-mediated transgene product 5 (~92%). Together, these data suggest that preferential transduction of adult RGCs by recombinant AAV is mediated by the heparan sulfate proteoglycan receptor expressed by these neurons.

#### EXAMPLE 10

##### 10 CONSTRUCTION OF A RAAV VECTOR EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 165

The human VEGF-165 cDNA was cloned from the PCR-Blunt II Topo Vector (Invitrogen) into the pD10-CMV rAAV vector as an EcoR1 fragment (pD10-VEGFUC). The pD10-VEGFUC vector is illustrated schematically in Figure 21, and its 15 nucleotide sequence is shown in Figure 22. The VEGFUC rAAV virus was packaged using the triple transfection method and purified by column chromatography.

Briefly, a cell pellet is resuspended in TNM buffer: 20mM Tris pH 8.0, 150mM NaCl, 2mM  $MgCl_2$ . Deoxycholic Acid is added to 0.5% to lyse the cells. 50u/ml Benzonase is added and the lysed cells are incubated at 37 degrees to digest any nucleic 20 acids. The cell debris is pelleted and the supernatant is filtered through a 0.45um filter and then a 0.22um filter. The virus is then loaded onto a 1.5ml Heparin sulfate column using the Biocad. The column is then washed with 20mM Tris pH 8.0, 100mM NaCl. The rAAV particles are eluted with a gradient formed with increasing concentrations of NaCl. The fractions under the peak are pooled and filtered through a 0.22um filter before 25 overnight precipitation with 8% PEG 8000.  $CaCl_2$  is added to 25mM and the purified particles are pelleted and then resuspended in HBS#2: 150mM NaCl, 50mM Hepes pH7.4.

## EXAMPLE 11

INFECTION OF 293 CELLS WITH D10-VEGF RAAV RESULTS IN  
VEGF PROTEIN EXPRESSION

5           The functionality of the viral particles was assessed by infection of 293 cells with 3 different viral multiplicities of infection (MOIs);  $1 \times 10^7$ ,  $1 \times 10^8$  and  $1 \times 10^9$  viral particles per  $4 \times 10^5$  293 cells, in the presence of 1.5  $\mu$ M etoposide. At 48 hours post infection, tissue culture media (supers) and cell lysates were harvested. VEGF protein levels were determined using a Quantikine human VEGF sandwich ELISA kit (R and D Systems, 10 see Figure 23). VEGF protein concentrations are given in pg/ml. The two highest MOIs gave values significantly above that of the cells infected with a negative control virus. The levels of secreted VEGF were approximately 4-7 fold higher than those of the lysates.

## EXAMPLE 12

INFECTION OF RETINAL PIGMENT EPITHELIAL (RPE) CELLS WITH D10-VEGF RAAV  
15           RESULTS IN VEGF PROTEIN SECRETION

          VEGF expression levels in a monolayer of cultured primary (or very early passage) human fetal RPE cells infected with D10-VEGF 165 rAAV were clearly elevated relative to endogenous levels. Cells were infected with a range of rAAV particles from 0 to 20  $1 \times 10^5$  per cell. VEGF expression was dose dependent, increased over time, and secretion appeared to be somewhat higher from the apical surface. In a representative experiment, RPE cells infected with  $1 \times 10^5$  viral particles secreted  $> 100 \text{ ng}/1 \times 10^6$  cells from the apical surface and  $50 \text{ ng}/1 \times 10^6$  cells from the basal surface at 8 days post infection. The polarity of VEGF secretion from human fetal RPE cells infected with 25 different MOIs is shown in Figure 24.

### EXAMPLE 13

#### INFECTION OF RETINAL PIGMENT EPITHELIAL (RPE) CELLS WITH VEGF RAV RESULTS IN VEGF PROTEIN SECRETION AND DECREASED MEMBRANE CONDUCTANCE

5           Infection of cultured human fetal RPE cells with recombinant VEGF adenovirus (AV) results in secretion of very high levels of VEGF from both the apical and basal surfaces of the RPE. MOI's of 0 to 1,000 or 0 to 10,000 particles per cell were used in two separate experiments. In both cases, expression levels increased over time, peaking at approximately 100-200 ug/1 x 10<sup>6</sup> cells at the highest MOI's (see Figure 25). In  
10 addition, the total transepithelial membrane resistance of the RPE monolayer decreased significantly at all MOIs, and by approximately 4-5 fold at the highest MOIs (see Figure 26).

### EXAMPLE 14

#### CONSTRUCTION OF A RAAV VECTOR EXPRESSING SOLUBLE FLT-1 (SFLT-1) RECEPTOR

15           The sFlt-1 cDNA was cloned from the Blunt II Topo Vector (Invitrogen) into the pD10-CMV rAAV vector as an EcoR1 fragment (pD10-sFlt-1). The pD10-sFlt-1 vector is illustrated schematically in Figure 27, and its nucleotide sequence is shown in Figure 28. The human sFlt-1 rAAV virus was packaged using the triple transfection  
20 technique and purified by column chromatography.

### EXAMPLE 15

#### IN VITRO ASSAY FOR ANTI-ANGIOGENIC ACTIVITY

25           This example describes the HMVEC (human dermal microvascular endothelial cell) proliferation assay, which can be utilized to determine the anti-angiogenic activity of a molecule by inhibition of VEGF stimulated proliferation (see Kupprion et al., 1998. JBC 273:29635-29640).

Briefly, HMVEC cells obtained from Clonetics (catalog #2543), are seeded in a 96 well culture dish at a density of 2,000 cells per well in 100 ul assay media and incubated at 37°C for 3-5 hours. The assay media is EBM media, or endothelial basal media (Clonetics, catalog # CC-3121) containing 5% FBS and 1% pen/strep. Dilutions of  
5 anti-angiogenic samples are added in triplicate (50 ul each, for final well volume of 200 ul), immediately followed by 50 ul 20 ng/ml recombinant VEGF (R and D Systems, final concentration 5 ng/ml, or 0.1 nM). The samples are conditioned media from 293 cells transiently transfected with a pD10 rAAV plasmid, by standard methods, or from 293 cells infected with an rAAV virus. Culture media is collected from 24-48 hours post-  
10 transfection or post-infection. After the addition of sample and recombinant VEGF, the cells are incubated for 48 hours at 37°C, when they are pulsed with 1 uCi/well <sup>3</sup>H-thymidine (Amersham, catalog # TRK300). The stock of 1 mCi/ml <sup>3</sup>H-thymidine is diluted 1:10 in assay media, and 10 ul added per well. The cells are incubated for an additional 18 hours, at which point 100 ul media is removed and the cells are lysed by the addition of 40  
15 ul of 1M NaOH per well. Finally, the cells are harvested with a Tomtec Harvester, transferred to Filtermat paper (Wallac), 10 ml of scintillation fluid added and the incorporation of <sup>3</sup>H-thymidine determined by scintillation counting.

Inhibition of HMVEC proliferation by conditioned media from sFlt-1 rAAV infected 293 cells is shown in Figure.34. Complete inhibition of proliferation (induced by  
20 0.1 nM VEGF) was observed at approximately at 1 nM sFlt-1, and partial inhibition at approximately 0.3 nM and 0.1 nM sFlt-1 protein. This inhibition was not seen with HMVEC cells treated with conditioned media from lacZ rAAV infected cells, or cells treated with recombinant VEGF alone. To generate conditioned media, 4 x 10<sup>5</sup> 293 cells were infected with 1 x 10<sup>11</sup> total particles sFlt-1 rAAV or a CMV-lacZ control rAAV. If  
25 one assumes an infectious particle ratio of 1:1,000 to 1:10,000, this is an MOI of less than or equal to 2.5 x 10<sup>2</sup> per cell. All samples were run in triplicate, and means and standard deviations are shown. Background incorporation of <sup>3</sup>H-thymidine in cells not stimulated with exogenous VEGF was subtracted from all samples, leading to a negative value in one

case. The total amount of sFlt-1 protein in the conditioned media was determined by a sandwich Elisa (antibodies purchased from R and D Systems).

5

## EXAMPLE 16

## ANIMAL MODEL FOR NEOVASCULARIZATION BY SUBRETINAL INJECTION OF VEGF RAAV

This example describes an animal model that, after subretinal injection of a recombinant virus (rAAV) containing an angiogenic transgene (VEGF), generates  
10 subretinal neovascularization and choroidal neovascularization. As noted above, choroidal neovascularization is a hallmark of exudative or wet Age-related Macular Degeneration (AMD), the leading cause of blindness in the elderly population. Retinal neovascularization occurs in diseases such as diabetic retinopathy and retinopathy of prematurity (ROP), the most common cause of blindness in the young.

15 Briefly, subretinal injections of 2 $\mu$ l AAV-VEGF (titer:  $5.8 \times 10^{13}$  particles/ml) were made in a bleb under the retina just outside the apical membrane of the RPE. These injections were made 3-3.5 months before the animals were sacrificed. After sacrifice animals were examined for the extent and duration of neovascularization induced by rAAV vectors using fundus photography, fluorescein angiography (Figure 35),  
20 histology (Figure 36), and immunochemistry (Figure 37). As described in more detail below, these figures demonstrate in three different ways that AAV mediated overexpression of VEGF in the RPE can generate choroidal neovascularization.

More specifically, Figure 35A is an image of the fundus showing retinal blood vessels from a live animal before it was sacrificed for the serial sectioning shown in  
25 Figure 36. Note that the blood vessels are larger in diameter in the AAV-VEGF injected area (black arrow). Figure 35B, is a fluorescein angiogram from the same animal taken shortly after the fundus image in 35A. Two minutes after fluorescein injection (intramuscular) significant leakage of fluorescein was observed at the AAV-VEGF injection site (black arrows).

Figure 36 (panels A-D) are a series of epoxy sections taken after sacrifice of the animal. Figure 36A is a section taken from half of the eye furthest from AAV-VEGF injection site, showing normal photoreceptors and blood vessels (the arrow points to photoreceptors with normal morphology). Moving from this section toward the AAV-VEGF injection site, monotonically increasing photoreceptor disorganization and new blood vessel formation was observed (data not shown).

Figures 36B and C are epoxy sections from the AAV-VEGF injection site. The short arrows show new blood vessel growth and the long arrows show a pathologically disorganized photoreceptor layer. Figure 36D is also an epoxy section from the AAV-VEGF injection site. The arrow points to a blood vessel breaking through Bruch's Membrane, probably from the choroid.

Figures 37(A-D) show lectin / BrdU double-staining of rat retina (A-B) and choroid (C-D). Green staining is the lectin staining of endothelial cells, and red staining is BrdU staining of dividing cells. Green cells with red dots are dividing endothelial cells, which are part of the newly formed blood vessels.

More specifically, Figure 37A is an image of the at the AAV-VEGF injection site showing extensive BrdU staining. Note that there are many more blood vessels compared to that seen at points distant from the AAV-VEGF injection site in panel B. The lectin staining is fuzzy because the blood vessels are bloated with dividing endothelial cells. Figure 37B is an image of the retina furthest from the AAV-VEGF injection site. This image shows minimal BrdU staining. In contrast, lectin staining is clear and sharply defined. Figure 37C is an image of the choroids at the AAV-VEGF injection site, which also shows extensive BrdU staining. The lectin image is not shown since it binds indiscriminately throughout choroid and sclera. Figure 37D is an image of the choroids furthest from the AAV-VEGF injection site, and shows minimal BrdU staining.

#### EXAMPLE 17

INJECTION OF THERAPEUTIC ANTI-ANGIOGENIC RAAV INTO AN ANIMAL MODEL FOR  
OCULAR NEOVASCULARIZATION

This example demonstrates the ability of anti-angiogenic molecules to prevent neovascularization in the rat model described above. Briefly, in four animals rAAV-sFlt-1 or rAAV-PEDF were injected together with rAAV-VEGF into the subretinal space of one eye; the contralateral eye received an injection of rAAV-VEGF and rAAV-GFP. Six weeks after injection, electroretinographic analysis (ERGs) were obtained from both eyes of each animals simultaneously. The a- or b- wave amplitude from the test eye (AAV-VEGF+AAV-sFlt-1) is designated as  $A_t$  or  $B_t$ . The a- or b- wave amplitude from the control eye (AAV-VEGF+AAV-GFP) is designated as  $A_c$  or  $B_c$ , respectively. In each eye ERG a- and b- waves were measured and for each animal the amplitude ratio was calculated as percent change in the test eye relative to the control eye:

$$\text{ERG Amplitude Ratio} = (A_t - A_c) / A_c \text{ or } (B_t - B_c) / B_c$$

The amplitude ratio for a- and b- waves are plotted in Figure 38. Briefly, significant functional rescue was obtained in three/four animals using sFlt-1 and two/four animals using PEDF. Figure 39 shows comparison ERGs of test and control eye of sFlt-1 treated rats. The dark-solid line shows that the eye rescued with sFlt-1 has a- and b- wave amplitudes approximately twice as large as the control eye (light-dashed line). This data indicates that sFlt-1 or PEDF can be used to rescue retinal function that is lost during neovascularization.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

## CLAIMS

We claim:

1. A method of treating or preventing diseases of the eye, comprising, administering intraocularly a gene delivery vector which directs the expression of a neurotrophic factor, such that said disease of the eye is treated or prevented.
2. The method according to claim 1 wherein said neurotrophic factor is NGF, BDNF, CNTF, NT-3, or, NT-4.
3. The method according to claim 1 wherein said neurotrophic factor is a FGF.
4. The method according to claim 3 wherein said FGF is FGF-2, FGF-5, FGF-18, FGF-20, or, FGF-21.
5. The method according to claim 1 wherein said disease of the eye is macular degeneration.
6. The method according to claim 1 wherein said disease of the eye is diabetic retinopathy.
7. The method according to claim 1 wherein said disease of the eye is an inherited retinal degeneration.
8. The method according to claim 7 wherein said inherited retinal degeneration is retinitis pigmentosa.



9. The method according to claim 1 wherein said disease of the eye is glaucoma.
10. The method according to claim 1 wherein said disease of the eye is a surgery-induced retinopathy.
11. The method according to claim 1 wherein said disease of the eye is retinal detachment.
12. The method according to claim 1 wherein said disease of the eye is a photic retinopathy.
13. The method according to claim 1 wherein said disease of the eye is a toxic retinopathy.
14. The method according to claim 1 wherein said disease of the eye is a trauma-induced retinopathy.
15. The method according to claim 1 wherein said gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.
16. The method according to claim 1 wherein said gene delivery vector is a recombinant adeno-associated viral vector.
17. A method of inhibiting neovascular disease of the eye, comprising, administering intraocularly a gene delivery vector which directs the expression of an anti-angiogenic factor, such that said neovascular disease of the eye is inhibited.

18. The method according to claim 17 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, soluble Tie-2 receptor, or, a single chain anti-VEGF antibody.

19. The method according to claim 17 wherein said neovascular disease of the eye is diabetic retinopathy, wet AMD, and retinopathy of prematurity.

20. The method according to claim 17 wherein said gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.

21. The method according to claim 17 wherein said gene delivery vector is a recombinant adeno-associated viral vector.

22. A gene delivery vector which directs the expression of a neurotrophic factor, or an anti-angiogenic factor.

23. The gene delivery vector according to claim 22 wherein said neurotrophic factor is NGF, BDNF, CNTF, NT-3, or, NT-4.

24. The gene delivery vector according to claim 22 wherein said neurotrophic factor is a FGF.

25. The gene delivery vector according to claim 22 wherein said FGF is FGF-2, FGF-5, FGF-18, FGF-20, or, FGF-21.

26. The gene delivery vector according to claim 22 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, soluble Tie-2 receptor, or, a single chain anti-VEGF antibody.

27. The gene delivery vector according to claim 22 wherein said vector is generated from a retrovirus.

28. The gene delivery vector according to claim 27 wherein said retrovirus is HIV or FIV.

29. The gene delivery vector according to claim 22 wherein said vector is generated from a recombinant adenó-associated virus.

30. A non-human animal model of neovascularization of the eye, comprising an animal having an angiogenic transgene in the eye.

31. The non-human animal model according to claim 30 wherein said neovascularization is retinal neovascularization.

32. The non-human animal model according to claim 30 wherein said neovascularization is choroidal neovascularization.

33. The non-human animal model according to claim 30 wherein said animal is a mouse or rat.

34. The non-human animal model according to claim 30 wherein said angiogenic transgene encodes VEGF.

35. The non-human animal model according to claim 30 wherein said angiogenic transgene encodes an angiopoietin.

36. A method for making a non-human animal model of neovascularization of the eye, comprising administering to a non-human animal a gene delivery vector which directs the expression of an angiogenic transgene.

37. The method according to claim 36 wherein said gene delivery vector is administered subretinally.

38. The method according to claim 36 wherein said gene delivery vector is administered intravitreally.

39. The method according to claim 36 wherein said gene delivery vector is rAV or rAAV.

40. The method according to claim 36 wherein said angiogenic transgene is a nucleic acid molecule which encodes VEGF.

41. The method according to claim 36 wherein said angiogenic transgene is a nucleic acid molecule which encodes an angiopoietin.

42. A method for determining the ability of an anti-angiogenic factor to inhibit neovascularization of the eye, comprising: (a) administering to an animal model according to any one of claims 30 to 35 an anti-angiogenic factor, and (b) determining the ability of said anti-angiogenic factor to inhibit neovascularization of the eye.

43. The method according to claim 42 wherein said anti-angiogenic factor is administered subretinally.

44. The method according to claim 42 wherein said anti-angiogenic factor is administered intravitreally.





Fig. 1

ACCATGTAGCGGCCCTGCGGCTCGCTCGCTCACTGAGGCCGCCGGGCAAGCCCGGGCGTCGGGCGACCTTTGGT  
CGCCCGGCTCAGTGAGCGAGCGAGCGCGCAGAGAGGAGTGCCCACTCCATCACTAGGGGTTCTTGTAAGTAAT  
GATTAACCCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGGAATTTGGCCGGGAATTTGACTCTAGGCCATTG  
CATACGTTGTATCTATATCATAATATGTACATTTATTTGGCTCATGTCCAATATGACCGCCATGTTGACATTGATT  
ATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAAC  
TTACGGTAAATGGCCGCTGGCTGACCGCCCAACGACCCCGCCCATTGACGTCAATAATGACGTATGTTCCATA  
GTAACGCCAATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCA  
AGTGTATCATATGCCAAGTCCGCCCTATTGACGTCAATGACGGTAAATGGCCGCTGGCATTATGCCCAAGTACA  
TGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGG  
CAGTACACCAATGGGCGTGGATAGCGGTTTGAATCACGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAG  
TTTGTTTTGGCACCAAAATCAACGGGACTTTCAAAATGTCGTAATAACCCGCGCCGTTGACGCAATGGGCGTA  
GGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACGTCAGATCGCTGGAGACGCCATCCACGC  
TGTTTTGACCTCCATAGAGACACGGGACCGATCCAGCCTCCGCGCCGGGAACGGTGCAATTGGAACGCGGATTCC  
CCGTGCCAAGAGTGACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGT  
TTTTGGCTTGGGGCTATACACCCCGCTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTTAT  
TGACCATATTATGACCACTCCCTATTGGTGACGATACTTTCATTACTAATCCATAACATGGCTCTTTGCCCAACT  
ATCTCTATTGGCTATATGCCAATACTCTGTCTTCAGAGACTGACACGGACTCTGTATTTTACAGGATGGGGTCCA  
TTTATTATTTACAAATTCACATATACAACAACGCGTCCCGGTGCCCGCAGTTTTATTAAACATAGCGTGGGATC  
TCCGACATCTCGGGTACGTGTTCCGACATGGGCTCTTCTCGGTAGCGCGGAGCTTCCACATCCGAGCCCTGGTC  
CCATCGGTCCAGCGGCTCATGGTGGCTCGGCAGCTCCTTGCTCTAACAGTGGAGGCCAGACTTAGGCACAGCACA  
TGCCACCACCACAGTGTGCCGACAAAGCCGTGGCGGTAGGGTATGTGTCTGAAATGAGCTCGGAGATTGGGCT  
CGCACCTGGACGAGATGGAAGACTTAAGGCAGCGGAGAGAGATGACGGCAGCTGAGTTGTTGTATTTCTGATAA  
GAGTCAGAGGTAACCTCCGTTGCGGTGCTGTTAACGGTGGAGGCGAGTGTAGTCTGAGCAGTACTCGTTGCTGCCG  
GCGGCCACCAGACATAATAGCTGACAGACTAACAGACTGTTCTTTCCATGGGTCTTTTCTGCACTCACCGTCGTC  
GACCTAAGAATTCAGGCTAAGCTTCTAGGTATCGATCTCGAGCAAGTCTAGAGGAGACCACAACGGTTTCCCTC  
TAGCGGATCAATTCGCGCCCCCCCCCTAACGTTACTGGCCGAAGCGCTTGAATAAGGCCGGTGTGCGTTTGTCT  
ATATGTTATTTCCACCATTATGCGCTCTTTGGCAATGTAGGGCCCGGAAACCTGGCCCTGTCTTCTTACGAGC  
ATTCTAGGGGTCTTTCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCTGTAAGGAAGCAGTTCTCTGGA  
AGCTTCTTGAAGACAAACAGCTCTGTAGCGACCTTTGACGACAGCGGAACCCCACTGGCGACAGGTGCTCT  
GCGGCCAAAAGCCAGGTGTATAAGATACACCTGCAAGGCGGACAAACCCAGTGCCACGTTGTGAGTTGGATAGTT  
GTGGAAGAGTCAATGGCTCTCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCAGAAGGTACCCATTGTAT  
GGGATCTGATCTGGGGCTCGGTGCATGCTTTACATGTGTTAGTCAAGTTAAAAAAGCTTAGGCCCCCGA  
ACCACGGGACGTTGTTTTCTTTGAAAAACGATAATACCATGGCGCGGGAGCATCACACGCTGCCAGCCCT  
GCCGGAGGACGGGCGAGCGGCTTCCCGCGGGCCACTTCAAGGACCCCAAGCGGCTGTACTGCAAGAACGGG  
GCTTCTCTGCGCATCCACCCGACGGCGAGTGGACGGGTCGCGAGAAGAGCGACCCACACATCAAACTACAA  
CTTCAAGCAGAAGAGAGAGGGGTTGTCTATCAAGGAGTGTGTGCAACCGTTACCTTGCTATGAAAGAAGATGG  
AAGATTACTAGCTTCTAAATGTGTACAGACGAGTGTCTTTTTTGAACGATTGAGTCTAATAACTACAATCTT  
ACCGGTCAAGGAAATACACAGTGGTATGTGGCACTGAAACGAACCTGGCAGTATAAACTTGGATCCAAAACAGGA  
CCTGGGCGAAGACTATACTTTTTCTTCAATGTCTGTAAGAGCTGATCTAATGGCAGCATCTGATCTCATTTTA  
CATGAAGCTGGTGGCATCCCTGTGACCCCTCCCGAGTGCCTCTCTGGCCCTGGAAGTTGCCACTCAGTGGCCACC  
AGCCTTGTCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCTTCTATAATATATGGGGTGGAGGG  
GGTGGTATGGAGCAAGGGCAAGTTGGGAAGACAACCTGTAGGGCTGCGGGGCTATTGGGAACCAAGCTGGAGTG  
CAGTGGCACAATCTTGGCTCACTGCAATCTCGCCTCTGGGTTCAAGCGATTCTCTGCTCAGCCTCCCGAGTTG


*Fig. 2A*

TTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTGTGTTTTTGGTAGAGACGGGGTTTACCATAATTGGC  
CAGGCTGGTCTCCAATCTTAATCTCAGGTGATCTACCCACCTTGGCTCCCAAATTGCTGGGATTACAGGCGTGAA  
CCACTGCTCCCTTCCCTGTCTTCTGATTTAAAATACTATACCAGCAGGAGGACGTCAGACACAGCATAGGCTA  
CCTGGCCATGCCCAACCGGTGGGACATTTGAGTTGCTTGGCTGGCACTGTCTCTCATGCGTTGGGTCCACTCAGTA  
GATGCTGTTGAATTATCGGATCCACTACGCTTAGAGCTCGCTGATCAGCCTCGACTGTGCTTCTAGTTGCCAGC  
CATCTGTTGTTTGGCCCTCCCGTGCCTTCTTGACCCTGGAAGGTGCCACTCCACTGTCTTCTTAATAAAAT  
GAGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGTGGGGTGGGCAGGACAGCAAGGGGA  
GGATTGGGAAGACAATAGCAGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCGCGCTGGAGGATCATCCAGCCA  
ATTCCCTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATTAACTACAAGGAACCCCTAGTGATGGAG  
TTGGCACTCCCTCTCTGCGGCTCGCTCGCTCACTGAGGCGGGCGACCAAGGTGCGCCGACGCCGGGCTTTG  
CCGGGCGGCTCAGTGAGCGAGCGAGCGGCGAGGGGTGGGCGAAGAACTCCAGCATGAGATCCCGCGCTGGAGGA  
TCATCCAGCGGGCTCCCGAAACGATTCCGAAGCCCAACCTTTCATAGAAGCGGGGTGGAATCGAAATCTCGT  
GATGGCAGGTTGGGCGTGGCTTGGTGGTCATTTCGAACCCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAGGCGA  
TAGAAGGCGATGCGCTGCGAATCGGAGCGGCGATACCGTAAGCACGAGGAAGCGTCAGCCATTGCGCGCAAG  
CTCTTCAGCAATATCACGGGTAGCCAACGCTATGCTCTGATAGCGGTCCGCCACCCAGCCGGCCACAGTCGATGA  
ATCCAGAAAAGCGGCCATTTCCACCATGATATTCGGCAAGCAGGCATCGCCATGGGTACGACGAGATCCTCGCG  
TCGGGATGCGCGCTTGAGCCTGGCGAAGAGTTGGCTGGCGGAGCGCCCTGATGCTCTTCGTCAGATCATCTG  
ATCGACAAGACCGGCTTCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCAATGGGAGGTAG  
CCGATCAAGCGTATGCAGCGCGGCTTGCATCAGCCATGATGGATACTTCTCGGCAGGAGCAAGGTGAGATGAC  
AGGAGATCCTGCCCGGCACTTCGCCAATAGCAGCCAGTCCCTTCCGCTTCAGTGACAAGCTCGAGCACAGTGC  
GCAAGGAACGCCGCTGCTGGCCAGCCAGCATAGCGCGCTGCTCGTCTGCAATTCTCAGGGCACCGGACAGGT  
CGGCTTTGACAAAAAGAACCGGGCGCCCTGCGCTGACAGCGGAACCGGCGGATCAGAGCAGCGGATTGTCTGT  
TGTGCCAGTCATAGCCGAATAGCCTCTCCACCCAGCGCGGAGAACCTGCGTGCAATCCATCTTGTTCATCAT  
GCGAAACGATCCTCATCTGTCTCTTGATCAGATCTTGATCCCTGCGGCATCAGATCCTTGGCGGCAAGAAAGCCA  
TCCAGTTTACTTTGAGGGCTTCCCAACCTTACCAGAGGGCGCCCGAGTGGCAATTCCGGTTGCTTGTGCTCAT  
AAAACGCCAGTCTAGCTATCGCCATGTAAGCCCACTGCAAGCTACCTGCTTTCTCTTGGCTTGGCTTTCCCT  
TGTCCAGATAGCCAGTAGCTGACATTATCCGGGGTCAGCACCGTTTCTGCGGACTGGCTTTCTACGTGTTGCGT  
TCCTTTAGCAGCCCTTGGCGCTGAGTGTGCGGCGAGGTGAAGCTGTCAATTCGCGTTAAATTTTGTAAATC  
AGCTCATTTTTTAACCAATAGGCGGAAATCGGCAAAATCCCTTATAAATCAAAAGATAGCCGAGATAGGGTGAAG  
TGTGTTCCAGTTTGAACAAGAGTCCACTATTAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATC  
AGGGCGATGGCGGATCAGCTTATGCGGTGTGAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGGGCTC  
TTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTGTTGCGCTGCGGCGAGCGGTATCAGTCACTCAAGGCGG  
TAATACGTTATCCACAGAAATCAGGGGATAACGAGGAAGAACATGTAGCAAAAGGCCAGCAAAAGGCCAGGAAC  
CGTAAAAAGGCCGCTTGTGGCGTTTTTCATAGGCTCGGCCCCCTGACGAGCATCAGAAAAATCGACGCTCAAG  
TCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACAGGCGTTTCCCTTGAAGCTCCCTCGTGCGCTCTCCTG  
TTCCGACCTGCGCTTACCGGATACCTGTGCGCTTCTCCCTTGGGAAGCGTGGCGCTTCTCATAGTCAAGC  
TGAGGTATCTCAGTTGCGGTGAGGTGTTGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTAGCCCGACCG  
CTGCGCTTATCCGGTAACTATCGTCTTGAGTCAACCCGGTAAGACAGGCTTATCGCCACTGGCAGCAGCACTG  
GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGTACAGAGTTCTTGAAGTGGTGGCTAACTACGGGTACCT  
AGAAGGACAGTATTTGGTATCTGCGCTGTGCTGAAGCCAGTTACCTTCGAAAAAGAGTTGGTAGCTCTTGATCCGG  
CAACAAACCACCGCTGGTAGCGCGGTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGA  
AGATCCTTTGATCTTTCTTACTGAACGGTGATCCCAACCGGAATT

*Fig. 2B*

*Fig. 3*



*Fig. 4*





Fig. 5

*Fig. 6*






Fig. 7

*Fig. 8*




A




B

*Fig. 9*




OUTER  
SEGMENTS —  
INNER  
OUTER NUCLEAR LAYER  
(photoreceptors)

ganglion cells



RETINA

Fig. 10



*Fig. 11*






Fig. 12




Fig. 13

OUTER NUCLEAR LAYER THICKNESS AT p60




Fig. 14




Fig. 15

# AAV-LacZ Transduction of Retinal Ganglia






Fig. 16

Time Course of AAV-Medicated Transgene  
Expression in the Ganglion Cell layer



Time after intraocular injection of AAV

*Fig. 17*

# Localization of AAV-Medicated LacZ Gene Product in Retrograde Labeled RCG




Fig. 18

# Quantification of Flourogold and LacZ Positive Cells in the Ganglion Cell Layer Following Intravitreal Injection of rAAV-LacZ





Fig. 19



Localization of Heparin sulfate Proteoglycan, the Cellular  
Receptor for AAV, in the Adult Rat Retina



*Fig. 20*




Fig. 21


## Nucleotide Sequence of pD10-VEGFuc

AAACTTGGGCGCGGAATTCGACTCTAGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTATATTGGCTCATGTCCAATATGACCGCA  
TGTTCACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGGGTACATAACTTACGGTAAA  
TGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATATGACGTATGTTCCCATAGTAAGCCCAATAGGGACTTTCATTGACGTCAAT  
GGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCTATTGACGTCAATGACGGTAAATGGCCCGC  
TGGCATTATGCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGGGTTTGGCAGTA  
CACCAATGGGCGTGGATAGCGGTTTGACTCACGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTGTTGGCACCATAATCAACGGGACT  
TTCCAAAATGTCTGAATAACCCCGCCCGTTGACGCAATGGGCGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAG  
ATCGCTGGAGAGCCATCCACGCTGTTTTGACCTCCATAGAAGACACGGGACCGATCCAGCCTCCGGGCCGGGAACGGTGATTGGAACCGGATTCC  
CGTGCCAAAGAGTACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTGGCTTGGGCTTATACCCC  
CGGCTCCTTATGCTATAGTGATGGTATAGCTTAGCCTATAGGTGTGGGTATTGACCATTATTGACCACTCCCTATTGGTGACGATACTTTCATTACT  
AATCCATAACATGGCTCTTTGCCAACAATATCTCTATTGGCTATATGCCAATACTCTGTCTTCAGAGACTGACACGGACTCTGTATTTTACAGGATGG  
GTCCATTATATTACAAATTCACATATACAACGCCGTCGCCGTCAGTGTGTTTATTAACATAGCGTGGGATCTCCGACATCTCGGTACGT  
GTTCCGGACATGGGCTCTTCTCCGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTCCCATCGTCCAGCGGCTCATGGTGGTCCGAGCTCTTGCTC  
CTAACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCACCACCACAGTGTGCGGCACAAGCCGTTGGCGGTAGGGTATGTGCTGAAAATGAGCTCG  
AGATTGGGCTCGACCTGGAGCGAGATGGAAGCTTAAGGCAGCGGCAGAAGAATGACAGCGAGCTGAGTTGTTGTAATCTGATAAGAGTCAGAGGTAAC  
TCCGTTGGGCTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTGTTGCTGCGCGCGGCCACCAGACATAATAGCTGACAGACTAACAGAC  
TGTTCTTTCCATGGGCTTTTCTGCACTCACCGTGTGACCTAAGAATTGCGCTTCGAAACCATGAACCTTCTGCTGTCTTGGGTGCATTGGAGCCTT  
GCCCTGCTGCTCTACCTCCACCATGCCAAGTGGTCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCATCACGAAGTGGTGAAGTTCATGGATGT  
CTATCAGCGCAGTACTGCCATCCAATCGAGACCTGGTGGACATCTTCAGGAGTACCTGATGAGATCGAGTACATCTTCAAGCATCTGTGTGCCCC  
TGATGGATGCGGGGCTGCTGCAATGACGAGGGCTGGAGTGTGTCCTGAGGAGTCCAACATCACCATGCAGATTATGGGATCAAACTCACCA  
GGCAGCACATAGGAGAGATGAGCTTCTACAGCACAACAAATGTGAATGCAGACCAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCTTGCTC  
AGAGCGGAGAAGCATTGTTGTGACAAGATCCGACAGCTGTAATGTTCTGCAAAAACACAGACTCGGTTGCAAGGCGAGGAGCTTGAGTTAAACG  
AACGTAATGTCAGATGTGACAAGCCGAGGCGGTGAGCCGGGAGGAGGAAGAGCTCCCTCAGGTTTCGGGAACAGATCTCTACAGGAAAGACTGA  
TACAGAAAGGGCAATTACGGCTAAGCTTCTAGGTATCGATCTCGAGCAAGTCTAGAAAGCCATGGATATCGGATCCACTACGCTTAGAGCTCGTGA  
TCAGCTCGACTGTGCTTCTAGTTGCCAGCCATCTGTGTTTGGCCCTCCCGGTGCTTCTTGACCTGGAAGTGGCACTCCCACTGTCTTTCTTA  
ATAAATGAGGAATTCATCGCATTTGTCTGAGTAGGTGTCATTCTATTCTGGGGGTGGGTGGGGCAGGACAGCAAGGGGAGGATTGGGAAGACAATA  
GCAGGGGGGTGGGCAAGAACTCCAGCATGAGATCCCGCGCTGGAGGATCATCCAGTACCAAGTCCCATCAGTGATGGAGTTGGCACTCCCTCTCTG  
CGCTCGCTCGCTCACTGAGGCGGGCGACCAAGGTGCGCCGAGCGCCGGGCTTGGCCGGGCGGCTCAGTGAGCGAGCGAGCGCCAGCGATTCTCT  
TGTTTGCTCCAGACTCTCAGCAATGACCTGATAGCCTTTGTAGAGCCTCTCAAAATAGCTACCTCTCCGCAATGAATTTATCAGTAGAACGGTTGA  
ATATCATATTGATGGTGAATTTGACTGTCTCGGCCCTTCTCACCCTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAATATATGAGGGT  
CTAAAAATTTTATCCTTGCGTTGAAATAAGGCTTCTCCGCAAAAGTATTACAGGTCATAATGTTTTGGTACAACCGATTAGCTTTATGCTCTGAG  
GCTTTATTGCTTAATTTGCTAATCTTTGCCCTTGCTGTATGATTTATGGATGTGGAATTCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTA  
TTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCCATAGTTAAGCCAGCCCGACACCCGCCAACCCGCTGACGCGCCCTGACGG  
GCTTGCTGCTCCCGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGAGCTGCATGTGTGAGAGTTTACCCTCATCACCAGAACCGCGGAGACG  
AAAGGGCTCGTGATACGCTATTTTATAGGTTAATGTGATGATAATGTTTCTTAGACGTGAGTGGCACTTTTGGGGAATGTGCGCGGAACCC  
CTATTGTTTATTTTCTAAATACATTCAATATGTATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATATTGAAAAGGAAGATATGAGT


Fig. 22A

ATTCAACATTTCCGTGTCGCCCTTATTCCTTTTTTGCGGCATTTTGCTTCTCTGTTTTGCTCACCAGAAACGCTGGTGAAAGTAAAGATGCTGAAGA  
 TCAGTTGGGTGCACGAGTGGGTACATCGAAGTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTGCCCCGAAGAAGCTTTTCCAATGATGAGCACTT  
 TTAAGTTCCTGTATGTGGCGGGTATTATCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGGCATACACTATTCTCAGAATGACTTGGTTGAGTAC  
 TCACCAAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAAGTCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCT  
 GACAACGATCGGAGSACCGAAGGAGCTAACCGCTTTTTGCACAACATGGGGGATCATGTAACCTGCGCTTGATCGTTGGGAACCGAGCTGAATGAAGCCA  
 TACCAAAGCAGCAGCGTGACACCAGATGCCGTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAACAA  
 TTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACCTCTGCGCTCGGCCCTTCGGCTGGCTGGTTTATTGCTGATAAATCTGAGCCGGTGAGCG  
 TGGGTCTCGCGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA  
 ATAGACAGATCGCTGAGATAGGTGCTCACTGATTAAGCATTGGTAACCTGTCAGACCAAGTTACTCATATATACTTTAGATTGATTTAAACCTTCATTTT  
 TAATTTAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAA  
 GATCAAAGATCTTCTTGAGATCCTTTTTCTGCGGTAATCTGCTGCTTGCAAAACAAAAAACCCGCTACCAGCGGTGGTTTGTGTCGGGATCAAG  
 AGCTACCAACTCTTTTTCCGAAGTAACCTGGCTTCAGCAGAGCGCAGATACCAATACTGTCTTCTAGTGTAGCCGAGTTAGGCCACCACTTCAAGAAC  
 TCTGTAGCACCCTACATACCTCGCTCTGCTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTCTGTCTTACCGGGTTGGACTCAAGACGATA  
 GTTACCGGATAAGGCGCAGCGCTCGGCTGAACGGGGGTTCTGTGACACAGCCAGCTTGGAGCGAAGCCTACACCGAACTGAGATACCTACAGCGTG  
 AGCTATGAGAAAGCGCCACGCTTCCGAAGGGAGAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCAGAGGGAGCTTCCAGGG  
 GGAAACGCTGGTATCTTTATAGTCTGTGGGTTTCCGCCCTCTGACTTGAGCGTCGATTTTGTGATGCTGTCAGGGGGCGGAGCCTATGGAAAA  
 CGCCAGCAACCGGCTTTTACGGTTCTGGGCTTTTCTGGCCTTTTCTCATATGTTCTTTCTGCGTTATCCCTGATTCTGTGGATAACCGTATTA  
 CCGCCTTGAGTGAGTGATACCGCTCGCCGACCGCAACGACGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAACCGCCT  
 CTCCCGCGCGTTGGCGATTCAATATGCACTGGCGGCTGCTGCTCACTGAGGCGCCCGGGCAAGCCCGGGCGTGGGGGACCTTTGTGCGCC  
 GGCTCAGTGAGCGAGCGAGCGCAGAGAGGAGTGCCCACTCCATCACTGAT

*Fig. 22B*



*Fig. 23*



Time after transfection (Day) and Polarity

Fig. 24

# VEGF Secretion by hRPE After Infection with VEGF AV




Fig. 25

Time after Infection (Day) and Polarity

# Resistance of hRPE After Infection with VEGF AV




Fig. 26




Fig. 27



## Nucleotide Sequence of pD10-SF1t-1

AAAACCTGCGCCGCGGAATTTGACTCTAGGCCATTGCATACGTTGTATCTATATCATAAATGTACATTTATATTGGCTCATGTCCAATATGACCGC  
CATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAACTTACGG  
TAAATGGCCCGCTGGCTGACGCGCCACGACCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGAATTTCCATTGAC  
GTCAATGGGTGGAGTATTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAAT  
GGCCCGCCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGT  
TTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTTTTGGCAGCAAA  
ATCAACGGGACTTTCAAAATGTGTAATAACCCGCGCCGTTGACGCAATGGGCGGTAGGCGGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTT  
TAGTGAACCGTCAGATCGCTGGAGAGCCATCCACGCTGTTTGACCTCCATAGAGACACCGGACCGATCCAGCCTCCGCGGCGGGAACGGTGCA  
TTGGAACGCGGATTCGCCGTGCAAGAGTGACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCAATGCTATAGTGTTTTGG  
CTTGGGGCTTATACCCCCGCTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGTTATTGACCATTATTGACCACTCCCTATTGG  
TGACGATACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAATATCTCTATTGGCTATATGCCAATACTCTGTCCTTCAGAGACTGACACGGA  
CTCTGTATTTTACAGGATGGGTCCTATTATTATTACAAATTCACATATACAACAACGCGTCCCGGTGCGGCGAGTTTATTAAACATAGCGTG  
GGATCTCCGACATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCGGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTCCATCGTCCAGCGCT  
CATGGTCTGCTCGGACGCTCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCACCACCAGTGTGCGGCAAGGCGGTGGCGG  
TAGGGTATGTGTGAAAATGAGCTCGGAGATTGGCTCGCACCTGGACGAGATGGAAGACTTAAGGCAGCGGAGAGAAGATGCAGGACGCTGAGT  
TGTGTATTCTGATAAGAGTCAGAGGTAACCTCCGTTGCGGTGCTGTAAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGCTGCGCGCGCGC  
CACCAGACATAATAGCTGACAGACTAACAGACTGTTCCCTTCCATGGGTCTTTCTGCACTCACCGTCTGACCTAAGAATTCCGCCCTTTCACCATGG  
TCAGTACTGGGACACCGGGGCTCTGCTGTGCGGCTGCTCAGCTGTCTGCTTCTACAGGATCTAGTTCAGGTTCAAAATTAAGAGTCTGAACTGA  
GTTTAAAGGACCCAGCAGATCATGCAAGCAGGCCAGACACTGCATCTCCAATGCAGGGGGGAAGCAGCCATAAATGGTCTTTGCTGAAATGGTGA  
GTAAGGAAAGCGAAAGGCTGAGCATAAATCTGCTGTGGAAGAAATGGCAACAATTTGCACTACTTTAACCTTGAACACAGCTCAAGCAAAAC  
ACACTGGCTTCTACAGCTGCAAAATATCTAGCTGTACCTACTTCAAGAAGAAGGAACAGAATCTGCAATCTATATATTTATTAGTGATACAGGTAGAC  
CTTTCGTAGAGATGTACAGTGAAATCCCGAAATATACACATGACTGAAGGAAGGAGCTCGTCATTCCCTGCGGGTTACGTCACCTAACATCACTG  
TTACTTTAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAAACGCATAATCTGGGACAGTAGAAGGGCTTCATCATATCAATGCAACGTACA  
AAGAAATAGGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTGTGTAAGCAAACTATCTCACATCGACAAACCAATACAATCATAGATGTC  
AAATAAGCACACCAGCCAGTCAAATTAAGAGGCTACTTCTGCTCAATTTGACTGCTACCCTCCCTTGAACAGGAGGTTCAAATGACCT  
GGAGTTACCTGATGAAAAAATAAGAGAGCTTCCGTAAGGCGAGCAATTGACCAAGCAATCCCATGCCAATATTTACAGTGTCTTACTATTG  
ACAAAATGCAACAAGAGCAAGGACTTTATACTTGTGCTGTGAAGAGTGGACCATCATTCAAATCTGTTAACACCTCAGTGCAATATATGATAAG  
CATTCATCACTGTGAAACATCGAAACAGCAGGTGCTTGAACCGTAGCTGGCAAGCGCTTACCAGCTCTCTATGAAAGTGAAGGCAATTCCTCGC  
CGGAAGTTGATGTTAAAAAGATGGGTACCTGGCAGTGAAGAAATCTGCTCGCTATTGACTCGTGGCTACTCGTTAATTATCAAGGACGTAACGAA  
AGGATGACGGGAATTATACAATCTTGCTGAGCATAAAACAGTCAATGTGTTTAAAAACCTCACTGCCACTCTAATTGTCAATGTGAACCCAGATT  
ACGAAAAGGCCGTGTCATCGTTTCCAGACCGGCTCTTACCCACTGGGACAGACAAATCTGACTTGTACCGCATATGGTATCCCTCAACCTACAA  
TCAAGTGGTTCTGGACCCCTGTAACCATATCATTCCGAAGCAAGGTGTGACTTTTGTTCGAATATGAAGAGTCTTTATCTGGATGCTGACAGCA  
ACATGGGAACAGAATTGAGAGCATCACTCAGCGCATGGCAATATAGAAGGAAGAATAAGATGGCTAGCACCTTGGTTGTGGCTGACTCTAGAATTT  
CTGGAATCTACATTTGCATAGCTTCCAATAAAGTTGGGACTGTGGGAAGAAACATAAGCTTTATACAGATGTGCCAAATGGGTTTCATGTTAACT  
TGGAAAAATGCCGACGSAAGGAGAGGACCTGAACTGTCTTGACAGTTAACAAGTTCTTATACAGAGACGTTACTTGGATTTTACTGCGGACAGTTA  
ATAACAGAACATGCACACTACAGTATTAGCAAGCAAAAAATGGCCATCACTAAGGAGCACTCCATCACTCTTAATCTTACCATCATGAATGTTTCCCTGC  
AAGATTACGGACCTATGCTGACAGAGCCAGGAATGTATACAGGGGAAGAATCTCCAGAAGAAAGAAATTACAATCAGAGGTGAGCACTGCAACA  
AAAAGGCTGTTTCTCTCGGATCTCCAAATTTAAAGCACAAGGAATGATTGACCACACAAAGTAATGTAAACATTAAAGGACTCATTAAAAAGTAA  
CAGTTGCTCATATCATCTTGATTATTGTCACTGTTGCTAACTTTCAGGCTCAAGGGCGAATTCAGGCCTAAGCTTCTAGGTATCGATCTCGAGCAA  
GTCTAGAAAGCCATGGATATCGGATCCACTACGGTTAGAGCTCGCTGATCAGCTCGACTGTGCTCTAGTTGCCAGCCATCTGTTGTTGCCCTC

Fig. 28A

CCCCGTGCTTCTTGACCTGGAAGGTGCCACTCCACTGTCTTTCTAATAAATGAGGAAATTGCATCGCATTGCTGAGTAGGTGTCATTCTAT  
TCTGGGGGGTGGGTGGGGCAGGACAGCAAGGGGAGGATTGGGAAGACAATAGCAGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCGCGCTGGA  
GGATCATCCAGTAGCAAGTCCCATCAGTGATGGAGTTGGCCACTCCCTCTCTGCGGCTCGCTCGCTCACTGAGGCGGGCGACCAAGGTGCGCGA  
CGCCCGGCTTTGCCGGGGGGCTCAGTGAGCGAGCGAGCGGCCAGGATTCTTGTGTTGCTCCAGACTCTCAGGCAATGACCTGATAGCTTTGT  
AGAGACCTCTAAAAATAGCTACCTCTCCGGCATGAATTTATCAGCTAGAAGGTTGAATATCATATTGATGGTGATTTGACTGCTCCGGCTTTCT  
CACCGCTTTGAATCTTTACCTACACATTAAGTCAAGGCTTTAAATATATGAGGTTCTAAAAATTTTATCCTTGCTGAAATAAGGCTTCT  
CCCGCAAAGTATTACAGGTCATATGTTTTGGTACAACCGATTAGCTTTATGCTCTGAGGCTTTATGCTTAATTTGCTAATCTTTGCTTGC  
CTGTATGATTTATTGGATGTTGGAATTCCTGATGCGGTTATTTCTCTTACGCATCTGTGCGGTTATTCACACCGCATATGTCAGTCTCAGTACAAT  
CTGCTCTGATGCGCATAGTTAAGCCAGCCCGACACCGCCAACCCGCTGACGCGCTGACGGGCTTGTCTGCTCCCGCATCCGCTTACAGACA  
AGCTGTGACCGTCTCCGGGAGCTGCATGTGTGAGAGTTTTACCGCTCATCCGAAACGCGGAGACGAAAGGGCTCGTGATAGCCTATTTTATA  
GGTTAATGTCATGATAAATGGTTTTCTAGACGTGAGTGGCACTTTTCGGGAAATGTGCGCGGAACCCCTATTGTTATTTTCTAAATACATTC  
AAATATGTATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATTGAAAAAGGAGAGTATGAGTATTCACATTTCCGTGCGCTTAT  
TCCCTTTTTGGGCACTTTGCTTCTGTTTTGCTCAGCCAGAAACGCTGCTGAAAGTAAAGATGCTGAAGATCAGTTGGGTGCAGAGTGGGTTA  
CATCGAAGTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTGCGCCGGAAGAACGTTTTCCAATGATGAGCACTTTAAAGTTCTGCTATGTGGCG  
GGTATTATCCCGTATTGACCGCGGCAAGAGCACTCGGTCGCGCATACACTATTCTCAGAAAGTACTTGGTTGAGTACTCACCAGTCACAGAAAAGCA  
TCTTACGGATGGCATGACAGTAAGAGAATTATGAGTGTGCCATAACCATGAGTGATAACACTGCGGCCAAGTACTTCTGACAACGATCGGAGACC  
GAAGGAGCTAACCGCTTTTTGCAACAATGGGGATCATGTAACCTGATCGTTGGAACCGGAGCTGAATGAAGCCATACCAACGACGAGCG  
TGACACCAGGATGCCGTGATGCAATGGCAACAGTTGCGCAACTATTAACTGGCGAAGTACTTACTTAGCTTCCGGCAACAATTAAGACTGGAT  
GGAGGCGGATAAAGTTGAGGACCACTTCTGCGCTCGGCCCTCCGCTGCTGCTTTATTGCTGATAAATCTGGAGCCGCTGAGCTGGGTCTCGCG  
TATCATTCAGCACTGGGGCCAGATGGTAAGCCCTCCGCTATCCTAGTTATCTACAGACGGGAGTCAGGCAACTATGGATGAACGAATAGACAGAT  
CGCTGAGATAGGTGCTCACTGATTAAGCATTGGTAAGTGTGAGCAAGTTTACTCATATATACTTTAGATTGATTTAAACTTCATTTTAATTTAA  
AAGGATCTAGGTGAAGATCCTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTGCTTCCACTGAGCGTCAGACCCGCTAGAAAAGATCAA  
AGGATCTTCTTGAGATCCTTTTTTCTGCGGTAATCTGCTGCTTGCAACAAAAAACCCGCTACCAGCGGTGGTTTGTGCGGATCAAGAGCT  
ACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGCGCAGATACCAATACTGTCTTCTAGTGATAGCGTAGTTAGGCCACCACTTCAAGAACTC  
TGAGCAGCGCTACATACCTCGCTCTGCTAATCCTGTTACAGTGGCTGCTGCAAGTGGGATAAGTCTGCTTACCAGGTTGACTCAAGACGATA  
GTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGTTCTGTCACACAGCCAGCTTGAGCGAAGCACTACACCAACTGAGATACCTACAGCG  
TGAGCTATGAGAAAGCGCCAGCTTCCGAAAGGAGAAAGCGGACAGGTATCCGTAAGCGGAGGTCGGAACAGGAGAGCGACAGGAGCTTCC  
AGGGGAAACGCTGGTATCTTTATAGTCTGTGCGGTTTCCGCACTCTGACTGAGCGTCGATTTTGTGATGCTGTCAGGGGGCGGAGCTATG  
GAAAAACGCGACCAACGCGGCTTTTACGTTCTGCGCTTTTGTGCGCTTTTGTGCTCATGTTCTTTCTGCGTTATCCCTGATTCTGTGATAA  
CCGTATTACCGCTTTGAGTGAAGTGATACCGCTCGCGCAGCGAAGCAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACG  
CAAACCGCTCTCCCGCGCTTGGCCGATTATTAATGAGCTGGCGCTCGCTCGCTCACTGAGGCGCCCGGCAAGCCGGGCGTGGGCGAC  
CTTTGCTGCGCGGCTCAGTGAGCGAGCGAGCGCAGAGAGGAGTGGCCAACTCCATCACTGAT

*Fig. 28B*

HumanFGF-20

atggctcccttagccgaagtcgggggctttctgggcggcctggagggcttgggccagcag  
M A P L A E V G G F L G G L E G L G Q Q

gtgggttcgcatttctgttgccctctgccggggagcggccgcgctgctggcgagcgc  
V G S H F L L P P A G E R P P L L G E R

aggagcgcggcggagcggagcgcgcggcggcggggcggcgcagctggcgacactg  
R S A A E R S A R G G P G A A Q L A H L

cacggcatcctgcgcgcggcagctctattgccgcaccggcttccacctgcagatcctg  
H G I L R R R Q L Y C R T G F H L Q I L

cccgacggcagcgtgcagggcaccggcaggaccacagcctcttcggtatcttgaattc  
P D G S V Q G T R Q D H S L F G I L E F

atcagtggtggcagtgaggactggtcagtattagaggtgtggacagtggtctctatcttga  
I S V A V G L V S I R G V D S G L Y L G

atgaatgacaaaggagaactctatggatcagagaaacttacttccgaatgcacatttagg  
M N D K G E L Y G S E K L T S E C I F R

gagcagtttgaagagaactggtataacacctattcatctaacatatataaacatggagac  
E Q F E E N W Y N T Y S S N I Y K H G D

actggccgcaggtatthtggcacttaacaaagacggaactccaagagatggcgccagg  
T G R R Y F V A L N K D G T P R D G A R

tccaagaggcatcagaaattacacatttcttacctagaccagtggtccagaaagagtt  
S K R H Q K F T H F L P R P V D P E R V

ccagaattgtacaaggacctactgatgtacactga  
P E L Y K D L L M Y T

*Fig. 29*

Mouse FGF-21 cDNA in pGEM-T

gagcgcagccctgatggaatggatgagatctagagttgggaccctgggactgtgggtccg    SEQ ID NO: 1  
                  M E W M R S R V G T L G L W V R    SEQ ID NO: 2

actgctgctggctgtcttcctgctgggggtctaccaagcatacccatccctgactccag  
L L L A V F L L G V Y Q A Y P I P D S S

ccccctcctccagtttgggggtcaagtccggcagaggtacctctacacagatgacgacca  
P L L Q F G G Q V R Q R Y L Y T D D D Q

agacactgaagcccacctggagatcaggaggatggaacagtggtaggcgcagcacaccg  
D T E A H L E I R E D G T V V G A A H R

cagtccagaaagtctcctggagctcaaagcctgaagccaggggtcattcaaatcctggg  
S P E S L L E L K A L K P G V I Q I L G

tgtcaaagcctctaggtttcttccaacagccagatggagctctctatggatcgctca  
V K A S R F L C Q Q P D G A L Y G S P H

ctttgatcctgaggcctgcagcttcagagaactgtgctggaggacggttacaatgtgta  
F D P E A C S F R E L L L E D G Y N V Y

ccagtctgaagcccatggcctgccccctgcgtctgcctcagaaggactccccaaccagga  
Q S E A H G L P L R L P Q K D S P N Q D

tgcaacatcctgggacctgtgcgttcttgcctatgccaggcctgctccacgagcccca  
A T S W G P V R F L P M P G L L H E P Q

agaccaagcaggattcctgccccagagccccagatgtgggtcctctgacccctgag  
D Q A G F L P P E P P D V G S S D P L S

catggtagagccttacagggccgaagccccagctatgcgtcctgactcttctgaatc  
M V E P L Q G R S P S Y A S

*Fig. 30*




Fig. 31

AAAATTGCGGCCGCGGAATTTGACTCTAGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACC  
GCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGAGTTCCGGTTACATAACTT  
ACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC  
ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCTATTGACGTCAATGA  
CGGTAATGGCCCGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTGGCAGTACATCTAGTATTAGTCATCGCTATTACCATG  
GTGATGCGGTTTTGGCAGTACACCAATGGGGTGGATAGCGGTTTGACTCAGGGGATTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGT  
TTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAAATAACCCCGCCCGTTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGTCTATAT  
AAGCAGAGCTCGTTTASTGAACCGTCAGATCGCTGGAGACGCCATCCACGCTGTTTGACTCCATAGAAGACACCGGACCGATCCAGCCTCCGC  
GGCCGGGAACGGTGCAATTGGAACGGGATTCCCGTGCCAAGAGTGACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGC  
ATGCTATACTGTTTTTGGCTTGGGGCTATACACCCCGCTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTATTATGACCATT  
ATTGACCACTCCCTTATTGGTGACGATACTTCCATTACTAATCCATAACATGGCTCTTTGCCACAATCTCTCTATTGGCTATATGCCAATACTCT  
GTCCTTCAGAGACTGACACGGACTCTGTATTTTACAGGATGGGGTCCATTATTTACAAATTCACATATACAACAACCGCGTCCCGGTGCC  
GCAGTTTTTATTAACATAGCGTGGGATCTCCGACATCTCGGGTACGTGTTCCGGACATGGGCTCTCTCCGGTAGCGGGGAGCTTCACATCCGA  
GCCCTGGTCCCATCGTCCAGCGGCTCATGTCGCTCGGCAGCTCCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCACCACC  
ACCAAGTGTCCGCACAAGCGCGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGAGATTGGCTCGCACCTGGACGCAGATGGAAGACTTAAGGC  
AGCGGCAGAGAAGATGCAGGCAGCTGAGTTGTTGTATTCTGATAAGAGTCAGAGGTAACCTCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTA  
GTCTGACGAGTACTCGTTGCTGCCGCGCGGCCACCAGACATAATAGCTGACAGACTAACAGACTGTTCCCTTCCATGGGTCTTTCTGCACTACC  
GTGTCGACCTAAGAAATCAGGTATGGCTGCTGTTCTATCACTACCTGCCAGCTCTGCCAGAGAGCGGTGGTCTGGTGCCTCCACCAGGTCA  
CTTCAAGACCCAAAACGTCTGTACTGCAAAAACGGTGGTTTCTTCTGCGCATCCACCCGACGGCCGAGTGGACGGGTCCGCGAGAAGAGCGAC  
CCACACATCAAACTACAACCTCAAGCAGAAGAGAGAGGGGTGTGTCTATCAAGGAGTGTGTGCAAAACGTTACCTTGCTATGAAAGAAGATGGAA  
GATTACTAGCTCTCAATATGTTTACAGACGAGTGTCTTTTTTGAACGATTGGAGTCTAATAACTACAATACTTACCGGTCAAGGAATACACCAG  
TTGTATGTGGCACTGAAACGAACGGGCAGTATAAACTGGATCCAAAACAGGACCTGGGCAGAAAGCTATACTTTTTCTTCCAATGTCTGCTAAG  
AGCTGATCTTAATGGCAGCATCTGATCTCATTTTACATGAAGCTTCTAGGTATCGATCTCGAGCAAGTCTAGAAAGCCATGATATCGGATCCACT  
ACGCGTTAGAGCTCGTGATCAGCTCGACTGTGCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCGTGCTTCTTGACCTGGAAGGT  
GCCACTCCCACTGTCTTTCTAATAAAATGAGGAATTCATCGCATTTGCTGAGTAGGTGTCATTCTATTCTGGGGGTGGGGTGGGGCAGGACA  
GCAAGGGGGAGGATTGGGAAGACAATAGCAGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCGCGCTGGAGGATCATCCAGCTAGCAAGTCCCA  
TCAGTGATGGAGTTGGCACTCCCTCTCTGCGCGCTCGTCTGCTCACTGAGCGGGCGACCAAGGTGCGCCGACGCCCGGGCTTTGCCCGGGCGG  
CCTCAGTGAGCGAGCGAGCGGCCAGCGATTCTCTGTTTGTCTCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGC  
TACCTCTCCGCATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTATTGACTGTCTCGGCCTTTCTACCCGTTTGAATCTTTA  
CCTACACATTACTCAGGCATTGCATTTAAAAATATGAGGGTTCTAAAAATTTTATCCTTGCGTTGAAATAAAGCTTCTCCCGCAAAGTATTAC  
AGGGTCATAATGTTTTTGGTACAACCGATTAGCTTTATGCTCTGAGGCTTATTGCTTAATTTGCTAATCTTTGCCCTTGCTGTATGATTATT  
GGATGTTGGAATTCCTGATCGGATTTTCTCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACCTCTCAGTACAATC

*Fig. 32A*

TGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACCCCGTGACGGCCCTGACGGGCTTGCTGCTCCCGGCATCCGCTTACAGAC  
AAGCTGTGACCGTCTCCGGGAGCTGTCATGTGTGACAGGTTTTCACCGTCATCACCGAAACGGCGAGACGAAAGGGCTCGTGATACGCTATTTTT  
ATAGGTTAATGTCATGATAAATAGGTTTCTTAGAGCTCAGGTGGCACTTTTCGGGGAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATA  
CATTCAAATATGTATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATGTACCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGAATC  
GGGAGCGGCGATACCGTAAAGCAGGAGGAGCGGTGAGCCATTTCGCTTCAGCAATATCAGGGTAGCCAACGCTATGCTCTGATAGCGGTCCGCCA  
CACCAGCGCGGCACAGTCGATGAATCCAGAAAGCGGCCATTTCCACCATGATATTCGGCAAGCAGGCATCGCCATGGGTACGACGAGATCCTC  
GCCGTGGGCGATGCGCGCTTGAGCTGGCGAACAGTTGCGCTGGCGCGAGCCCTGATGCTCTTCGTCAGATCATCTGATCGACAAGACCGGCT  
TCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCAATGGGAGGTAGCCGATCAAGCGTATGCGACCGCGCATTGTCATCAG  
CCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCGGCACTTCGCCAATAGCAGCCAGTCCCTTCCGCTTCAGT  
GACAAGCTCGAGCAGCTGCGCAAGGAACGCCCGTCTGGCCAGCCACGATAGCCGCGCTGCCCTGCTCTGAGTTTCATTGAGGACCGGACAGG  
TCGGTCTTGACAAAAAGAACCGGGCGCCCTGCGCTGACAGCGGGAACAGCGCGCATCAGAGCAGCCGATTGTCTGTTGGCCAGTCATAGCCGA  
ATAGCCTCTCCACCAAGCGGCGGAGAACCTGCGTGCAATCCATCTTGTTCATATGCGAAACGATCCTCATCCTGTCTTGTATCAGATCTTGA  
TCCCTGCGCCATCAGATCCTTGGCGGCAAGAAAGCCATCCAGTTTACTTTGACGGGCTTCCCAACCTTACCAGAGGGCGCCCGAGTGGCAATTCC  
GGTTCGCTTGTCTGCATAAAACCGCCAGTCTAGCTATCGCCATGTAAGCCACTGCAAGCTACCTGCTTCTCTTTGCGCTTGGCTTTCCCTTG  
TCCAGATAGCCAGTAGCTGACATTCATCCGGGTGAGCAGCGTTTCTGCGACTGGCTTTCTACGTGTTCCGCTTCTTTAGCAGCCCTTGGCGCC  
TGAGTGTCTGCGGCGAGGTGAAGCTGTCAATTCGCGTTAAATTTTGTTAATCAGCTCATTTTAAACCAATAGCCGAATCGGCAAAATCCCT  
TATAAATCAAAGAATAGCCGAGATAGGTTGAGTGTGTTCCAGTTTGAACAAGAGTCCACTATTAAGAAGCTGGAATCCACGTCAAAGGGC  
GAAAAACCGTCTATCAGGGCGATGGCGATCAGCTTATGCGGTGTGAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGGCGCTCTCCG  
CTTCTCGCTCACTGACTCGCTGCGCTCGCTGTTGCGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAAACGTTATCCACAGAATCAGG  
GGATAACGAGGAAAGACATGCGGCGGCCACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAGGCGCGGTTGCTGGCGTTTTTC  
ATAGGCTCCGCCCCCTGACGAGCATCAGAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAGATACAGGCGTTTCCCC  
TGGAGCTCCCTCGTGGCTCTCTGTTCCGACCTGCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAGCGTGGCGCTTCTCATAGC  
TCAGCTGTAGGTATCTCAGTTGCGGTGAGGTGCTGCTCCAAGCTGGGCTGTGTGACGAACCCCGTTTCAGCCGACCGCTGCGCTTATCCG  
GTAACATCTGCTTTGAGTCCAACCCGTAAGACAGCACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGAGGCGG  
TGCTACAGAGTTCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGAAAA  
AGAGTTGGTAGCTCTTGATCCGCAACAAACCACCGTGGTAGCGCGGTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCA  
AGAAGATCCTTTGATCTTTTCTTACTGAACGGTGATCCCACCGGAATTCGGGCCCATGTTCTTCTGCGTTATCCCTGATTCTGTGGAATCCG  
TATTACCGCCTTTGAGTGAGCTGATACCGCTCGCGCAGCGGAACGACCGAGCGAGGAGTCAAGTGAAGGAGGAAGCGGAAGCGCCCAATACGC  
AAACCGCTCTCCCGCGGCTTGGCGGATTCAATATGAGCTGGCGGCTGCTGCTCACTGAGGCGCGCGGCAAGCCGGGCTGGGCGA  
CCTTTGTCGCCCGGCTCAGTGAGCGAGCGAGCGCAGAGAGGAGTGGCAACTCCATCACTGAT

*Fig. 32B*





Fig. 33



Inhibition of HMVEC Proliferation by sFlt-1 rAAV



sFlt-1 Protein in Conditioned Media (in nM)

FIGURE 34




Figure 35. Fluorescein Angiography




Figure 36. Epoxy Sections






Figure 37. Lectin and BrdU staining






Figure 39. ERG of 070900 Rat#4 on 082300 (6 wk)

## SEQUENCE LISTING

<110> Manning, William C., Jr.  
 Dwarki, Varavani J.  
 Rëndahl, Katherine  
 Zhou, Shang-Zhen  
 McGee, Laura H.  
 Lau, Dana  
 Flannery, John G.  
 Miller, Sheldon  
 Wang, Fei  
 Di Polo, Adriana

<120> USE OF RECOMBINANT GENE DELIVERY VECTORS  
 FOR TREATING OR PREVENTING DISEASES OF THE EYE

<130> PP01588.005 (20263.40)

<140> US/09,665,493

<141> 2000-09-20

<160> 12

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 6514

<212> DNA

<213> Homo sapien

<400> 1

accatgttagc	ggccctgcgc	gctcgcctgc	tactgagggc	cgcccgggca	aagcccgggc	60
gtcggggcgac	ctttgggtcgc	ccggcctcag	tgagcgagcg	agcgcgcgaga	gagggagtg	120
ccaactccat	cactaggggt	tccttgtagt	taatgattaa	cccgccatgc	tacttatcta	180
cgtagccatg	ctctagggaa	ttggcgcg	aatttcgact	ctaggccatt	gcatacgttg	240
tatctatatc	ataatatgta	catttatatt	ggctcatgtc	caatatgacc	gccatgttga	300
cattgattat	tgactagtta	ttaatagtaa	tcaattacgg	ggtcattagt	tcatagccca	360
tatatggagt	tccgcgttac	ataacttacg	gtaaatggcc	cgccctggctg	accgccaac	420
gaccccgcc	cattgacgtc	aataatgacg	tatgttccca	tagtaacgcc	aatagggact	480
ttccattgac	gtcaatgggt	ggagtattta	cggtaaactg	cccacttggc	agtacatcaa	540
gtgtatcata	tgccaagtcc	gccccctatt	gacgtcaatg	acggtaaagt	gcccgcctgg	600
cattatgccc	agtacatgac	cttacgggac	tttctactt	ggcagtagat	ctacgtatta	660
gtcatcgcta	ttaccatggt	gatgcggttt	tggcagtaca	ccaatggg	tggtatagcg	720
tttgactcac	ggggatttcc	aagtctccac	cccattgacg	tcaatgggag	tttgtttttg	780
caccaaaatc	aacgggactt	tccaaaatgt	cgtaataacc	ccgccccgtt	gacgcaaagt	840
ggcggtaggc	gtgtacgggt	ggaggcttat	ataagcagag	ctcgtttagt	gaaccgtcag	900
atcgcttggg	gacgcatcc	acgctgtttt	gacctccata	gaagacaccg	ggaccgatcc	960
agcctccg	gcccgggaacg	gtgcattgga	acgcggttc	cccgtgcca	gagtgcgta	1020
agtaccgcct	atagactcta	taggcacacc	cctttggctc	ttatgcatgc	tatactgttt	1080
ttggcttggg	gcctatacac	ccccgctcct	tatgctatag	gtgatggtat	agcttagcct	1140
ataggtgtgg	gttattgacc	attattgacc	actcccctat	tggtgacgat	actttccatt	1200
actaatccat	aacatggctc	tttgccacaa	ctatctctat	tggtatatatg	ccaatactct	1260
gtccttcaga	gactgacacg	gactctgtat	ttttacagga	tgggggtccat	ttattattta	1320
caaattcaca	tatacaacaa	cgccgtcccc	cgtgcccga	gtttttatta	aacatagcgt	1380

actaatccat	aacatggctc	tttgccacaa	ctatctctat	tggctatatg	ccaatactct	1260
gtccttcaga	gactgacacg	gactctgtat	ttttacagga	tgggggtccat	ttattatttta	1320
caaattcaca	tatacaacaa	cgccgtcccc	cgtgcccgca	gtttttatta	aacatagcgt	1380
gggatctccg	acatctcggg	tacgtgttcc	ggacatgggc	tcttctccgg	tagcggcgga	1440
gcttccacat	cagagccctg	gtcccacccg	tccagcggct	catggctcgt	cggcagctcc	1500
ttgtccctaa	cagtggaggc	cagacttagg	cacagcacia	tgccccccac	caccagtgtg	1560
ccgcacaagg	ccgtggcggg	agggtatgtg	tctgaaaatg	agctcggaga	ttgggctcgc	1620
acctggacgc	agatggaaga	cttaaggcag	cggcagaaga	agatgcaggc	agctgagttg	1680
ttgtattctg	ataagagtca	gaggtaactc	ccgttgccgt	gctgttaacg	gtggagggca	1740
gtgtagtctg	agcagtactc	gttgcgtccg	cgcgcgccac	cagacataat	agctgacaga	1800
ctaacagact	gttcctttcc	atgggtcttt	tctgcagtca	ccgtcgtcga	cctaagaatt	1860
caggcctaag	cttcctaggt	atcgatctcg	agcaagtcta	gagggagacc	acaacggttt	1920
ccctctagcg	ggatcaattc	cgcccccccc	cctaacgtta	ctggccgaag	ccgcttgga	1980
taaggccggg	gtgcgtttgt	ctatatgtta	ttttccacca	tattgccgtc	ttttggcaat	2040
gtgagggccc	ggaaacctgg	ccctgtcttc	ttgacgagca	ttcctagggg	tctttccctc	2100
ctcgccaaag	gaatgcaagg	tctgttgaa	ccgttgaaag	aagcagttcc	tctggaagct	2160
tcttgaagac	aaacaacgtc	tgtagcgacc	ctttgcaggc	agcggaaacc	cccacctggc	2220
gacaggtgcc	tctgcggcca	aaagccaagt	gtataagata	cacctgcaaa	ggcggcacaa	2280
ccccagtgcc	acgttgttgag	ttggatagtt	gtggaagag	tcaaatgggt	ctcctcaagc	2340
gtattcaaca	aggggctgaa	ggatgcccag	aaggtaaccc	attgtatggg	atctgatctg	2400
gggcctcggg	gcacatgott	tacatgtgtt	ttagtcaggt	taaaaaaacg	tctaggcccc	2460
ccgaaccacg	gggacgtggg	tttcctttga	aaaacacgat	aataccatgg	ccgcggggag	2520
catcaccacg	ctgccagccc	tgccggaggc	cggcggcagc	ggcgttttcc	cgccgggcca	2580
cttcaaggac	cccaagcggc	tgtactgcaa	gaacgggggc	ttcttctcgc	gcateccacc	2640
cgacggccga	gtggacgggg	tccgcgagaa	gagcgaccca	cacatcaaac	tacaacttca	2700
agcagaagag	agaggggttg	tgtctatcaa	aggagtgtgt	gcaaaccgtt	accttgctat	2760
gaaagaagat	ggaagattac	tagcttctaa	atgtgttaca	gacgagtgtt	tcttttttga	2820
acgattggag	tctaataact	acaatactta	ccggtcaagg	aaatacacca	gttggtatgt	2880
ggcactgaaa	cgaactgggc	agtataaaact	tggatccaaa	acaggacctg	ggcagaaagc	2940
tatacttttt	cttccaatgt	ctgctaagag	ctgatcttaa	tggcagcatc	tgatctcatt	3000
ttacatgaag	ctgggtggcat	ccctgtgacc	cctccccagt	gcctctcctg	gocctggaa	3060
ttgccactcc	agtgcaccac	agccttgtcc	taataaaatt	aagttgcatc	atcttctctg	3120
actaggtgtc	cttctataat	attatggggg	ggaggggggt	gggtatggagc	aagggggcaag	3180
ttgggaagac	aacctgtagg	gcctgcgggg	tctattggga	accaagctgg	agtgcagtgg	3240
cacaactctg	ctcactgca	atctccgct	cctgggttca	agcgattctc	ctgcctcagc	3300
ctcccgagtt	gttggggatt	caggcatgca	tgaccaggct	cagctaattt	ttgttttttt	3360
ggtagagacg	gggtttcacc	atattggcca	ggctgtgtct	caactcctaa	tctcaggtga	3420
tctacccacc	ttggcctccc	aaattgctgg	gattacaggc	gtgaaccact	gctcccttcc	3480
ctgtccttct	gattttaaaa	taactatacc	agcaggagga	cgtccagaca	cagcataggc	3540
tacctggcca	tgcccaaccg	gtgggacatt	tgagtgtcct	gcttggcact	gtcctctcat	3600
gcgttgggtc	cactcagtag	atgcctgttg	aattatcgga	tccactacgc	gttagagctc	3660
gctgatcagc	ctcgactgtg	ccttctagtt	ccagccatc	tggtgtttgc	ccctcccccg	3720
tgcttctcct	gacctgggaa	gggtgccact	ccactgtcct	ttcctaataa	aatgaggaaa	3780
ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	gggcaggaca	3840
gcaaggggga	ggattgggaa	gacaatagca	ggggggtggg	cgaagaactc	cagcatgaga	3900
tcccgcgct	ggaggatcat	ccagccaatt	ccctagagca	tggctacgta	gataagtagc	3960
atggcgggtt	aatcattaac	tacaaggaac	ccctagtgat	ggagtgggcc	actccctctc	4020
tgccgcctcg	ctcgtcact	gaggccgggc	gaccaaagg	cgcccgacgc	ccgggctttg	4080
cccgggcggc	ctcagtgagc	gagcgagcgc	gcaggggggtg	ggcgaagaac	tccagcatga	4140
gatccccgcg	ctggaggatc	atccagcggg	cgccccggaa	aacgattccg	aagcccaacc	4200
tttcatagaa	ggcggctggg	gaatcgaaat	ctcgtgatgg	cagggtgggc	gtcgtctggg	4260
cggtcatttc	gaaccccgga	gtcccgctca	gaagaactcg	tcaagaaggc	gatagaaggc	4320
gatgcgctgc	gaatcgggag	cggcgatacc	gtaaagcacg	aggaagcggg	cagcccattc	4380
gccgcccaagc	tcttcagcaa	tatcacgggt	agccaacgct	atgtcctgat	agcggctcgc	4440



cacacccagc	cggccacagt	cgatgaatcc	agaaaagcgg	ccattttcca	ccatgatatt	4500
cggcaagcag	gcacgcgccat	gggtcacgac	gagatccctcg	ccgtcgggca	tgcgcgcctt	4560
gagcctggcg	aacagttcgg	ctggcgcgag	ccccgatgc	tcttcgtcca	gatcatcctg	4620
atcgacaaga	ccggcttcca	tccgagtagc	tgctcgctcg	atgcgatgtt	tcgcttggtg	4680
gtcgaatggg	caggtagccg	gatcaagcgt	atgcagccgc	cgcattgcat	cagccatgat	4740
ggatactttc	tcggcaggag	caagggtgaga	tgacaggaga	tcctgccccg	gcacttcgcc	4800
caatagcagc	cagtcoccttc	ccgcttcagt	gacaacgtcg	agcacagctg	cgcagggaac	4860
gcccgtcgtg	gccagccacg	atagccgcgc	tgccctcgcc	tgcagttcat	tcaggggcacc	4920
ggacaggctcg	gtcttgacaa	aaagaaccgg	gcgccccctg	gctgacagcc	ggaacacggc	4980
ggcatcgagag	cagccgattg	tctgtttgtc	ccagtcatag	ccgaatagcc	tctccaccca	5040
agcggccgga	gaacctgcgt	gcaatccatc	ttgttcaatc	atgcgaaacg	atcctcatcc	5100
tgtctcttga	tcagatcttg	atccccctgc	ccatcagatc	cttggcggca	agaaagccat	5160
ccagtttact	ttgcagggct	tcccaacctt	accagagggc	gccccagctg	gcaattccgg	5220
ttcgcttgct	gtccataaaa	ccgcccagtc	tagctatcgc	catgtaagcc	cactgcaagc	5280
tacctgcttt	ctctttgctc	ttgcgttttc	ccttgtccag	atagcccagt	agctgacatt	5340
catcgggggt	cagcaccggt	tctgcggaat	ggctttctac	gtgttcgcgt	tccttttagca	5400
gcccttgctc	cctgagtgct	tgccgcagcg	tgaaagctgtc	aattccgcgt	taaatttttg	5460
ttaaatcagc	tcatttttta	accaataggc	cgaatccggc	aaaatccctt	ataaatcaaa	5520
agaatagccc	gagatagggt	tgagtgttgt	tccagtttgg	aacaagagtc	cactattaaa	5580
gaacgtggac	tccaacgtca	aagggcgaaa	aaccgtctat	cagggcgatg	gcggtacagc	5640
ttatgcggtg	tgaaataccg	cacagatgcg	taaggagaaa	ataccgcate	aggcgctctt	5700
ccgcttctct	gctcactgac	tcgctgcgct	cggctcgctc	gctgcggcga	gcggtatcag	5760
ctcactcaaa	ggcggtaata	cggttatcca	cagaatcagg	ggataacgca	ggaaagaaca	5820
tgtgagcaaa	aggccagcaa	aaggccagga	accgtaaaaa	ggccgcgttg	ctggcgcttt	5880
tccataggct	ccgccccctt	gacgagcatc	acaaaaatcg	acgctcaagt	cagaggtggc	5940
gaaacccgac	aggactataa	agataccagg	cgtttccccc	tggaaagctc	ctcgtgcgct	6000
ctcctgttcc	gaccctgcgc	cttaccggat	acctgtccgc	ctttctccct	tcgggaagcg	6060
tgggcgcttc	tcatagtctc	cgtgttaggt	atctcagttc	gggtgtaggtc	gttcgctcca	6120
agctgggctg	tgtgcacgaa	cccccgcttc	agcccgaccg	ctgcgcctta	tcgggtaaact	6180
atcgtcttga	gtccaacccg	gtaagacacg	acttatcgcc	actggcagca	gccactggta	6240
acaggattag	cagagcgagg	tatgtaggcg	gtgctacaga	gttcttgaag	tggtggccta	6300
actacggcta	cactagaagg	acagtatttg	gtatctgcgc	tctgctgaag	ccagttacct	6360
tcggaaaaag	agttggtagc	tcttgatccg	gcaaacaaac	caccgctggt	agcggcggtt	6420
ttttgtttgc	aagcagcaga	ttacgcgcag	aaaaaaagga	tctcaagaag	atcctttgat	6480
cttttcttac	tgaacgggtga	tccccacggg	aatt			6514

&lt;210&gt; 2

&lt;211&gt; 5610

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 2

aaaacttgcg	gccgcggaat	ttcgactcta	ggccattgca	tacgttgat	ctatatcata	60
atatgtacat	ttatatggc	tcattgtccaa	tatgaccgcc	atgttgacat	tgattattga	120
ctagttatta	atagtaatca	attacgggggt	cattagtcca	tagcccatat	atggagtcc	180
gcgttacata	acttacggta	aatggcccgc	ctggctgacc	gcccacgcac	ccccgcccat	240
tgcgtcaaat	aatgacgtat	gttcccatag	taacgccaat	agggactttc	cattgacgtc	300
aatgggtgga	gtattttacg	taaaactgcc	acttggcagt	acatcaagtg	tatcatatgc	360
caagtccgcc	ccctattgac	gtcaatgacg	gtaaatggcc	cgcctggcat	tatgccaggt	420
acatgacctt	acgggacttt	cctacttggc	agtagatcta	cgtattagtc	atcgctatta	480
ccatgggtgat	gcgggttttg	cagtacacca	atgggcgtgg	atagcggttt	gactcacggg	540
gattttccaag	tctccacccc	attgacgtca	atgggagttt	gttttggcac	caaaatcaac	600
gggactttcc	aaaatgtcgt	aataaccccg	ccccgttgac	gcaaatgggc	ggtaggcggtg	660

tacgggtggga	ggctctatata	agcagagctc	gttttagtgaa	ccgtcagatc	gcctggagac	720
gccatccacg	ctgttttgac	ctccatagaa	gacaccggga	ccgatccagc	ctcccgggcc	780
gggaacggtg	cattggaacg	cggattcccc	gtgccaaagag	tgacgtaagt	accgcctata	840
gactctatag	gcacaccctt	ttggctctta	tgcatgctat	actgtttttg	gcttggggcc	900
tatacaccoc	cgtcccttat	gotatagggtg	atggtatagc	ttagcctata	gggtgtgggtt	960
attgaccatt	attgaccact	ccctatttgg	tgacgatact	ttccattact	aatccataac	1020
atggctcttt	gccacaacta	tctctatttg	ctatatgcc	atactctgtc	cttcagagac	1080
tgacacggac	tctgtatttt	tacaggatgg	ggccaattta	ttatttacia	attcacatat	1140
acaacaacgc	cgtccccgt	gcccgcagtt	tttattaaac	atagcgtggg	atctccgaca	1200
tctcgggtac	gtgttccgga	catgggctct	tctccggtag	cggcggagct	tccacatccg	1260
agccctggtc	ccatccgtcc	agcggctcat	ggctcgtcgg	cagctccttg	ctcctaacag	1320
tggaggccag	acttaggcac	agcacaatgc	ccaccaccac	cagtgtgccg	cacaaggccg	1380
tggcggtagg	gtatgtgtct	gaaaatgagc	tccgagattg	ggctcgcacc	tggacgcaga	1440
tggaaagactt	aaggcagcgg	cagaagaaga	tgcaggcagc	tgagttgttg	tattctgata	1500
agagtcagag	gtaactcccg	ttgcgggtgt	gttaacggtg	gagggcagtg	tagtctgagc	1560
agtactcgtt	gctgcgcgc	gcccaccag	acataatagc	tgacagacta	acagactgtt	1620
cctttccatg	ggctctttct	gcagtcaccg	tgcgcagcct	aagaattcgc	ccttcgaaac	1680
catgaacttt	ctgctgtctt	gggtgcattg	gagccttgcc	ttgctgctct	acctccacca	1740
tgccaagtgg	tcccaggctg	cacccatggc	agaaggagga	gggcagaatc	atcacgaagt	1800
gggtgaagttc	atggatgtct	atcagcgcag	ctactgccat	ccaatcgaga	ccctgggtgga	1860
catcttccag	gagtaccctg	atgagatcga	gtacatcttc	aagccatcct	gtgtgcccct	1920
gatgcgatgc	gggggctgct	gcaatgacga	gggcctggag	tgtgtgccca	ctgaggagtc	1980
caacatcacc	atgcagatta	tgcggatcaa	acctcaccaa	ggccagcaca	taggagagat	2040
gagcttccta	cagcacaaca	aatgtgaatg	cagaccaaag	aaagatagag	caagacaaga	2100
aaatccctgt	gggccttgtc	cagagcggag	aaagcatttg	tttgtacaag	atccgcagac	2160
gtgtaaatgt	tccctgcaaaa	acacagactc	gogttgcaag	gcgaggcagc	ttgagttaaa	2220
cgaacgtact	tgcagatgtg	acaagccgag	gcggtgagcc	gggcaggagg	aaggagcctc	2280
cctcagggtt	tccggaacca	gatctctcac	caggaaagac	tgatacagaa	agggcgaatt	2340
caggccctaag	cttcctaggt	atcgatctcg	agcaagtcta	gaaagccatg	gatatcggat	2400
ccactacgcy	ttagagctcg	ctgatcagcc	tgcactgtgc	cttctagttg	ccagccatct	2460
gttgtttgcc	cctccccctg	gccttccttg	accctggaag	gtgccactcc	cactgtcctt	2520
tccataataa	atgaggaaat	tgcactgcac	tgtctgagta	gggtgtcatc	tattctgggg	2580
gggtgggtgg	ggcaggacag	caagggggag	gattgggaag	acaatagcag	gggggtgggc	2640
gaagaactcc	agcatgagat	ccccgcgctg	gaggatcatc	cagctagcaa	gtcccatcag	2700
tgatggagtt	ggccactccc	tctctgcgcg	ctcgtctcgt	cactgaggcc	gggcgaccaa	2760
aggctgcgcc	acgcccgggc	tttgcccggg	cggcctcagt	gagcgagcga	gcgcgccagc	2820
gattctcttg	tttgctccag	actctcaggc	aatgacctga	tagcctttgt	agagacctct	2880
caaaaatagc	taccctgtcc	ggcatgaatt	tatcagctag	aacggttgaa	tatcatattg	2940
atggtgattt	gactgtctcc	ggcctttctc	accggttgga	atctttacct	acacattact	3000
caggcattgc	atttaaaata	tatgagggtt	ctaaaaattt	ttatccttgc	gttgaaataa	3060
aggcttctcc	cgcaaaaagta	ttacagggtc	ataatgtttt	tggtaacaac	gatttagctt	3120
tatgctctga	ggctttattg	cttaattttg	ctaattcttt	gccttgccctg	tatgatttat	3180
tggatgttgg	aattcctgat	gcggtatttt	ctccttacgc	atctgtcggg	tatttcacac	3240
cgcatatggt	gcactctcag	tacaatctgc	tctgatgcgc	catagttaag	ccagccccga	3300
caccgcgcaa	caccgcgtga	cgcgcctga	cgggcttgct	tgctcccgcc	atccgcttac	3360
agacaagctg	tgaccgtctc	cgggagctgc	atggtgcaga	ggttttcacc	gtcatcaccg	3420
aaacgcgcga	gacgaaaagg	cctcgtgata	cgcctatttt	tatagggttaa	tgtcatgata	3480
ataatggttt	cttagacgtc	agggtggcact	tttcggggaa	atgtgcgcgg	aacccctatt	3540
tgtttatttt	tctaaatata	ttcaaatatg	tatccgctca	tgagacaata	accctgataa	3600
atgcttcaat	aatattgaaa	aaggaagagt	atgagtattc	aaatattccg	tgtcgccctt	3660
attccctttt	ttgcccattt	ttgccttctc	gtttttgtct	accagaaac	gctgggtgaaa	3720
gtaaaagatg	ctgaagatca	gttgggtgca	cagtggggtt	acatcgaaac	ggatctcaac	3780
agcggtaaga	tccttgagag	ttttcgcccc	gaagaacgtt	ttccaatgat	gagcactttt	3840
aaagtctcgc	tatgtggcgc	gggtattatcc	cgtattgacg	ccgggcaaga	gcaactcggc	3900

cgccgcatac	actattctca	gaatgacttg	gttagtact	caccagtcac	agaaaagcat	3960
cttacggatg	gcatgacagt	aagagaatta	tgcagtgtcg	ccataaccat	gagtataaac	4020
actgcggcca	acttacttct	gacaacgatc	ggaggaccga	aggagctaac	cgcttttttg	4080
cacaacatgg	gggatcatgt	aactcgctt	gacgttggg	aaccggagct	gaatgaagcc	4140
ataccaaacg	acgagcgtga	caccacgatg	cctgtagcaa	tggcaacaac	gttgcgcaaa	4200
ctattaactg	gcgaactact	tactctagct	tcccggcaac	aattaataga	ctggatggag	4260
gcggtataaag	ttgcaggacc	acttctgcgc	tggcccttc	cggctggctg	gtttattgct	4320
gataaatctg	gagccgggtga	gcgtgggtct	cgcggtatca	ttgcagcact	ggggccagat	4380
ggtaagccct	cccgtatcgt	agttatctac	acgacgggga	gtcaggcaac	tatggatgaa	4440
cgaaatagac	agatcgctga	gatagggtcc	tcactgatta	agcattggta	actgtcagac	4500
caagtttact	catatatact	ttagattgat	ttaaaacttc	atttttaatt	taaaaggatc	4560
taggtgaaga	tcctttttga	taatctcatg	acaaaaatcc	cttaacgtga	gttttcgttc	4620
cactgagcgt	cagaccccg	agaaaagatc	aaaggatctt	cttgagatcc	ttttttctg	4680
cgcgtaatct	gctgcttgca	aacaaaaaaa	ccaccgctac	cagcgggtgg	ttgtttgccc	4740
gatcaagagc	taccaactct	ttttccgaag	gtaactggct	tcagcagagc	gcagatacca	4800
aatactgtcc	ttctagtgtg	gccgtagtta	ggccaccact	tcaagaactc	tgtagcaccg	4860
octacatacc	tcgctctgct	aatcctgtta	ccagtggctg	ctgccagtgg	cgataagtcg	4920
tgtcttaccg	ggttggactc	aagacgatag	ttaccggata	aggcgcagcg	gtcgggctga	4980
acgggggggt	cgtgcacaca	gcccagcttg	gagcgaacga	cctacaccga	actgagatac	5040
ctacagcgtg	agctatgaga	aagcgcacag	cttcccgaag	ggagaaaggc	ggacaggtat	5100
ccggtaaagc	gcagggtcgg	aacaggagag	cgcacagagg	agcttccagg	gggaaacgcc	5160
tgggtatctt	atagtctgt	cgggtttcgc	cacctctgac	ttgagcgtcg	atttttgtga	5220
tgctcgtcag	gggggcggag	cctatggaaa	aacgccagca	acgcggcctt	tttacggttc	5280
ctggcctttt	gctggccttt	tgtccacatg	ttctttcctg	cgttatcccc	tgattctgtg	5340
gataaccgta	ttaccgcctt	tgagttagct	gataccgctc	gccgcagccg	aacgaccgag	5400
cgcagcagat	cagttagcga	ggaagcggaa	gagcgcccaa	tacgcaaacc	gcctctcccc	5460
gcgcgttggc	cgattcatta	atgcagctgg	cgcgctcgct	cgctcactga	ggccgcccgg	5520
gcaaagcccg	ggcgtcgggc	gacctttgt	cgcgcgcct	cagttagcga	gcgagcgcgc	5580
agagagggag	tggccaactc	catcactgat				5610

&lt;210&gt; 3

&lt;211&gt; 7096

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 3

aaaacttgcg	gcgcgggaat	ttcgactcta	ggccattgca	tacgttgat	ctatatcata	60
atatgtacat	ttatatggc	tcattgtcaa	tatgaccgcc	atgttgacat	tgattattga	120
ctagttatta	atagtaatca	attacggggt	cattagtcca	tagcccatat	atggagtcc	180
gcgttacata	acttacggta	aatggcccg	ctggctgacc	gcccacgac	ccccgccat	240
tgacgtcaat	aatgacgtat	gttcccatag	taacgccaat	agggactttc	cattgacgtc	300
aatgggtgga	gtatttacgg	taaactgcc	acttggcagt	acatcaagtg	tatcatatgc	360
caagtccgcc	ccctattgac	gtcaatgacg	gtaaatggcc	cgcctggcat	tatgccagt	420
acatgacctt	acgggacttt	cctacttggc	agtacatcta	cgtattagtc	atcgctatta	480
ccatggtgat	gcgggttttg	cagtacacca	atgggcgtgg	atagcggttt	gactcacggg	540
gattttcaa	tctccacccc	attgacgtca	atgggagttt	gtttttggca	caaaatcaac	600
gggactttcc	aaaatgtcgt	aataacccc	ccccgttgac	gcaaattggg	ggtaggcgtg	660
tacgggtgga	ggcttatata	agcagagctc	gttttagtgaa	cgcgcagatc	gcctggagac	720
gccatccacg	ctgttttgac	ctccatagaa	gacaccggga	ccgatccagc	ctccgcggcc	780
gggaacggtg	cattggaacg	cggattcccc	gtgccaagag	tgacgttaagt	acgcctata	840
gactctatag	gcacaccctt	ttggctctta	tgcattgat	actgtttttg	gcttggggcc	900
tataaccccc	cgtcccttat	gctatagggtg	atggatatagc	ttagcctata	ggtgtgggtt	960
attgaccatt	attgaccact	ccccatttgg	tgacgatact	ttccattact	aatccataac	1020
atggctcttt	gccacaacta	tctctattgg	ctatatgcca	atactctgtc	cttcagagac	1080

tgacacggac	tctgtatttt	tacaggatgg	gggccattta	ttattttacaa	attcacatat	1140
acaacaacgc	cgtcccccg	gccccgagtt	tttattaaac	atagcgtggg	atctccgaca	1200
tctcgggtac	gtgttccgga	catgggctct	tctccggtag	cggcggagct	tccacatccg	1260
agccctggtc	ccatccgtcc	agcggctcat	ggctcgctcg	cagctccttg	ctcctaacag	1320
tggaggccag	acttaggcac	agcacaatgc	ccaccaccac	cagtggtgcc	cacaaggccg	1380
tggcggtagg	gtatgtgtct	gaaaatgagc	tccgagattg	ggctcgcacc	tggacgcaga	1440
tgggaagactt	aaggcagcgg	cagaagaaga	tgcaggcagc	tgagttgttg	tattctgata	1500
agagtcagag	gtaactcccc	ttgcggtgct	gttaacggtg	gagggcagtg	tagtctgagc	1560
agtactcgtt	gctgccgcgc	gaatcaccag	acataatagc	tgacagacta	acagactggt	1620
cctttccatg	ggctctttct	gcagtcaccg	tcgtcgacct	aagaattcgc	cctttcacca	1680
tggtcagcta	ctgggacacc	ggggctcctgc	tgtgcgcgct	gctcagctgt	ctgcttctca	1740
caggatctag	ttcagggttca	aaattaaaag	atcctgaact	gagtttaaaa	ggcaccacagc	1800
acatcatgca	agcaggccag	acactgcatc	tccaatgcag	gggggaagca	gcccataaat	1860
ggtctttgccc	tgaaatgggtg	agtaaggaaa	gcgaaaggct	gagcataact	aaatctgcct	1920
gtggaagaaa	tggcaaacaa	ttctgcagta	ctttaaccctt	gaacacagct	caagcaaac	1980
acactggctt	ctacagctgc	aaatatctag	ctgtacctac	ttcaaagaag	aaggaaacag	2040
aatctgcaat	ctatatattt	attagtata	caggtagacc	tttcgtagag	atgtacagtg	2100
aaatccccga	aattatacac	atgactgaag	gaagggagct	cgtcattccc	tgccgggtta	2160
cgtcacctaa	catcactggt	actttaaaaa	agtttccact	tgacactttg	atccctgatg	2220
gaaaacgcac	aatctgggac	agtagaaagg	gcttcatcat	atcaaatgca	acgtacaaag	2280
aaatagggct	tctgacctgt	gaagcaacag	tcaatgggca	tttgtataag	acaaactatc	2340
tcacacatcg	acaaaccaat	acaatcatag	atgtccaaat	aagcacacca	cgcccagtca	2400
aattacttag	aggccatact	cttgtcctca	attgtactgc	tadcaactcc	ttgaacacga	2460
gagttcaaat	gacctggagt	taccctgatg	aaaaaaataa	gagagcttcc	gtaaggcgac	2520
gaattgacaa	aagcaattcc	catgccaca	tattctacag	tgttcttact	attgacaaaa	2580
tgacgaacaa	agacaaagga	ctttatactt	gtcgtgtaag	gagtggaacca	tcattcaaat	2640
ctgttaaacac	ctcagtgcat	atatatgata	aagcattcat	cactgtgaaa	catcgaaaac	2700
agcaggtgct	tgaaacccgta	gctggcaagc	ggctctaccg	gctctctatg	aaagtgaagg	2760
catttccctc	gocggaagtt	gtatgggtta	aagatggggt	acctgcgact	gagaaatctg	2820
ctcgctattt	gactcgtggc	tactcgttaa	ttatcaagga	cgtaactgaa	gaggatgcag	2880
ggaattatac	aatcttgctg	agcataaaac	agtcaaatgt	gtttaaaaac	ctcactgccca	2940
ctctaattgt	caatgtgaaa	cccagatttt	acgaaaaggc	cgtgtcatcg	tttccagacc	3000
cggctctcta	cccactgggc	agcagacaaa	tctgactttg	taccgcatat	ggtatccctc	3060
aacctacaat	caagtgggtc	tggcaccctt	gtaaccataa	tcattccgaa	gcaagggtgtg	3120
acttttggtc	caataatgaa	gagtccttta	tcttgatgac	tgacagcaac	atgggaaaca	3180
gaattgagag	catcaactcag	cgcattggcaa	taatagaagg	aaagaataag	atggctagca	3240
ccttggttgt	ggctgactct	agaatttctg	gaatctacat	ttgcatagct	tccaataaag	3300
ttgggactgt	gggaagaaac	ataagctttt	atatcacaga	tgtgccaaat	gggtttcatg	3360
tttaacttga	aaaaatgccg	acggaaggag	aggacctgaa	actgtccttg	acagttaaca	3420
agttcttata	cagagacggt	acttggattt	tactgoggac	agtttaatac	agaacaatgc	3480
actacagtat	tagcaagcaa	aaaatggcca	tcactaagga	gcactccatc	actcttaatc	3540
ttaccatcat	gaatggtttc	ctgcaagatt	caggcaccta	tgcttgcaga	gccagggaatg	3600
tatacacagg	ggaagaaatc	ctccagaaga	aagaaattac	aatcagaggt	gagcactgca	3660
acaaaaaggc	tgttttctct	cggatctcca	aattttaaag	cacaaggaat	gattgtacca	3720
cacaaagtaa	tgtaaaacat	taaaggactc	attaaaaagt	aacagtgtgc	tcatatcatc	3780
ttgattttatt	gtcactgttg	ctaactttca	ggctcaaggg	cgaattcagg	cctaagcttc	3840
ctaggtatcg	atctcgagca	agtctagaaa	gccatggata	tccgatccac	tacgcgttag	3900
agctcgctga	tcagcctoga	ctgtgccttc	tagttgccag	ccatctgttg	tttgccctc	3960
ccccgtgcct	tccttgacct	tggaaagggtg	cactcccact	gtcctttcct	aataaaaatga	4020
ggaaattgca	tgcgattgtc	tgagtgggtg	tcattctatt	ctgggggggtg	gggtggggca	4080
ggacagcaag	ggggaggatt	gggaagacaa	tagcaggggg	gtggggcgaag	aactccagca	4140
tgagatcccc	gcgctggagg	atcatccagc	tagcaagtcc	catcagtgat	ggagttggcc	4200
actccctctc	tgccgcctcg	ctcgcctcact	gagggccgggc	gaccaaagg	cgcccgacgc	4260
cggggctttg	cccgggcggc	ctcagtgagc	gagcgagcgc	gccagcgatt	ctcttgtttg	4320

ctccagactc	tcaggcaatg	acctgatagc	ctttgtagag	acctctcaaa	aatagctacc	4380
ctctccggca	tgaattttatc	agctagaacg	gttgaatatc	atattgatgg	tgatttgact	4440
gtctccggcc	tttctcacc	gtttgaatct	ttacctacac	attactcagg	cattgcattt	4500
aaaatatatg	agggttctaa	aaatttttat	ccttgcggtg	aaataaaggc	ttctcccgc	4560
aaagtattac	agggtcataa	tgtttttggg	acaaccgatt	tagctttatg	ctctgagggt	4620
ttattgctta	atttttgctaa	ttctttgcct	tgcctgtatg	atttattgga	tgttggaatt	4680
cctgatgcgg	tattttctcc	ttacgcatct	gtgcgggtatt	tcacaccgca	tatgggtgcac	4740
tctcagtaca	atctgctctg	atgccgcata	gttaagccag	ccccgcacac	cgccaacacc	4800
cgctgacgcg	cctgacggg	cttgtctgct	cccggcatcc	gcttacagac	aagctgtgac	4860
cgtctccggg	agctgcatgt	gtcagagggt	ttcacccgtca	tcaccgaaac	gcgcgagacg	4920
aaagggcctc	gtgatacgcc	tatttttata	ggttaatgtc	atgataataa	tgggtttctta	4980
gacgtcaggt	ggcacttttc	ggggaaatgt	gcgcggaacc	cctatttgtt	tatttttcta	5040
aatacattca	aatatgtatc	cgctcatgag	acaataaccc	tgataaatgc	ttcaataata	5100
ttgaaaaagg	aagagtatga	gtattcaaca	tttccgtgtc	gcccttattc	ccttttttgc	5160
ggcatttttg	cttctgtttt	ttgctcacc	agaaacgctg	gtgaaagttaa	aagatgctga	5220
agatcagttg	ggtgacagag	tgggttacat	cgaactggat	ctcaacagcg	gtaagatcct	5280
tgagagtttt	cgccccgaag	aacgttttcc	aatgatgagc	acttttaaa	ttctgctatg	5340
tggcgcggtta	ttatcccgta	ttgacgcgg	gcaagagcaa	ctcggtcgcc	gcatacacta	5400
ttctcagaat	gacttgggtg	agtactcaac	agtcacagaa	aagcatctta	cggatggcat	5460
gacagtaaga	gaattatgca	gtgctgccat	aacctagagt	gataaacctg	cggccaactt	5520
acttctgaca	acgatcggag	gaccgaagga	gctaaccgct	tttttgca	acatggggga	5580
tcatgtaact	cgcttggatc	gttgggaacc	ggagctgaat	gaagccatac	caaacgcaga	5640
gcgtgacacc	acgatgcctg	tagcaatggc	aacaacgttg	cgcaaaactat	taactggcga	5700
actacttact	ctagcttccc	ggcaacaatt	aatagactgg	atggaggcgg	ataaagttgc	5760
aggaccactt	ctgcgctcgg	cccttccggc	tggctggttt	attgctgata	aatctggagc	5820
cgggtgagcgt	gggtctcgcg	gtatcattgc	agcactgggg	ccagatggtta	agccctcccg	5880
tatcgtagtt	atctacacga	cggggagtc	ggcaactatg	gatgaacgaa	atagacagat	5940
cgctgagata	ggtgcctcac	tgattaaagca	ttggtaaactg	tcagaccaag	tttactcata	6000
tatactttag	tttgatttaa	aacttcattt	ttaatttaaa	aggatctagg	tgaagatcct	6060
ttttgataat	ctcatgacca	aatccctta	acgtgagttt	tcgttccact	gagcgtcaga	6120
ccccgtagaa	aagatcaaag	gatcttcttg	agatcctttt	tttctgcgcg	taatctgctg	6180
cttgcaaaaca	aaaaaaccac	cgctaccagc	ggtggtttgt	ttgccggatc	aagagctacc	6240
aaactotttt	ccgaaggtaa	ctggcttcag	cagagcgcag	ataccaaata	ctgtccttct	6300
agtgtagccg	tagttaggcc	accacttcaa	gaactctgta	gcaccgccta	catacctcgc	6360
tctgtaaatc	ctgttaaccag	tggctgctgc	cagtggcgat	aagtcgtgtc	ttaccgggtt	6420
ggactcaaga	cgatagttac	cggataaggc	gcagcggctc	ggctgaacgg	ggggttcgtg	6480
cacacagccc	agcttggagc	gaacgacct	caaccgaactg	agatacctac	agcgtgagct	6540
atgagaaagc	gccacgcttc	ccgaaggag	aaaggcggac	aggtatccgg	taagcggcag	6600
ggtcggaaca	ggagagcgca	cgaaggagct	tccaggggga	aacgcctggt	atctttatag	6660
tccgtgcggg	tttcgccacc	ctgacttga	gcgtcgattt	ttgtgatgct	cgtcaggggg	6720
gcggagccta	tggaaaaacg	ccagcaacgc	ggccttttta	cggttcctgg	ccttttgcgtg	6780
gccttttgc	cacatgttct	ttcttgcgtt	atccccctgat	tctgtggata	accgtattac	6840
cgcctttgag	tgagctgata	cgcctcgccg	cagccgaacg	accgagcgca	gcgagtcagt	6900
gagcgaggaa	gcggaagagc	gcccaatac	caaaccgcct	ctccccgcgc	gttggccgat	6960
tcattaatgc	agctggcgcg	ctcgtcgcgt	cactgaggcc	gccccggcaa	agcccggcg	7020
tccggcgacc	tttggtcgcc	cggcctcagt	gagcgagcga	gcgcgcagag	agggagtggc	7080
caactccatc	actgat					7096

<210> 4  
 <211> 636  
 <212> DNA  
 <213> Homo sapien

<400> 4

```

atggctccct tagccgaagt cgggggcttt ctggggcgcc tggagggtt gggccagcag      60
gtgggttcgc atttcctgtt gcctcctgcc ggggagcggc cgcgcctgct gggcgagcgc      120
aggagcgcgg cggagcggag cgcgcgcggc gggccggggg ctgcgcagct ggcgcacctg      180
cacggcatcc tgcgcgcggc gcagctctat tgccgcaccg gcttccacct gcagatcctg      240
cccgcggcca gcgtgcaggc caccgcgcag gaccacagcc tcttcggtat cttggaattc      300
atcagtgtgg cagtgggact ggtcagtatt agagggtgtg acagtggctc ctatcttgga      360
atgaatgaca aaggagaact ctatggatca gagaaactta cttccgaatg catctttagg      420
gagcagtttg aagagaactg gtataacacc tattcatcta acatatataa acatggagac      480
actggccgca ggtattttgt ggcacttaac aaagacggaa ctccaagaga tggcgccagg      540
tccaagaggc atcagaaatt tacacatttc ttacctagac cagtggatcc agaaagagtt      600
ccagaattgt acaaggacct actgatgtac acttga      636

```

<210> 5  
 <211> 211  
 <212> PRT  
 <213> Homo sapien

```

<400> 5
Met Ala Pro Leu Ala Glu Val Gly Gly Phe Leu Gly Gly Leu Glu Gly
  1          5          10          15
Leu Gly Gln Gln Val Gly Ser His Phe Leu Leu Pro Pro Ala Gly Glu
      20          25          30
Arg Pro Pro Leu Leu Gly Glu Arg Arg Ser Ala Ala Glu Arg Ser Ala
      35          40          45
Arg Gly Gly Pro Gly Ala Ala Gln Leu Ala His Leu His Gly Ile Leu
      50          55          60
Arg Arg Arg Gln Leu Tyr Cys Arg Thr Gly Phe His Leu Gln Ile Leu
      65          70          75          80
Pro Asp Gly Ser Val Gln Gly Thr Arg Gln Asp His Ser Leu Phe Gly
      85          90          95
Ile Leu Glu Phe Ile Ser Val Ala Val Gly Leu Val Ser Ile Arg Gly
      100         105         110
Val Asp Ser Gly Leu Tyr Leu Gly Met Asn Asp Lys Gly Glu Leu Tyr
      115         120         125
Gly Ser Glu Lys Leu Thr Ser Glu Cys Ile Phe Arg Glu Gln Phe Glu
      130         135         140
Glu Asn Trp Tyr Asn Thr Tyr Ser Ser Asn Ile Tyr Lys His Gly Asp
      145         150         155         160
Thr Gly Arg Arg Tyr Phe Val Ala Leu Asn Lys Asp Gly Thr Pro Arg
      165         170         175
Asp Gly Ala Arg Ser Lys Arg His Gln Lys Phe Thr His Phe Leu Pro
      180         185         190
Arg Pro Val Asp Pro Glu Arg Val Pro Glu Leu Tyr Lys Asp Leu Leu
      195         200         205
Met Tyr Thr
      210

```

<210> 6  
 <211> 659  
 <212> DNA  
 <213> Homo sapien

```

<400> 6
gagcgcagcc ctgatggaat ggatgagatc tagagttggg accctgggac tgtgggtccg      60

```

```

actgctgctg getgtcttcc tgetgggggt ctaccaagca taccatcc ctgactccag 120
ccccctctc cagtttgggg gtcaagtccg gcagaggtac ctctacacag atgacgacca 180
agacactgaa gccacactgg agatcagga ggatggaaca gtggtaggcg cagcacaccg 240
cagtcagaa agtctctgg agctcaaagc cttgaagcca ggggtcattc aaatctggg 300
tgtcaaagcc tctaggttcc tttgccaaca gccagatgga gctctctatg gatcgctca 360
ctttgatcct gaggcctgca gcttcagaga actgctgctg gaggacggtt acaatgtgta 420
ccagtctgaa gccatggcc tggccctggc tctgctcag aaggactccc caaaccagga 480
tgcaacatcc tggggacctg tgcgcttct gccatgcca ggcctgctc acgagcccca 540
agaccaagca ggattcctgc cccagagcc cccagatgtg ggctcctctg acccctgag 600
catggtagag cctttacagg gccgaagccc cagctatgct tctgactct tctgaatc 659

```

<210> 7  
 <211> 210  
 <212> PRT  
 <213> Homo sapien

```

<400> 7
Met Glu Trp Met Arg Ser Arg Val Gly Thr Leu Gly Leu Trp Val Arg
1 5 10 15
Leu Leu Leu Ala Val Phe Leu Leu Gly Val Tyr Gln Ala Tyr Pro Ile
20 25 30
Pro Asp Ser Ser Pro Leu Leu Gln Phe Gly Gly Gln Val Arg Gln Arg
35 40 45
Tyr Leu Tyr Thr Asp Asp Asp Gln Asp Thr Glu Ala His Leu Glu Ile
50 55 60
Arg Glu Asp Gly Thr Val Val Gly Ala Ala His Arg Ser Pro Glu Ser
65 70 75 80
Leu Leu Glu Leu Lys Ala Leu Lys Pro Gly Val Ile Gln Ile Leu Gly
85 90 95
Val Lys Ala Ser Arg Phe Leu Cys Gln Gln Pro Asp Gly Ala Leu Tyr
100 105 110
Gly Ser Pro His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Leu Leu
115 120 125
Leu Glu Asp Gly Tyr Asn Val Tyr Gln Ser Glu Ala His Gly Leu Pro
130 135 140
Leu Arg Leu Pro Gln Lys Asp Ser Pro Asn Gln Asp Ala Thr Ser Trp
145 150 155 160
Gly Pro Val Arg Phe Leu Pro Met Pro Gly Leu Leu His Glu Pro Gln
165 170 175
Asp Gln Ala Gly Phe Leu Pro Pro Glu Pro Pro Asp Val Gly Ser Ser
180 185 190
Asp Pro Leu Ser Met Val Glu Pro Leu Gln Gly Arg Ser Pro Ser Tyr
195 200 205
Ala Ser
210

```

<210> 8  
 <211> 5974  
 <212> DNA  
 <213> Homo sapien

```

<400> 8
aaaacttgcg gccgcggaat ttgactcta ggccattgca tacgttgat ctatatcata 60
atatgtacat ttatatggc tcatgtccaa tatgaccgc atgttgacat tgattattga 120

```

ctagttatta	atagtaatca	attacggggg	cattagttca	tagcccatat	atggagttcc	180
gcgttacata	acttacggta	aatggcccg	ctggctgacc	gcccacagac	ccccgccc	240
tgacgtcaat	aatgacgtat	gttcccatag	taacgccaat	agggactttc	cattgacgtc	300
aatgggtgga	gtattttacg	taaactgccc	acttggcagt	acatcaagt	tatcatatgc	360
caagtccgcc	ccctattgac	gtcaatgacg	gtaaatggcc	cgcctggcat	tatgccaggt	420
acatgacctt	acgggacttt	cctacttggc	agtacatcta	cgtattagtc	atcgctatta	480
ccatgggtgat	gcgggttttg	cagtaacca	atgggcgtgg	atagcgggtt	gactcacggg	540
gattttcaag	tctccacccc	attgacgtca	atgggagttt	gttttggcac	caaaatcaac	600
gggacttttc	aaaatgtcgt	aataaocccg	ccccgttgac	gcaaattggg	ggtaggcgtg	660
tacgggtggga	gggtctatata	agcagagctc	gtttagtga	ccgtcagatc	gcctggagac	720
gccatccacg	ctgtttttgac	ctccatagaa	gacaccggga	ccgatccagc	ctccgcggcc	780
gggaacgggtg	cattggaacg	cggattcccc	gtgccaaag	tgacgtaagt	accgcctata	840
gactctatag	gcacacccct	ttgggtctta	tgcatgctat	actgtttttg	gcttggggcc	900
tatacacccc	cgtccttatt	gctatagggt	atgggtatagc	ttagcctata	gggtgtgggtt	960
attgaccatt	attgaccact	cccctattgg	tgacgatact	ttccattact	aatccataac	1020
atggcttctt	gccacaacta	tctctattgg	ctatatggca	atactctgtc	cttcagagac	1080
tgacacggac	tctgtatttt	tacaggatgg	gggtccattta	ttattttaca	attcacatat	1140
acaacaacgc	cgtcccccg	gcccgcagtt	tttattaaac	atagcgtggg	atctccgaca	1200
tctcgggtac	gtgttccgga	catgggctct	tctccggtag	cggcggagct	tccacatccg	1260
agccctggtc	ccatccgtcc	agcgggtccat	ggtcgctcgg	cagctccttg	ctcctaacag	1320
tggaggccag	acttaggcac	agcacaatgc	ccaccaccac	cagtgtgccg	cacaaggccg	1380
tggcggtagg	gtatgtgtct	gaaaatgagc	tcggagattg	ggctcgcaac	tggacgcaga	1440
tgggaagactt	aaggcagcgg	cagaagaaga	tgacggcagc	tgagtgtgtg	tattctgata	1500
agagtcagag	gtaactcccg	ttgcgggtgt	gttaacgggtg	gagggcagtg	tagtctgagc	1560
agtactcgtt	gctgcgcgcg	gcgccaccag	acataatagc	tgacagacta	acagactgtt	1620
cctttccatg	ggctctttct	gcagtcacccg	tgcgcgacct	aagaattcag	gtatggctgc	1680
tgggttctatc	actaccctgc	cagctctgccc	agaagacggg	ggttctgggtg	ccttcccacc	1740
aggtcacttc	aaagacccaa	aacgtctgta	ctgcaaaaac	gggtggttct	tcttgcgcac	1800
ccaccccgac	ggccgagtg	acgggggtccg	cgagaagagc	gaccacacac	tcaaaactaca	1860
acttcaagca	gaagagagag	gggttgtgtc	tatcaaagga	gtgtgtgcaa	accgttacct	1920
tgctatgaaa	gaagatggaa	gattactagc	ttctaaatgt	gttacagacg	agtgtttctt	1980
ttttgaacga	ttggagtcta	ataactacaa	tacttacccg	tcaaggaaat	acaccagttg	2040
gtatgtggca	ctgaaacgaa	ctgggcagta	taaacttgga	tccaaaacag	gacctgggca	2100
gaaagctata	ctttttcttc	caatgtctgc	taagagctga	tcttaatggc	agcatctgat	2160
ctcattttac	atgaagcttc	ctaggatatc	atctcgagca	agctagaaaa	gccatggata	2220
tcggatccac	tacgcgttag	agctcgctga	tcagcctcga	ctgtgccttc	tagttgccag	2280
ccatctgttg	tttgcctctc	ccccgtgcct	tccttgacc	tggaagggtg	cactcccact	2340
gtcctttctc	aataaaatga	ggaaattgca	tcgcattgtc	tgagtagggtg	tcattctatt	2400
ctgggggggtg	gggtggggca	ggacagcaag	ggggaggatt	gggaagacaa	tagcaggggg	2460
gtggggcgaag	aactccagca	tgagatcccc	gcgctggagg	atcatccagc	tagcaagtcc	2520
catcagtgat	ggagttggcc	actccctctc	tgccgcctcg	ctcgtcact	gaggccgggc	2580
gaccaaagggt	cgcccagcgc	cggggtcttg	ccccggcggc	ctcagtgagc	gagcagcgc	2640
gccagcgatt	ctcttgtttg	ctccagactc	tcaggcaatg	acctgatagc	ctttgtagag	2700
acctctcaaa	aatagctacc	ctctccggca	tgaatttatc	agctagaacg	gttgaatatc	2760
atattgatgg	tgatttgact	gtctccggcc	tttctcacc	gtttgaatct	ttacctacac	2820
attactcagg	cattgcattt	aaaatatatg	agggtcttaa	aaatttttat	ccttgcgttg	2880
aaataaaggc	ttctcccgca	aaagtattac	agggtcataa	tgtttttggt	acaaccgatt	2940
tagcttttatg	ctctgaggct	ttattgtcta	attttgctaa	ttctttgcct	tgctgtatg	3000
attttattga	tgtttggaatt	cctgatgcgg	tattttctcc	ttacgcatct	gtgcggtatt	3060
tcacaccgca	tatggtgcac	tctcagtaaa	atctgctctg	atgccgcata	gttaagccag	3120
ccccgacacc	cgccaacacc	cgtgacgcg	ccctgacggg	cttgtctgct	cccggcatcc	3180
gcttacagac	aagctgtgac	cgtctccggg	agctgcatgt	gtcagagggt	ttcaccgta	3240
tcaccgaaac	gcgcgagacg	aaagggcctc	gtgatagccc	tatttttata	ggttaatgtc	3300
atgataataa	tgggtttctta	gacgtcaggt	ggcacttttc	ggggaaatgt	gcgcggaacc	3360



cctatattgtt	tattttttcta	aatacatttca	aatatgtatc	cgctcatgag	acaataaccc	3420
tgataaatgc	ttcaataatg	taaccgtcaa	gaaggcgata	gaaggcgatg	cgctgcgaat	3480
cgggagcggc	gataccgtaa	agcäcagagga	agcggtcagc	ccattcgctt	cagcaatata	3540
acgggtagcc	aacgctatgt	cctgatagcg	gtccgccaca	cccagccggc	cacagtcgat	3600
gaatccagaa	aagcggccat	tttccacccat	gatatctggc	aagcaggcat	cgccatgggt	3660
cacgacgaga	tcctcgccgt	cgggcacgcg	cgccttgagc	ctggcgaaca	gttcggctgg	3720
cgcgagcccc	tgatgctcct	cgtccagatc	atcctgatcg	acaagaccgg	cttccatccg	3780
agtacgtgct	cgtcgcgatg	gatgtttcgc	ttggtggtcg	aatgggcagg	tagccggatc	3840
aagcgtatgc	agccgcccga	ttgcacacgc	catgatggat	actttctcgg	caggagcaag	3900
gtgagatgac	aggagatcct	gccccggcac	ttcgcccaat	agcagccagt	cccttcccgc	3960
ttcagtgaca	acgtcagaca	cagctgcgca	aggaacgccc	gtcgtggcca	gccacgatag	4020
ccgcgctgcc	tcgtcctgca	gttcattcag	ggcaccggac	aggtcggctc	tgacaaaaag	4080
aaccggggcg	ccctgcgctg	acagccggaa	cacggcggca	tcagagcagc	cgattgtctg	4140
ttgtgcccag	tcatagcgca	atagcctctc	cacccaagcg	gcccggagaa	ctgcgtgcaa	4200
tccatcttgt	tcaatcatgc	gaaacgatcc	tcctcctgtc	tcttgatcag	atcttgatcc	4260
cctgcgccat	cagatccttg	gccgcaagaa	agccatccag	tttactttgc	agggcttccc	4320
aaccttacca	gagggcgccc	cagctggcaa	ttccggttcg	cttgcgtgct	ataaaaccgc	4380
ccagtcctagc	tatcgccatg	taagccact	gcaagctacc	tgctttctct	ttgcgcttgc	4440
gttttccctt	gtccagatag	cccagtagct	gacattcctc	cggggtcagc	accgtttctg	4500
cggactggct	ttctacgtgt	tccgcttcc	ttagcagccc	ttgcgcccctg	agtgccttgc	4560
gcagcgtgaa	gctgtcaatt	ccgcgtttaa	tttttgttaa	atcagctcat	tttttaacca	4620
ataggccgaa	atcggcacaaa	tcccttataa	atcaaaagaa	tagcccgaga	taggggttag	4680
tgttgttcca	gtttggaaca	agagtccact	attaaagaac	gtggactcca	acgtcaaagg	4740
gcgaaaaacc	gtctatcagg	gcgatggcgg	atcagcttat	gcggtgtgaa	ataccgcada	4800
gatgcgttaag	gagaaaatac	cgcacacagg	gctcttccgc	ttcctcgctc	actgactcgc	4860
tgcgtcgggt	cgttcggctg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacggg	4920
tatccacaga	atcaggggat	aacgcaggaa	agaacatgcg	gcgcgccaca	tgtgagcaaa	4980
aggccagcaa	aaggccagga	accgtaaaaa	ggcgcggttg	ctggcgtttt	tccataggct	5040
ccgccccctt	gacgagcatc	acaaaaatcg	acgctcaagt	cagaggtggc	gaaacccgac	5100
aggactataa	agataccagg	cgttttcccc	tggaagctcc	ctcgtgcgct	ctcctgttcc	5160
gaccctgccg	cttaccggat	acctgtccgc	ctttctccct	tcgggaagcg	tggcgctttc	5220
tcatagctca	cgtgttaggt	atctcagttc	gggttaggtc	gttcgctcca	agctgggctg	5280
tgtgcacgaa	ccccccgttc	agcccgaccg	ctgcgcctta	tcgggtaact	atcgtottga	5340
gtccaacccg	gtaagacacg	acttatcgcc	actggcagca	gccactggta	acaggattag	5400
cagaäcagagg	tatgtaggcg	gtgctacaga	gttcttgaag	tggtggccta	actacggcta	5460
cactagaagg	acagtatttg	gtatctgcgc	tctgctgaag	ccagttacct	tcggaaaaag	5520
agttggtagc	tcttgatccg	gcaaacacac	caccgctggg	agcggcggtt	ttttgtttgc	5580
aagcagcaga	ttacgcgcag	aaaaaaägga	tctcaagaag	atcctttgat	cttttcttac	5640
tgaacgggtga	tccccaccgg	aattgcggcc	catgttcttt	cctgcgttat	cccctgattc	5700
tgtggataac	cgtattaccg	cctttgagtg	agctgatacc	gctgcgcgca	gccgaacgac	5760
cgaäcgcagc	gagtcagtga	gcgaggaagc	ggaagagcgc	ccaatacgcä	aaccgcctct	5820
ccccgcgcgt	tggccgattc	attaatgcag	ctggcgcgct	cgtcgcctca	ctgaggccgc	5880
ccgggcaaaä	cccgggcgct	gggäcäcctt	tggtcgcccg	gcctcagtgä	gcgagcgcag	5940
gcgcagagag	ggagtggcca	actccatcac	tgat			5974

&lt;210&gt; 9

&lt;211&gt; 41

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide used for PCR amplification

&lt;400&gt; 9

ggtattttaa acttgcggcc gcggaatttc gactctaggc c

41

<210> 10

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide used for PCR amplification

<400> 10

gctgcccggg acttgctagc tggatgatcc tccagcgcg ggatctcatg

50

<210> 11

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 11

agatataagc ttaccatggg tgaaaagcgt ctgccccca aa

42

<210> 12

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 12

cgcgcgctcg agaccatgag gaatattatc caaagcgaaa ct

42